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 A successful kidney transplant is the best treatment for established renal 
failure, yet  around 300 patients per annum are denied transplants because they 
have antibodies, most notably directed against donor HLA or ABO in their 
blood, which have the potential to cause acute and chronic rejection of the 
transplant. Such antibodies are present in 25% (roughly 1750 of  the 7000 on 
the kidney transplant waiting list) of the patients listed for a deceased donor 
transplant. Programmes to remove antibody and transplant patients  across HLA 
antibody barriers have been developed, but are limited by a high rate of acute 
rejection. 
 This thesis explores the factors which may impact upon the 
pathogenicity of HLA-specific antibodies and also aims to enhance the 
understanding of the techniques used in the laboratory to define these 
antibodies. A range of studies were carried out examining factors such as the 
IgG subclass composition of the anti-HLA response. Assay variations were 
designed to enable a higher definition of antibody specificity to be achieved, 
and for the first time in the literature the direct quantification of HLA-specific 
antibodies in patient sera was performed. 
 In addition, proof of principle design and testing was carried out on a 
novel prototype therapeutic device for the selective depletion of HLA-specific 
antibodies directly from patient plasma and sera. The antibodies isolated from 
this approach were also used in studies to examine the factors which determine 
serum cytotoxicity. 
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1.1 Renal Transplantation: Historical Perspective 
 
 The origins of renal transplantation can be traced back to the first decade of the 
20th century and the pioneering work of Emerich Ullmann at the Vienna Medical 
School. In 1902 Ullmann performed the very first auto, allo, and xenotransplants using 
dogs and sheep [1], and later that same year attempted the first human kidney transplant 
when he grafted a pig kidney into a woman with end stage renal disease. Although 
unsuccessful these early experimental treatments led to advances in surgical techniques. 
Later that decade French surgeon Dr M Princeteau attempted further xenotransplant 
procedures, this time transplanting sections of rabbit kidney into children suffering from 
renal failure. These transplants were successful in producing a limited amount of urine 
for a few hours but ultimately failed within a few days leading surgeons to summise that 
‘unknown biochemical barriers’ were present which prevented long-term kidney graft 
survival. In 1906 another French surgeon Dr Mathieu Jaboulay followed in the footsteps 
of Ullmann and performed a pig to human xenotransplant. Unfortunately, the 32 year 
female patient died within one hour of having the pig kidney connected via an artery in 
her arm [2].  
 In 1933 Russian surgeon Yurii Voronoy performed the first human to human 
kidney allograft using a cadaveric donor [3]. The recipient was a 26 year old female 
admitted to hospital with acute mercury poisoning as the result of a failed suicide 
attempt. Although the kidney showed initial good function and urine production graft 
function soon worsened and the patient died 21 hours after transplant. The reasons for 
graft failure were clear with both the prolonged warm ischaemia time of the kidney and 
an apparent blood group incompatibility between donor and recipient both causal 
factors. Analysis of the case notes made by Voronoy at the time show that he had 
considerable insight into the immunological characteristics of organ rejection [3].  
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 Major advances in the understanding of transplant immunology came in the 
1940s and 1950s through the pioneering work of Sir Peter Medawar. A zoologist by 
training, Medawar was performing research into tissue culture techniques at Oxford 
during the second world war when he was tasked by the Medical Research Council to 
investigate why a skin graft from one human being was not accepted as a permanent 
graft by the recipient [4]. In collaboration with Peter Gibson and then subsequently 
Leslie Brent, Medawar noted fundamental differences between auto and allografting of 
human skin both microscopically and clinically, and correctly attributed these to an 
immunological process [5-8]. Using rabbits as a test species Medawar described the 
time delay from grafting to rejection (first set rejection) and how that delay was reduced 
and the immune response amplified following a second graft from the same donor 
animal (figure 1.1A). He described invasion of the graft by lymphocytes and 
demonstrated experimentally that these lymphocytes, rather than the antibodies that they 
produced were responsible for the graft destruction (figure 1.1B).  
 These observations led to the recognition of the immunological processes that 
underpin the allograft response; 1) That the immune response is inducible by the 
introduction of the allograft. 2) That the immune response displays memory, as a repeat 
graft is rejected both more quickly and more vigorously. 3) The immune response 
displays specificity, as a new graft from a previously unseen donor is rejected following 
a reversion to first set rejection kinetics. In 1960 Medawar was awarded the Nobel prize 
for his work on immunological tolerance alongside Macfarlane Burnet who first 
postulated the hypothesis of acquired tolerance. 
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Figure 1.1: Principles of first and second set rejection demonstrated by the seminal 
experiments of Medawar [4]. A) A skin graft from strain A into B displays 10-day 
duration ‘first set rejection’, a repeat graft shows accelerated ‘second set rejection’. 
Graft from another individual (Strain C) reverts back to first set rejection kinetics. B) 
Infusion of donor lymphocytes from strain A into a previously grafted strain B mouse 




 Further advances were made in the 1950s, notably by Joseph E Murray at the 
Peter Bent Brigham Hospital in Boston USA who, in 1954, performed the first 
completely successful kidney transplant. The transplant involved a pair of monozygotic 
twin brothers and took place without any form of immunosuppression. Scientists 
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be minimal as their immune systems should be indistinguishable from each other. In 
1956, Murray transplanted 20 year-old Edith Helm from her identical twin sister. At the 
time of her death in 2011 Edith had the longest surviving kidney transplant and was also 
the first person to safely give birth following renal transplantation [9]. 
 The 1950s also saw early attempts at suppressing the recipient immune system 
in order to accommodate allografts in non-identical twin donor-recipient pairs. Early 
animal studies using cortisone and total body irradiation managed to prolong the 
survival of skin grafts but only by a matter of a few days [10, 11].  These findings 
focused the efforts of researchers into finding immunosuppressive drugs whose effects 
mimicked those of irradiation. The first reported case of extended graft survival using 
drug therapy alone was reported in 1963 [12] when Goodwin and colleagues in Los 
Angeles used methotrexate and cyclophosphamide to depress bone marrow activity and 
allow a mother to daughter kidney allograft to be performed. The kidney survived for 
143 days with repeated rejection episodes associated with bone marrow recovery treated 
with prednisolone. Clinicians and surgeons soon realised that deliberate bone marrow 
depletion should be avoided due to the enhanced risk of infection, and studies 
performed by Schwartz and Dameschek demonstrated that 6-mercaptopurine (6-MP) 
could be used to induce immunosuppression at sub-myelotoxic doses [13]. Preclinical 
trials of 6-MP and its analogue azathioprine were carried out by Calne and Murray in 
Boston [14].  
 It is important to note that the advances described above took place at a time 
where there was little or no understanding of immunological screening or 
histocompatibility testing. The importance of the genetically determined major 
histocompatibility complex (MHC) in the immune response to allografts had been 
determined from studies using inbred mice strains performed by George Snell [15] 
inspired by earlier investigations from Peter Gorer [16]. It was only after the discovery 
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of the first human leukocyte antigen (HLA) in 1958 by Jean Dausset [17] and the 
subsequent discovery that very same year of anti-leukocyte antibodies (later shown to 
be directed against non-self HLA) by Van Rood [18], that the clinical utility of tissue 
matching and histocompatibility testing became a possibility. The description in 1964 
by Terasaki and McClelland of the microcytotoxicity test allowed HLA antigens to be 
determined serologically using minute quantities of patient or donor sera [19, 20]. This 
in turn led to rapid advances in the classification of HLA antigens.  
 Despite these advances in tissue compatibility testing undoubtedly the most 
important advance in the pre-transplant testing regimen was the recognition that 
observing the guidelines of ABO compatibility and a negative pre-transplant cytotoxic 
crossmatch were the key points to avoiding hyperacute rejection. Hyperacute rejection 
as a result of ABO incompatibility was first reported in 1964, and strict guidelines were 
soon put in place to observe ABO barriers [21]. In 1965 the first reported case of 
hyperacute rejection in an ABO-compatible transplant was reported, with subsequent 
cases confirming that graft loss could be caused by pre-formed anti-graft 
lymphocytotoxic antibodies [22-24]. The weight of this evidence highlighting the effect 
of pre-formed cytotoxic antibodies on transplant survival led Terasaki to immediately 
recommend and implement the routine use of his lymphocytotoxic crossmatch test [25]. 
 With the continued improvement in tissue matching that took place over the 
subsequent decades came the commonly held view that tissue matching would need to 
be perfected in order to sustain graft survival in the longer-term. This hypothesis would 
soon be shown to be true in the bone marrow transplant setting with even small degrees 
of HLA disparity between donor and recipient leading to graft versus host disease 
(GVHD) or graft failure, however these results were not replicated in kidney transplant 
studies [26, 27]. Although HLA matched grafts were shown to have the best survival 
and function, unexpectedly these studies showed there was no cumulative impact of 
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HLA mismatches on graft survival. This has been consistently shown in many 
transplant cohorts since with virtually all studies showing a statistical significance 
between different levels of HLA mismatching, however unless there is a near perfect 
HLA match between donor and recipient the impact of HLA matching is greatly 
diminished.  
 These advances in matching went hand in hand with important advances in 
immunosuppressive regimens throughout the 1970s, 80s and 90s. The importance of 
anti-lymphocyte globulin (ALG) was first demonstrated in the 1960s [28], given in 
conjunction with aziothioprine and prednisone, and as the name suggests ALG was a 
potent inhibitor of the lymphocyte response. The management of the dose of ALG was 
often difficult with under administration leading to potential allograft rejection and 
over-dosing leaving the patient liable to the severe side-effects of the drug; primarily 
infection and bone marrow disease. The development of the rosette inhibition test in the 
1970s led to a more detailed clinical evaluation of ALG [29]. However, ALG suffered 
from batch to batch variability and this was not adequately addressed until the 
development of monoclonal antibodies [30]. OKT3 was a first generation monoclonal 
antibody specific for all T cell subsets used to treat rejection [31-33]. The discovery in 
the mid-1970s of cyclosporine would drastically improve the safety and reliability of 
solid organ transplantation. A potent suppressor of both humoral and cellular immunity, 
cyclosporine had a powerful and easily reversible effect on T cell activity. In animal 
studies cyclosporine did not depress the bone marrow and was less toxic to other 
organs, unlike aziothioprine [34]. When transferred to human trials, cyclosporine 
showed an ability to prevent rejection, either alone or in combination with other agents, 
far greater than any previously tested agent [35]. However, the large dosages required 
carried many serious side-effects, most notably nephrotoxicity. It was therefore 
necessary to combine lower dosages of cyclosporine with established agents such as 
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prednisone to taper these harmful effects. The prognosis of various solid organ 
transplant procedures was greatly improved as a consequence [36, 37].  
 Cyclosporine remained the mainstay of immunosuppression until 1989 when 
studies performed in liver transplant patients demonstrated that replacing cyclosporine 
with tacrolimus could rescue rejecting liver allografts [38], with further studies showing 
that tacrolimus could also rescue failing cardiac and renal allografts [39]. Harmful side-
effects were seen to be comparable in magnitude to those associated with cyclosporine.  
 Further advances continue to be made in both the determination of 
histocompatibility and also in immunosuppression protocols. A more contemporary 
analysis will be given later in the context of antibody incompatible transplantation.
   
    
1.2 Renal Transplantation: The Growing Need   
 
 Due to the increasing success of renal transplantation and the great 
improvements in the safety of the procedure, the numbers of patients with end stage 
renal disease (ESRD) being put forward for transplantation each year far outstrips the 
number of cadaveric donors entering the donor pool. This problem is acutely felt in the 
UK, as the cadaveric donation rate is currently the lowest in Europe. The highest 
donation rate in Europe is seen in Spain, where three times the number of donors per 
head of population is observed compared to the UK. The reasons for this disparity are 
numerous and complex, with issues surrounding consent (Spain has a policy of assumed 
consent on organ donation), and age of potential donor involved. 
 Alternative strategies are increasingly being used to increase the potential donor 
pool and attempt to meet the demand for organs. The introduction of harvesting organs 
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from donors following cardiac death (DCD) has lead to a 300% increase in the use of 
this donor group in the last three years. For the financial year ending 31st March 2012 
674 DCD transplants were carried out accounting for one in four of all kidney 
transplants performed in the UK in that period.  
In addition, virtually all transplant centres have made concerted efforts to 
increase the rate of live donation, to the extent that in 2011-12, a total of 1009, over 1/3 
of all transplants performed in the UK were taken from live donors, usually from close 
relatives of the patient. Despite these efforts data from the UK renal registry suggest 
that an additional 4000 kidney transplants need to be performed each year to meet 
demand, a 50% increase at least on current transplantation rates (figure 1.2).  
 
 
Figure 1.2: The number of deceased and living donors for the period 2001 to 2011. 
Both the number of transplants performed and the number of available donors has 
remained fairly consistent during this period, however the number of patients awaiting 
transplant has for the most part increased (Source: NHS Blood and Transplant, Activity 
Report 2011). 
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There are also considerable cost savings to be made following renal 
transplantation. For example, from the second year of graft survival onwards there is an 
annual saving in the region of £25,000 per year in comparison to maintaining patients 
on dialysis. Therefore, UK transplant activity in the region of 2500 grafts per year 
delivers a cost saving in the region of £60 million per year of graft survival over the cost 
of maintaining patients on dialysis. 
  
 
1.3 The Immune Response 
 
 The ability to recognize and respond to a bewildering array of potentially 
harmful foreign entities is the central task of the human immune system. Our immune 
system is a vast and complex interaction between many different cell types and 
molecules, the aim of which is to protect the host tissues from harm. The function of the 
immune system can be summarised into two key functions: 1) To recognise foreign 
organisms or substances that have entered the body and caused damage. 2) To remove 
the source of the tissue damage.  
 The immune response itself can be separated into two main areas, the innate 
immune response and the adaptive (acquired) immune response. Organisms that are 
able to breach our bodies’ first-line physiological and anatomical barriers (skin, mucous 
secretions) will first encounter the innate immune system. This first-line immune 
defence response acts rapidly but is fairly indiscriminate, acting to destroy a wide range 
of pathogens. Acting in synergy with the innate response is the adaptive response which 
is much more sophisticated and specific for a particular antigen. As will be discussed in 
more detail in section 1.3.2 the adaptive response can also display immunological 
memory. However, this response takes much longer to develop and in reality many 
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initial immune responses will be comprised of a combination of both innate and 




Figure 1.3: Overview of the Innate and Adaptive Immune Systems. The main 
elements of both the innate and adaptive arms of the human immune system. A detailed 
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1.3.1 The Innate Immune Response 
 
 The innate immune response is a powerful first-line defence against host attack, 
so much so that in non-vertebrate species the innate response is sufficient for immune 
protection. A wide array of both haematopoietic and non-haematopoietic cells and 
molecules are integral to the innate response (table 1.1). 
 




 The innate immune system is charged with trying to kill infectious particles the 
moment they are detected in the body, the actions of the innate immune response also 
alert the cells that operate the adaptive response. Importantly, although a powerful 
response the potency of the innate response does not improve upon repeat exposure to 
the same foreign agent. The innate response recognizes broadly conserved components 
of infectious antigens (sometimes referred to as pathogen associated molecular patterns, 
PAMPs) and is able to respond to these ‘danger signals’. Although chemically distinct, 
these PAMPs have some shared features, notably that they are produced only by 
microbes and not by the host cells. In addition, they are usually essential for the survival 
Component of Innate Immunity Examples









Natural Killer (NK) cells
Dendritic Cells
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  David	  Lowe	  PhD	  Thesis	  2013	  	  
	   13	  
of these microorganisms and they are usually invariant structures shared by entire 
classes of microbes. For example, all gram-negative bacteria have lipopolysaccharide 
(LPS), therefore host cells containing receptors for LPS can recognise essentially all 
gram-negative bacteria. The constitutive expression of these pattern recognition 
receptors on cells such as macrophages, for example, allows a rapid response of the 
innate immune system to such infections. The innate response can directly engulf 
pathogens via phagocytosis or alternatively can attack them via the release of 
destructive enzymes such as proteases or lysozymes, with macrophages, neutrophils and 
components of the complement protein system being key players. This response occurs 
extremely rapidly, and indeed the innate response has to response this quickly when one 
considers that in the nutrient-rich environment of the human body pathogenic bacteria 
are often able to divide every twenty minutes [40].   
 
 
1.3.2 The Adaptive Immune Response  
 
 Adaptive immune responses typically take around 4-5 days to develop and 
provide a more specialized and potent immune response mechanism. Often, innate 
immunity alone is not sufficient for pathogen clearance and assistance from adaptive 
immunity is required. Some examples of the key differences between innate and 
adaptive immunity are listed in table 1.2. 
 Most notably, adaptive immunity displays immunological memory and this is 
mediated by the two cell types which mediate adaptive immunity, the T- and B-
lymphocytes. Arising from progenitor cells in the bone marrow, B-lymphocytes are 
responsible for antibody humoral immunity and T-lymphocytes and natural killer (NK) 
cells are responsible for cell-mediated immunity. Humoral immunity involves the 
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production of antibodies, molecules that can specifically recognize an almost infinite 
diversity of antigens and can also recruit various components of the immune response 
(this is discussed in more detail in section 1.5). Cell-mediated immunity comprises of 
cytotoxic T-cells (Tc) and the T-helper cell sub-groups (Th-1, Th-2). NK cells and 
dendritic cells also play a role in cell-mediated immune responses.  
 




   
 Both T-cells and B-cells have surface receptors that recognize antigen. Each 
immature circulating lymphocyte expresses a prototype antigen receptor that is highly 
specific for a particular antigen.  There are over one billion lymphocytes circulating in 
the human body, therefore there are only a very small number of circulating 
lymphocytes specific for each antigen that may be encountered. Lymphocytes that have 
Innate Immunity Adaptive Immunity
Distribution All living organisms Vertebrates only
Specificity Non-specific response Antigen specific response
Response time Immediate potent response Time delay between 
exposure and response
Components Physical Barriers
Cells: Macrophages B cells (humoral immunity)
Neutrophils




Memory No immunological memory Immunological memory:
Shortened lag-time and enhanced
response to repeat exposure
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not yet encountered their cognate antigen are small, rather featureless cells termed naïve 
lymphocytes.   
 Upon encountering their specific antigen naïve T- and B-lymphocytes 
differentiate and become effector lymphocytes that are capable of eliciting immune 
responses via a number of different mechanisms. The way in which T- and B-
lymphocytes encounter and recognize antigen is fundamentally different. B-
lymphocytes are able to recognize antigen in soluble unbound form circulating in either 
the blood or the lymphatic system. T-cells, on the other hand require antigen to be 
presented to them specifically by antigen-presenting cells (typically dendritic cells or 
macrophages).  
 The cellular (T-cell mediated) adaptive immune response is initiated following 
an innate immune response whereby immature dendritic cells are able to engulf a 
pathogen by phagocytosis. This can initially be achieved in a receptor-independent 
manner or alternatively following recognition of bacterial LPS by cell surface receptors 
as discussed earlier. The immature dendritic cell then migrates to peripheral lymphoid 
tissue such as the lymph node, spleen, or mucosa-associated lymphoid tissue (MALT) 
where the pathogen is degraded into smaller pieces which are then processed and 
presented via the membrane bound major histocompatibility complex (MHC) molecule 
(a more detailed description of this process is given in section 1.4).  
  
 
1.3.3 Clonal selection 
 
 As the human immune system can potentially produce hundreds of thousands, if 
not millions, of different T- and B-lymphocyte specificities, it is not practical to have 
large populations of lymphocytes recognising each specificity circulating at any given 
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time. Therefore the human immune system has developed to maintain a vast repertoire 
of potential antigen reactivity could be maintained but with far fewer circulating 
lymphocytes. Using the strategy of clonal selection (figure 1.4), lymphocytes that 
interact with their specific antigenic target, undergo successive waves of proliferation 
resulting in many more lymphocytes with identical antigenic specificity. In the case of 
B-cells each subsequent clone will become a plasma cell equivalent of the original 
parent lymphocyte capable of producing antibody molecules of exact specificity (a more 
detailed overview of the antibody molecule is given in section 1.5). T-cells will 
differentiate into various effector cells of either T-helper (Th), T-cytotoxic (Tc) or T-
regulatory (Treg) type. Typically this process will take several days, hence the time-lag 
associated with adaptive immunity. Importantly however, a number of clones of both 
the T- and B-lymphocyte lineage will differentiate into memory cells capable of 
eliciting a greatly enhanced and potent response when repeat challenge with the same 
antigen occurs [41, 42]. This immunological memory is a key hallmark of the adaptive 
immune response and makes for a highly effective immune mechanism. 
 Any T lymphocytes which display self-reactivity (i.e makes a specific contact 
with a protein defined as self) are destroyed by apoptosis at a very early stage of 
development within the thymus. This is a process known as clonal deletion, which 
operates in tandem with clonal selection to maintain a non-self reactive pathogenic 
specific lymphocyte pool. This pool is capable of eliciting a rapid immune response 
when required. 
 Similarly, B lymphocytes are also tested for self-reactivity within the bone 
marrow. B cells found to display enhanced levels of self-reactivity can either be 
removed by apoptosis in a process known as clonal deletion [43], or alternatively clonal 
anergy can occur whereby B cells are maintained in a state of permanent 
unresponsiveness [44].  
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Figure 1.4: Clonal selection for the generation of effector and memory 
lymphocytes following antigen specific primary activation. Following specific 
activation of either a T- or B-lymphocyte a range of effector and memory cell 
populations can be propagated. 
 
 
1.3.4 Cluster of Differentiation (CD) 
 
 The cluster of differentiation (sometimes referred to as the cluster of 
designation) is abbreviated to CD and serves as a nomenclature system used to identify 
cell surface molecules found on different leukocyte subsets. The CD nomenclature was 
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Antigens which was held in Paris in 1982 [45]. The key benefit to this system of 
categorization was that it allowed monoclonal antibodies to be uniformally and 
unequivocally identified by the surface marker against which they are directed, 
regardless of the laboratory performing the research. A newly identified surface 
molecule is designated a unique CD designation once two or more separate monoclonal 
antibodies bind to the molecule. In the case where only one monoclonal antibody has 
been shown to be specific for a potential marker then the abbreviation CDw is used 
[45]. 
 The CD nomenclature allows the definition of key cells involved in the immune 
response by virtue of the different combinations of markers found on their cell surface. 
The distribution of key CD antigens on important cells of the immune response are 
shown in figure 1.5. Many cells are defined primarily by virtue of the distribution of CD 
markers on their cell surface, and these markers are often used to associate particular 
cells with their function, e.g the CD8+ cytotoxic T-cell (refer to figure 1.5). Indeed it is 
important to remember that the CD molecules are more than just markers used to 
identify cell types but have important immunological functions, such as acting as 
ligands, receptors, or as cellular adhesion molecules. There are currently around 350 
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Figure 1.5: Cluster of differentiation (CD) markers for key cells involved in the 
immune response. Note all leukocytes are CD45+, and as a consequence CD45 is often 
dropped when referring to leukocyte subsets. 
 
 
1.3.5 The T-cell receptor. 
 
 The T-cell receptor (TCR) is a molecule found on the surface of T cells and is 
responsible for recognizing antigens bound to major histocompatibility complex (MHC) 
molecules. The TCR is a heterodimer composed of α and β chains, or less commonly,γ
and δchains. Each subunit chain of the TCR consists of a constant and variable region. 
The constant regions span the T-cell membrane, and the variable regions, which are 
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Figure 1.6: Simplified diagram of the TCR/CD3 complex. Upon binding of 
peptide/MHC complexes with the variable region of the TCR, a propagation of complex 
intracellular activation signals into the lymphocyte occurs which is mediated by the 
CD3 complex utilizing intracellular tyrosine activation motifs (ITAMS). 
 
 
 The TCR does not bind its antigen directly, it recognizes antigen only when 
presented by a class I or class II MHC molecule (sections 1.3.6 and 1.4). When the TCR 
does ligate antigen it relays a signal to activate the T-cell via an associated complex of 
transmembrane polypeptides, termed the CD3 complex (figure 1.6). The TCR is non-
covalently linked to the CD3 complex, and it is the CD3 complex which activates the T-
cells via phosphorylation of its attached intracellular tyrosine activation motifs 
(ITAM’s).  This signal transduction is assisted by the CD4/CD8 co-receptors, which 
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1.3.6 The B cell 
  
As outlined in figure 1.4, B cells can be stimulated to undergo proliferation 
(clonal expansion) and further differentiate into antibody secreting plasma cells, and 
long-lived memory B cells. The current understanding of how this process is performed 
and regulated is outlined below. 
The B cell lineage contains a variety of cells with differing functions and a wide 
variety of surface (CD) markers. B1 cells, characterized by the surface marker CD5, are 
able to produce low-affinity ‘natural antibody’ independent of T-cell help, whereas as 
the B2 cells are involved more in the adaptive immune response. These B2 cells are 
initially formed in the bone marrow, and are then released as immature B cells 
whereupon they continuously circulate through secondary lymphoid organs such as the 
lymph node and spleen until they encounter antigen (figure 1.7). Upon activation, the B 
cell then interacts with its cognate T-helper cell [47]. This interaction involves the 
processing and presentation of antigen by the B cell, which then presents the antigen, 
complexed with the MHC class II molecule, for recognition by the TCR (figure 1.6).  
A number of factors make B cells vitally important antigen presenting cells 
(APCs). Firstly, as outlined in figure 1.4, B cells have the ability to clonally expand and 
therefore rapidly amplify a specific immune response. Secondly, B cells are able to take 
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Figure 1.7: B cell differentiation. B1 cells are recently discovered B cells capable of 
producing low affinity natural antibody [47]. These B1 cells may differentiate into 
CD24+/27+/38+ regulatory B cells which play an important role in regulating T cell 
mediated responses. B2 cells are typically immature B cells produced in the bone 
marrow which migrate to the germinal centres where they encounter antigen, interact 




In addition, B cells are powerful mediators and regulators of specific T cell 
responses. B cells produce cytokines which act upon T cells, for example the activated 
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differentiation into memory T-cells [48].  Regulatory B-cells, thought to derive from the 
B1 lineage and characterized by surface expression of markers CD24, CD27, and CD38 
(figure 1.7), also inhibit T-cell specific responses primarily due to release of interleukin-
10 (IL-10). These regulatory B-cells are thought to constitute around 5% of circulating 
B cells [49]. 
The fate of the activated B cells can follow one of two paths. They can either 
develop into extrafollicular plasmablasts that produce low affinity antibody, or they can 
enter the germinal centre where they undergo somatic hypermutation and class switch 
recombination (described in more detail in section 1.5). Within the germinal centre, B 
cells with higher affinity for antigen are positively selected and are then able to 
differentiate into either memory B cells or antibody producing plasma cells (figures 1.4 
and 1.7). A small proportion of these B cells migrate to the bone marrow where they 
reside as long-lived plasma cells. These cells occupy a limited number of niche sites 
within the bone marrow and although they are unable to proliferate, they are able to act 
as long-term ‘factories’ constantly producing IgG [47]. The structure, function, and 
relevance to transplantation of the IgG molecule is discussed in detail in section 1.5. 
The importance of the B cell in the immune response to transplantation is 
highlighted by the fact that a number of immunosuppressive strategies have been 
developed which target B cell functions and effector mechanisms. Direct B cell 
depletion can be achieved crudely via splenectomy, or more selectively via the 
administration of monoclonal antibodies which directly bind to markers expressed on 
the B cell surface. Anti-thymocyte globulin (ATG) and the anti-CD52 antibody 
alemtuzumab (Campath-1H) are both used to deplete B cell populations, although both 
of these agents will also deplete T cells [47]. The anti-CD20 monoclonal antibody 
rituximab is more specific to B cells but has the therapeutic limitation that the 
terminally differentiated antibody producing plasma cell does not express CD20 [50]. 
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The development of potent anti-CD19 antibodies may offer an improved efficacy as 
CD19 is expressed both earlier in the B cell lineage compared to CD20, but has also 
been shown to deplete bone marrow residing long-lived plasma cells by up to 50% [51, 
52]. 
Specific depletion of the plasma cells is an attractive target for specific immune 
depletion and the proteasome inhibitor Bortezomib is currently being assessed for its 
ability to both deplete HLA-specific antibody pre-transplant, but also to treat rejection 
episodes post-transplant [53-55]. When plasma cells manufacture IgG a proportion of 
the protein will be mis-folded, and under normal conditions this mis-folded protein is 
degraded within the proteasome and then recycled within the cell. Bortezomib prevents 
the degradation of mis-folded proteins which then build up within the cells and lead to 
apoptosis of the plasma cell. Recent studies have shown that Bortezomib can lead to 
modest reductions in circulating levels of HLA-specific antibodies in sensitized patients 
[56], but it appears unlikely that Bortezomib will be suitable for use as a desensitizing 
agent when given in isolation [57, 58]. Further studies have suggested that Bortezomib 
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1.4 The Major Histocompatibility Complex (MHC) 
 
 
1.4.1 The Major Histocompatibility Complex (MHC): Structure 
 
 As has been discussed earlier, T cells only recognize antigens that have been 
degraded and presented by class I and II MHC molecules. The molecules of the major 
histocompatibility complex play a fundamental role in the immune system, primarily 
allowing the distinction to be made between self and non-self.  
 The MHC, or its equivalent, is a set of genes found in all species of vertebrates 
first discovered by Peter Gorer in the 1930s when he was studying antibodies to red 
blood cell antigens in mouse models [59].  Subsequently, George Snell coined the term 
histocompatibility (H) antigen to describe antigens capable of provoking graft rejection 
and that differences in the H-2 antigen first described by Gorer provoked the strongest 
graft rejection response [15].  The human MHC was subsequently described by Jean 
Dausset in the 1950s [17]. 
 The human MHC is located on the short arm of chromosome six and comprises 
of two sets of genes encoding the human leukocyte antigen (HLA) system which lie 
either side of a genetic region (often referred to as the MHC class III region) which 
includes a range of genes encoding proteins involved in immune regulation (figure 1.8).  
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Figure 1.8: Map of the human major histocompatibility complex on chromosome 
6.  Class I HLA (HLA-A,B,C) loci and class II HLA (HLA-DR, DP, DQ) are encoded 
alongside a range of genes encoding proteins involved in immune responses (e.g 
complement proteins, proteins involved in antigen processing and presentation). 
 
 
 The MHC class I region contains the genes required for HLA class I molecules. 
The HLA class I molecule consists of a heavy polypeptide alpha (α) chain of 
approximately 44kDa which is noncovalently linked to a 12kDa polypeptide called β2-
microglobulin. The heavy chain is organized into three extracellular domains (α1, α2, 
and α3), that are anchored to the cell surface by a hydrophobic anchor region. A short 
hydrophilic sequence carries the C-terminus end of the molecule into the cytoplasm 
(figure 1.9). 
 The HLA class II molecule is also a transmembrane glycoprotein, but differs 
structurally from the class I molecule as it lacks β2-microglobulin and instead consists 
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into membrane distal α1 and β1 domains above the membrane proximal α2 and β2 





Figure 1.9: Basic structure of the class I and class II HLA molecules. The antigen 
binding portion consists of α1 and α2 domains for class I and α1 and β1 domains for class 
II in association with antigenic peptide. 
 
 
There is significant structural homology between class I and class II HLA 
molecules.  This is particularly apparent in the membrane distal portion of both class I 
and class II HLA molecules, the region where peptide presentation and T cell 
recognition occurs. In the class I molecule the α1 and α2 domains combine to form two 
alpha helices which lie parallel to each other and above a β-pleated sheet ‘floor’ to 
produce a very distinct ‘groove’ into which an antigenic peptide is situated and held in 
position due to the presence of conserved ‘anchor’ residues in the peptide sequence. The 
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α1 and β1 domains. This structure in association with the antigenic peptide is often said 
to resemble ‘sausages on a barbeque’ (figure 1.10).  The nature of the peptide binding 
groove differs slightly between class I and class II MHC. The peptide binding groove of 
the class I molecule is closed at either end and allows the binding of an antigenic 
peptide typically 8-10 amino acids in length. The class II binding groove is significantly 
more ‘open-ended’ allowing for a greater degree of peptide binding flexibility with 10-





Figure 1.10: The peptide binding groove of the MHC class I and class II molecules. 
The antigenic peptide can be seen between the two parallel alpha helices producing a 
recognition complex seen by the T cell (circled). The class II peptide binding groove is 
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1.4.2 The Major Histocompatibility Complex (MHC): Function 
 
 
 The MHC molecule has a range of functions, the main one being to present 
peptides to T-cells, but they can also act as inhibitory ligands for NK cells via 
interaction with a range of NK cell surface receptors, most notably killer cell 
immunoglobulin-like receptors (KIRs) and the NKG2A receptor [60, 61]. 
 The MHC class I molecule primarily presents antigen that derives from 
intracellular pathogen such as viruses. As viruses can attack virtually any nucleated cell 
the immune system responds by incorporating MHC class I expression on virtually all 
nucleated cells also. The processed peptide is presented by the MHC class I molecule 
for recognition by the CD8 positive cytotoxic T-cell (Tc). The CD8 positive T-cell 
induces the death of the infected cell before the infected cell can multiply. Initially the 
naïve cytotoxic T-cells are activated when the T-cell receptor (TCR) recognizes and 
interacts with a peptide-MHC class I complex. The CD8 positive T-cell can induce 
apoptosis of the infected cell via the release of the granular components, perforins, 
granzymes, and granulysin. Upon recognition of target antigen, CD8 positive cytotoxic 
T-cells release perforins and granzymes onto the surface of the target cell. Perforin 
allows granzymes to enter the target cell and cause apoptosis [62].  
 Once the infected cells have been cleared the majority of the cytotoxic T-cells 
die and are cleared by phagocytosis. A small number remain to serve as memory T-
cells. These memory T-cells can respond rapidly upon encountering the same antigen, 
differentiating into an effector cell population in a fraction of the time required 
following the primary response to antigen. 
 Class II MHC molecules are primarily expressed on professional antigen cells 
such as B lymphocytes, dendritic cells, and macrophages. Importantly, class II 
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expression can also be induced on capillary endothelial and epithelial cells by γ-
interferon [63]. The function of the MHC class II molecule is to present antigen of 
extracellular origin  to CD4 positive T-helper (Th) cells.  
 Antigen is internalized by endocytosis, processed, then presented by the MHC 
class II molecule. The TCR/CD3 complex of the T-helper cell binds to the peptide-
MHC complex, this interaction is strengthened by the binding of the T-helper cell 
marker CD4 to a conserved region of the MHC class II molecule. This close interaction 
causes the intracellular kinases present on the TCR, CD3 and CD4 proteins to activate 
each other via phosphorylation. This in turn causes the activation of the major 
biochemical pathways within the T-helper cell, the so-called signal 1 of Th-cell 
activation. Following receipt of the initial activation signal the naïve T-helper cell then 
seeks a second confirmatory signal designed to ensure that T-cell activation is in 
response to foreign antigen and not due to auto-reactivity. This signal 2 involves an 
interaction between the CD28 molecule expressed on the T-helper cell and either the 
CD80 or CD86 protein expressed alongside the MHC class II complex on the antigen 
presenting cell [64].  
 Following the second signal the T-helper cell proliferates, mediated by a potent 
release of the growth factor interleukin-2 (IL-2).  Activated T-helper cells also begin to 
express a fully functional form of the IL-2 receptor (IL-2R), so IL-2 acts in an autocrine 
manner to stimulate proliferation. The released IL-2 can act upon its cell of origin or an 
adjacent cells leading to a potent clonal expansion response. The activated T-helper cell 
can then further differentiate into Th-1 or Th-2 cells depending on its local cytokine 
environment. Th-1 cells are induced in response to interferon-gamma (IFN-γ), and Th-2 
cells arise from interleukin-4 (IL-4) stimulation.  
 The Th-1 type response is characterized by the production of IFN-γ which in 
turn activates macrophages and allows them to mediate their potent bactericidal 
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properties. Th-1 cells also induce B cells to produce opsonizing antibodies, resulting in 
a powerful B-cell mediated immune response. Both Th-1 and Th-2 cells can provide the 
required co-stimulatory signals to B-cells in order that they can start producing 
antibodies by encouraging differentiation of B cells into antibody secreting plasma cells 
(figure 1.4). Signals derived from both Th-1 and Th-2 subsets can also insitigate class 
switching of activated B-cells to produce antibodies of different isotype (discussed in 
more detail in section 1.5).  
 In the context of transplantation differences in the MHC between graft donor 
and recipient can be detected by host T-cells. The two main routes by which foreign 
MHC is detected are by direct and indirect allorecognition (figure 1.11). Direct 
allorecognition occurs when host T-cells recognize an intact graft MHC molecule as 
foreign and mounts an immune response directly. The alternative route, indirect 
allorecognition, occurs when graft MHC is internalized and presented as antigen 
peptides in the context of recipient MHC on antigen presenting cells. Direct 
allorecognition is thought to be more important in acute rejection, particularly in the 
presence of MHC disparity between donor and recipient. Indirect recognition is thought 
to contribute to rejection by activating macrophages leading to fibrosis, although 
alloantibody is generated by the indirect pathway only [65].   
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Figure 1.11: Direct and indirect allorecognition. Direct allorecognition: The whole 
donor MHC/peptide is recognized by the T cell. In contrast, for indirect allorecognition 
foreign MHC sequences are presented as peptides in the context of self-MHC. 
 
 
1.4.3 The Major Histocompatibility Complex (MHC): Polymorphism 
 
 The MHC has evolved into a highly polymorphic system based upon multiple 
alleles at each locus. This evolution has most likely emerged as a consequence of 
pathogen-driven selection, with those alleles providing a ‘survival advantage’ for the 
individual being selected. For example, an allele which provides enhanced protection 
from an infectious organism would be selected. The class I and class II genes located on 
chromosome 6 are the most polymorphic in the entire human genome, with over 1200 
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has been under extreme evolutionary pressure with mutation rates of genes within this 
region far in excess of those at other genetic loci [66, 67]. 
 The HLA-class I alpha chain molecules are broadly divided into the products of 
the HLA-A, B, and C genes and all are highly polymorphic. HLA-class II molecules 
exhibit virtually all of their polymorphism in the different beta-chain genes (HLA-DRβ, 




Table 1.3: HLA Class I and Class II. Number of different protein variants for each 
locus identified to date. Source: HLA Nomenclature (http://hla.alleles.org), accessed 





 The amino acid differences that contribute to this polymorphism are largely 
restricted to the α1 and α2 domains of the class I molecule and the β1 domain of class 
II. Significantly most of these differences are located around the α-helices and β-pleated 
sheet structure that defines the antigen presenting region (figure 1.10). This is the region 
Locus Number+of+allotypes Locus Number+of+allotypes
A 1571 DRB1 959
B 2156 DRB3 46
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of the molecule that directly interacts with the TCR, and further supports the 
observation that HLA-polymorphism occurs as a result of selection pressure and 
repeated host-pathogen interaction. 
The genes of the MHC are inherited in a Mendelian co-dominant manner, with 
the whole haplotype inherited as a single trait, one from each parent and both are 
expressed. Infrequently, meiotic cross-over events and recombination events may occur 








1.5.1 Antibodies: Structure and Function 
 
 
 As discussed previously, B cells can be activated following Th cell interaction 
with MHC/peptide complexes, and can differentiate into antibody secreting plasma cells 
(figure 1.4).  The first function of an antibody is to recognize and to bind foreign 
material or antigen. This is achieved by recognizing molecular structures on the surface 
of foreign material termed epitopes which differ from those of the host. The human 
immune system is capable of raising a specific antibody response to billions of different 
molecular structures, and the mechanisms by which this is made possible are discussed 
later. 
 Antibodies, or immunoglobulins as they are also known, have a relatively 
simple structure consisting of two identical units involved in antigen binding,- the Fab 
fragments (fragment for antibody binding). These are the regions that confer the binding 
specificity on the antibody molecule, and as such contains regions of amino acid 
sequence variation. The presence of two identical Fab fragments per molecules also 
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serves to enhance the binding ability to antigen. The ‘tail’ region of the antibody 
molecule is termed the Fc (fragment crystallizable) region, and is the portion of the 
molecule associated with effector functions (figure 1.12). 
 
 
    
Figure 1.12: Simplified diagram of antibody structure. Two identical heavy chains 
(H) and two light chains (L) combine to make the structure shown.  
 
 
 The fine structure of the immunoglobulin monomer was elucidated by Rodney 
Porter and Gerald Edelman [69], and in the 1980s both were jointly awarded the Nobel 
prize for their contribution in this area. By selectively breaking down the disulphide 
bonds which hold together the immunoglobulin structure it could be clearly 
demonstrated that the molecule consisted of four chains. By the addition of papain the 
molecule was broken down into the Fc and individual Fab fragments. Treating with 
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Figure 1.13: The structure of the immunoglobulin monomer elucidated by Porter 
and Edelman [69]. Proteolytic cleavage of the molecule by papain and pepsin; 
selectively cleaving with papain produces two separate Fab fragment capable of antigen 
binding but the molecule is no longer able to precipitate antigen. Pepsin digestion led to 
the production of a Fab2 fragment which retained both binding sites and thus maintained 
the ability to precipitate antigen. 
 
 
 The process by which antibody binding diversity is produced is via a complex 
system of gene rearrangements involving the genes encoding the heavy and light chains 
of the immunoglobulin molecule (figure 1.12). The variable region of the human heavy 
(H) chain contains three gene segments termed V (variable), D (diversity), and J 
(joining), whereas the light (L) chain contains V and J only. There are multiple human 
heavy and light chains (table 1.4), and these can undergo recombination to produce 
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by the different pairing of heavy and light gene, as any heavy chain can pair with any 
light chain. 
 
Table 1.4: Approximate numbers of potential gene segments encoded human 
immunoglobulin heavy and light chains. 
 
 
To further increase the potential diversity, post-recombination modifications can 
be made to the heavy and light chain genes. Following recombination, nucleotides can 
be added or subtracted at the ‘joins’ between the gene segments, for example P-
nucleotides can be added when uneven cleavage occurs at the site of recombination. 
Similarly addition of extra nucleotides, termed N-nucleotides by the enzyme terminal 
deoxynucleotidyl transferase (TdT) also enhances this junctional diversity. 
Following the production of a functional antibody molecule further diversity can 
be achieved via somatic mutation of the V gene of the heavy and light chains. Point 
mutations in the V regions of rapidly proliferating B-cells can occur in the germinal 
centres of lymphoid follicles, and as such is antigen-driven. This mutation can often 
result in a mutated immunoglobulin with an even higher affinity for its cognate antigen. 
These antibodies are then able to better compete for the limited amounts of specific 
antigen and become the dominant antibody, thus raising the overall affinity of the 
immune response in a process known as affinity maturation. 
 
 
V D J V J
50 27 6 35 5
Light Chain (L)Heavy Chain (H)
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Figure 1.14: Overview of heavy chain (H) recombination. Diversity (D) and Joining 
(J) gene segments are joined first, then a Variable (V) gene segment is added to produce 
the fully recombined heavy chain gene. 
 
 
 There are five classes of immunoglobulin termed Immunoglobulin G, (IgG), 
IgM, IgA, IgE, and IgD. All classes share the same four-chain antibody structure as 
outlined in figure 1.12. However, key differences between the classes are observed in 
the heavy chain with the most pronounced situated in the Fc portion (table 1.5). The Fc 
portion is crucial to the activation of effector mechanisms upon binding to antigen. The 
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The different immunoglobulin classes have distinct roles to play in the immune 
system and this is reflected by the differences in their respective structures. If we 
consider them individually in the order of their concentration in human serum this can 
be explained.  
Immunoglobulin G (IgG) is the most prominent antibody class in serum and 
other mucosal tissues. It is able to coat target cells and promote a stable interaction with 
phagocytic cells in a process known as opsonisation. IgG can also eliminate antigen 
through activation of the complement system via the classical pathway (explained in 
section 1.6), an effector mechanism which is dependent on the particular subclass of 
IgG involved. As shown in table 1.5 IgG1 and IgG3 are the most potent activators of the 
complement cascade, with IgG2 having little or no complement activating capacity, and 
IgG4 none at all. IgG can also interact with various Fc portion specific cell surface 
molecules (Fc receptors). Fc receptors typically consist of a ligand binding α-chain, 
usually complexed with a transmembrane region that is a dimer of the common γ-chain 
(FcRγ). Binding of Ig to Fc receptors activates various cell signaling functions, for 
Location Complement
Ig Class Subclasses Molecular Form  (Concentration) Activation Properties
IgG IgG1 Monomer Serum (~9mg/ml) [++] Major immunoglobulin of acquired
IgG2 Dimer Serum (3mg/ml) [+-] immunity
IgG3 Monomer Serum (~2mg/ml) [+++]
IgG4 Monomer Serum (~1mg/ml) [-] Can cross the placenta
IgA IgA1 Monomer Serum (3mg/ml)  [+] Found in gastrointestinal, 
IgA2 Dimer Secretions:  [+] respiratory, and genitourinary
Secretory milk, colustrum, tears tract mucosa
IgM Pentamer Serum (~1.5mg/ml) [++++] Secreted early in acquired immune response
IgE Monomer Serum (~0.05ug/ml) [-] Involved in allergry and anti-paristic  response
IgD Monomer Serum (~30ug/ml) [-] Membrane bound immunoglobulin
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example binding of IgG to FcγRI expressed on monocytes, macrophages and dendritic 
cells results in enhanced phagocytosis, up-regulation of antigen presentation, and in the 
mediation of extracellular killing of target cells referred to as antibody-dependant 
cellular cytotoxicity (ADCC).  
 IgM is pentameric in structure and is highly effective at complement activation 
as a consequence of this (see section 1.6). IgM is also the major class of antibody 
associated with a primary immune response.  
 IgA is found in three distinct soluble forms (table 1.5), with monomeric and 
dimeric (linked by a polypeptide known as the J chain) found in the serum. These 
antibodies complex pathogens to effector cells via interaction with IgA specific Fc 
receptors. Secretory IgA is a complex of dimeric J chain-linked IgA and a secretory 
protein and is a key defence mechanism against microbial attack of the human mucosal 
surfaces. IgA has two subclasses IgA1 and IgA2, the shorter IgA2 molecule is more 
resistant to attack from proteases released by bacterial pathogens. 
 IgE is monomeric and found at low concentrations in the serum, probably due to 
the fact that most IgE is bound to IgE specific Fc receptors expressed by mast cells. IgE 
is the major class of antibody associated with an acute inflammatory response, where 
antigen binding to Fc-bound IgE results in cross-linking and a potent degranulation of 
mast cells leading to a powerful inflammatory response. This often leads to unwanted 
hypersensitivity in response to certain antigens, resulting in a state of allergy. Finally, 
IgD is an antibody class found primarily on the B-cell surface where it is thought to be 
involved in some way in the control of lymphocyte activation.  
 The production of antibodies of the various different classes occurs at different 
rates in a distinct order governed by gene order and under strict T-lymphocyte control. 
This is demonstrated in mouse models where T-cell deficient mice show greatly 
reduced degrees of immunoglobulin class switching [70]. The early antibody response 
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is typified by a powerful IgM response which usually falls off rapidly to be replaced by 
a more gradual and sustained IgG response, which results in much higher IgG titres.  
Therefore in the process of class switching the variable (antigen-binding) region of the 
molecule remains unchanged but the Fc region is altered, thus the specificity remains 
but the potential effector function of the antibody is altered. Figure 1.15 shows the order 






Figure 1.15: The order of immunoglobulin heavy chain genes on chromosome 14. 
This is the usual order of antigen specific antibody maturation, leading to an adaptation 




 Activated B cells migrate from the bone marrow to peripheral lymphoid organs 
such as the spleen, or gut-associated lymphoid tissues (GALT), and undergo antigen 
driven clonal expansion (figure 1.4).  At this point B-cells may undergo class switching 
via a process termed class switch recombination (CSR) in response to signals generated 
by extracellular cytokines [72]. CSR may occur via a T-cell dependent mechanism 
involving the interaction between the CD40 cell membrane protein expressed on B-cell 
with the CD40 ligand (CD40L) on T-cells, or by CD40 independent mechanisms 
involving direct super-antigenic stimulation [73]. Superantigens are substances capable 
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of binding to the Vβ domain of the TCR and residues in the alpha chain of the class II 
MHC molecule simultaneously resulting in T-cell activation. 
 Class switching uses distinct regions of the gene sequence to achieve 
recombination. During CSR portions of the heavy chain gene sequence are deleted from 
the chromosome at specialized ‘switch regions’ (S regions) by the actions of a number 
of enzymes such as Activation Induced Deaminase (AID), Uracil DNA glycosylase 
[74]. Regions surrounding the deleted sequence are rejoined such that a functional gene 
is produced but the heavy chain isotype has been substituted via a process known as 
non-homologous end-joining (figure 1.16). 
 The immunoglobulin class of a particular antibody has a profound effect on the 
functional capability of the molecule. The ability of an antibody to mediate targeted cell 
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Figure 1.16: Immunoglobulin heavy chain class-switching. A T-cell regulated 
process of DNA excision and repair leads to the formation of a new antibody with 
altered heavy chain usage but maintaining the original binding specificity. Breaks in the 
DNA are initiated at specific ‘switch’ points (red asterix). Binding specificity is denoted 




1.6 The Complement System 
 
   The complement system is comprised of a group of around 30 plasma proteins 
that can become activated and then interact in a powerful cascade that culminates in the 
production of a potent immunological complex capable of rapid and widespread target 
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cell lysis. However, in addition, as part of the complement cascade various components 
can fulfill a range of immune effector functions.  There are three routes by which the 
complement system can be initiated, the classical pathway, the alternative pathway, and 
the mannose binding lectin (MBL) pathway. Complement factors are given the letter C 
followed by a number, with the factors named in their order of discovery rather than 
sequence of reaction. Thus the sequence of reaction is C1, C4, C2, C3, C5, C6, C7, C8 
and C9. Cleaved products are designated a lower case letter following the number with 
the letter “a‟ for the smaller product and letter “b‟ for the larger product (the exception 
to this is factor C2 where the larger fragment is factor C2a and the smaller fragment 
C2b). The larger fragments have specific enzymatic activity resulting in cleavage of 
subsequent complement proteins. Alternative pathway factors are given letters instead 
of numbers, for example factor B and factor D. In the MBL pathway, the initial 
enzymes to be activated are called MASP-1 and MASP-2 (mannose-binding-lectin 
associated serine proteases). An overview of the pathways of complement activation are 
shown in figure 1.17. As figure 1.17 shows, although the pathways are each inititated 
differently they do converge into a common final pathway culminating in the formation 
of the C5-C9 membrane attack complex (MAC). The key to each pathway is to reach 
the point at which the C3 cleaving molecular complex is formed.    
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Figure 1.17: Simplified overview of the three pathways of complement activation. 
All three pathways converge onto the final common pathway. Classical and MBL 
pathways cleave C4 and subsequently C3. Protein complexes responsible for protein 
cleavage are marked with an overline. 
 
 
The MBL pathway is initiated when MBL associates with two serine proteases 
called MASP-1 and MASP-2. The resulting complex is able to bind extracellular sugar 
moieties on the surface of pathogens, which in turn activates MASP-2 to cleave the C4 
and C2 complement proteins to generate C4b2a [75]. C4b2a is the key C3 convertase 
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 The classical pathway is initiated by an antibody-antigen interaction and 
involves the C1q hexameric complex C1qrs (figure 1.17). When the C1qrs complex is 
cross-linked with at least two immunoglobulin Fc portions of pathogen bound antibody 
it induces a conformational change in the C1qrs complex resulting in autolytic cleavage 
of C1r and C1s. Cleaved C1s results in the formation of an active serine protease which 
in turn cleaves C4 generating C4b, which binds covalently to proteins or carbohydrate 
on the surface of the pathogen. To prevent an auto-reactive response unbound C4b is 
quickly inactivated. Pathogen bound C4b then binds to the C2a fragment of the C2 
molecule, which is first cleaved by activated C1s, to form the C4b2a complex, or C3 
convertase. 
 The alternative pathway was discovered after the classical pathway and is an 
alternative means of complement activation. The activation of the alternative pathway 
does not depend on the presence of proteins such as immunoglobulins or MBL, and is 
more likely to be initiated following interaction with immune complexes. As shown in 
figure 1.17 the classical and MBL pathways are activators of the alternative pathway as 
they are able to generate C3b. The alternative pathway begins with a low rate of 
spontaneous hydrolysis of plasma C3 to form C3(H2O). C3(H2O) has an altered 
conformation which binds to factor B. Which in turn is then cleaved by factor D to 
release Ba and form a fluid-phase C3(H2O)Bb complex. The C3(H2O)Bb complex is a 
C3 convertase and cleaves C3 to C3a and C3b most of which is rapidly inactivated. 
Some C3b molecules attach to pathogen or host cell surfaces and bind factor B. Factor 
B is cleaved by factor D to form Ba and C3bBb. The bound C3bBb molecule is called 
the alternative pathway C3 convertase and functions in much the same way as C4b2a in 
the classical and MBL pathways.  
 Each pathway then follows a common final pathway, which is initiated when C3 
convertase is complexed with the C3b fragment to form C5 convertase (figure 1.17). 
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This step is also a key amplification stage with C3 being by far the most abundant 
complement protein. Cleavage by C5 convertase results in C5b which binds C6 to form 
C5b6 which in turn binds C7, and the resulting complex is then able to insert itself into 
the cell wall following a conformational change which exposes a hydrophobic residue 
on the C7 protein. C8 then binds to the C5b portion of the C5b67 complex and recruits 
and polymerises up to 16 molecules of C9 to form the MAC. The MAC has a 
hydrophobic external surface which allow it to insert itself into the lipid bilayer of the 
cell membrane. A hydrophilic inner channel with a diameter of around 100 Å then 
allows the free passage of water and other solutes resulting in rapid and potent cellular 
destruction [76]. 
 In addition to the formation of MAC, the cleaved products of all pathways of 
complement activation, in particular following C3 and C5 cleavage, fulfill a variety of 
immunological functions augmenting the potency of the complement system. Some of 
these are summarized in table 1.6. 
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1.7 HLA Specific Antibodies 
 
1.7.1 HLA Specific Antibodies: Specificity 
 
 HLA-specific antibodies recognise epitopes, and the definition of an epitope can 
be given as: ‘A localised region on the surface of an antigen that is capable of eliciting 
an immune response and of combining with a specific antibody to counter that 
response’.  So HLA-specific antibodies recognise a region of the HLA molecule that is 
primarily non-self, but more importantly may be shared amongst many HLA. Recent 
studies have also shown that hydrophobicity and electrostatic charge of the epitope 
defining residues play a key role in antibody recognition and binding [77, 78]. 
 Much recent work has been performed in this area to identify potential 
immunogenic sites on the HLA molecule against which a HLA-specific antibody can be 
raised. Worldwide registries have been set up that aim to document the currently 
identified repertoire of HLA epitopes, and to establish a common nomenclature for 
identifying these antibodies. Presently, epitope designations are based upon three-
dimensional molecular modeling of the HLA protein and the amino acid residues found 
in polymorphic positions. Typically these epitope reactivates are determined using 
single antigen bead panels, which themselves have technical problems as will be 
discussed in section 1.10. As of 2012 there were 69 verified HLA-class I specific 
epitopes, 53 HLA-DR, 17 HLA-DQ, and 8 HLA-DP, although as will be discussed 
further in chapter 3 there are likely to be many more epitopes identified and verified in 
the future [79, 80]. Computer algorithms have been designed to allow the HLA-
technician to interpret HLA antibody assay data in terms of epitope structure, the 
HLAMatchmaker program is a free to use algorithm (www.hlamatchmaker.net) that 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  David	  Lowe	  PhD	  Thesis	  2013	  	  
	   49	  
will provide a likely epitope level interpretation for any HLA-specific binding profile 
[81-87].  
 To add further complexity to the epitope specific nature of antibody recognition 
it has also been demonstrated that some HLA-specific antibodies have contact residues 
on the HLA-bound peptide (see figure 1.9) [88]. This may cause problems in 
identifying these antibody specificities in the single antigen bead assays, where bound 
peptide repertoires are likely to differ significantly from those found in the individuals 
and binding may be prevented. 
 It is important to consider the epitope recognizing surface of the antibody 
molecule, which typically has three heavy chain regions and three light chain regions 
that form the primary ‘contact surface’ with antigen. These regions, termed 
complementarity determining regions (CDRs) bind to the ‘functional epitopes’ on the 
antigen which typically comprise 15-30 amino acid residues covering an area in the 
region of 700-1000Å [89].  
 Using the three-dimensional HLA modeling software program, Cn3d (available 
online: www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml), it is possible to examine 
the structure of the molecule and how the epitope is situated and presented to antibody. 
Figure 1.18 shows the position of the common  HLA-A2 specific epitopes 
designated 62G and 142T [80]. 
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Figure 1.18: Three-dimensional structure of the HLA-A2 molecule (top-view). The 
62G and 142T epitopes are labeled and sit either side of the bound peptide (brown). 
 
 
1.7.2 HLA Specific Antibodies: Role in antibody-mediated rejection 
 
 
 HLA-specific antibody can be stimulated in response to graft mismatched HLA 
antigen, paternal mismatched antigens through pregnancy, and via HLA antigens 
expressed on donor cells following blood transfusion.  
 Hyperacute antibody-mediated rejection (AMR) due to HLA-specific antibodies 
was first recognized in the 1960s [24]. The introduction of the cytotoxic crossmatch test 
that same decade drastically reduced the incidence of hyperacute rejection [25]. Over 
recent years, in the context of antibody incompatible transplantation, AMR has again 
become a major challenge to successful renal transplantation[90-92]. 
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 AMR is a consequence of the interaction between donor HLA-specific 
antibodies (DSA) and the HLA expressing cells of the graft vascular endothelium.  The 
binding of DSA on the graft endothelium can lead to localized classical pathway 
complement activation and subsequent cell death leading to ischaemic injury to parts of 
or the entire donor kidney [93]. Consequently, the endothelium loses integrity and free 
passage of coagulation factors ensues leading to vascular thrombosis [94]. 
 AMR can be either acute or chronic, and is often associated with detectable 
levels of circulating DSA [95]. To diagnose acute AMR in a renal transplant biopsy 
there are a number of key histological features which are mandatory. The main feature 
of unequivocal AMR diagnosis is capillaritis, often in conjunction with glomerulitis and 
presence of circulating antibodies specific for donor HLA [96]. The identification of 
C4d has also emerged as a marker for AMR in the clinical transplant setting, which 
suggests that antibodies may not be the sole mediator of acute or chronic rejection [97]. 
Current treatment protocols for acute or chronic AMR are not fully effective, with 
various agents used in a combination of dosages. For example, one study showed that 
post-transplant intravenous immunoglobulin (IVIg) in highly sensitized patients lead to 
improved one-year survival outcomes and lower levels of HLA-specific antibodies [98]. 
Other studies demonstrated the benefit of multiple treatments of plasmapheresis to 
reduce DSA levels leading to more effective and reproducible reduction of humoral 
rejection rates when compared to IVIg [99]. The introduction of the proteasome 
inhibitor bortezomib, the therapeutic agent used to selectively target plasma cells 
discussed in section 1.3.6, is the first agent to effectively shut down antibody production 
in vivo [100]. However, studies have indicated that as antiviral antibody levels stay 
stable following bortezomib treatment it may not be as effective as first hoped on the 
long-lived bone marrow niche plasma cells [57].  
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Some centres have reported cases where the use of the monoclonal antibody 
specific for the C5 protein of the complement cascade eculizumab has been indicated to 
treat rejection. Binding of eculizumab to the C5 protein inhibits formation of the 
membrane attack complex (MAC) as outlined in section 1.6 and prevents complement 
mediated damage to graft tissue. One case study detailed the use of eculizumab in 
combination with IVIg and plasmapheresis to salvage a kidney graft undergoing severe 
AMR [101]. Locally we have published data describing the use of eculizumab to treat 
AMR following three separate HLA incompatible transplants [102]. From this data we 
concluded that although the use of eculizumab was not completely successful in 
abrogating the rejection, particularly in the face of extremely high DSA levels, a 
positive effect of eculizumab could be seen in all three cases. Therefore, eculizumab, 
like bortezomib discussed in more detail in section 1.3.6, constitutes a useful addition to 
the therapeutic repertoire used to treat AMR. Further randomized clinical trials are 
required to fully assess the efficacy of eculizumab.  
 
 
1.8 Transplanting the sensitised patient   
  
 Aside from the chronic lack of available donors there are a number of other 
factors that can preclude renal transplantation. These can include patient age, presence 
of other co-morbid factors (heart failure, diabetes, obesity), or even religious or cultural 
beliefs, which can prevent the receipt of a donor organ. However, by far the most 
common preventative factor to renal transplantation is an immunological one- namely 
the presence of antibodies in the patients’ blood. The most frequently encountered 
antibodies are those directed against blood group ABO and non-self HLA. It is 
estimated that around 250 transplants per year are prevented in the UK due to the 
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presence of an antibody incompatibility. Antibodies directed against a transplanted 
organ can cause rejection, this rejection may occur in different phases depending on the 
titre (strength) and specificity of the antibody: 
 
1. Hyperacute rejection: graft destruction occurring within minutes of graft 
reperfusion. Histologically, the markers associated with HAR are neutrophil and 
platelet margination in the glomerular and peritubular capillaries leading to acute 
tubular injury. 
2. Accelerated acute rejection: Distinct from hyperacute rejection and usually 
occurs within 2-3 days as a consequence of a specific memory T-cell response. 
3. Acute rejection: distinct from hyperacute rejction as graft rejection usually 
occurs within the first two weeks following transplantation. Histologically the central 
feature of acute rejection is injury to the endothelium within the microvasculature.  
4. Chronic rejection: progressive loss of graft function which may occur months or 
years after transplantation.  The histologic features of chronic rejection are namely 
glomerular basement membrane duplication (chronic transplant glomerulopathy) and/or 
arterial intimal fibrosis.  
 
The fate of the sensitised patient can be placed into one of the following categories:  
 
1. Continue to wait for a deceased donor transplant. This option may be suitable 
for patients who have an ABO antibody barrier with their living donor but are negative 
for anti-HLA antibodies. For patients with an ABO barrier and broadly reactive HLA-
specific antibodies this may not be a suitable choice as the chance of receiving an offer 
of a cadaveric kidney would be very low. 
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2. Look for an alternative live donor. Other potential live donors could be 
approached, some of whom may turn out to be suitable for standard live donor 
transplantation. 
3. Enter the paired exchange transplant program. When histocompatibility testing 
has identified a barrier to transplant with a prospective live donor it is then common 
practice to advise these patients to register for a possible exchange transplantation. In 
exchange transplantation, recipients who have antibody-incompatible donors are entered 
into a donor-recipient matching pool. These incompatible pairs are then matched to 
other incompatible pairs such that new antibody-compatible transplant pairs can be 
created. This approach was first performed at the Johns Hopkins University in 2005 
[92] and has also been successfully performed in the Netherlands [103], with the first 
exchange transplantation performed in the UK in 2007. 
 
If none of the above options are suitable, then the option of proceeding to antibody 
incompatible transplantation incorporating antibody removal therapy (desensitisation) 
can be explored.  
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1.9 Antibody Incompatible Transplantation  
 
 
 Antibody incompatible transplantation (AIT) can be successful following the 
reduction of potentially graft destructive antibodies in the patient serum prior to 
transplant. There are a number of approaches that have been used historically to reduce 
the circulating levels of anti-HLA antibodies. Some transplant units use combinations of 
IVIg or the B cell specific monoclonal antibody rituximab, however these treatments are 
much less effective when patients have particularly high starting levels of antibody 
[104, 105]. It is therefore often preferable to use antibody removal therapy. These 




Patient blood is passed through a plasma filter or is simply centrifuged. The 
plasma component, which contains the antibodies, is removed and discarded. However, 
along with the antibodies the plasma component also contains albumin and other 
clotting factors and these have to be replaced with fresh donor plasma. This treatment 
has been used clinically in other scenarios, notably to remove antibody of vasculitis 
triggering antibody in conditions such as renal vasculitis [106]. Depending on the size 
of the patient, only 3-4 litres of plasma can be treated per session[107]. In addition the 
efficacy of plasma exchange is limited as a significant proportion of antibodies are 
found in the extravascular space. Furthermore antibody can be re-synthesised between 
plasma exchange treatments further decreasing treatment efficacy. 
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Double-filtration plasmapheresis (DFPP). 
 
 Plasma is separated as for plasma exchange but is then passed through a second 
filter which operates via size exclusion. This filter traps larger molecules and 
consequently smaller plasma proteins which need to be replaced in standard plasma 
exchange such as albumin and lower molecular weight clotting factors are allowed to 
pass back into the patient. Although some clotting factors are still depleted potentially 
increasing the risk of bleeding during subsequent surgery. This approach is much better 
tolerated by the patient and typically DFPP treatment volumes can be 6-8 litres per 
session, usually only limited by fluid shift out of the vascular compartment [108]. Care 
must be taken clinically to reduce the risk of infection following reduction of antibody 
mediated immunity, and also DFPP can be unsuitable for patients with compromised 
cardiac function[107]. 
 
Protein A immunoadsorption. 
 
Once again plasma is removed as for plasma exchange, but is then passed 
through a column containing immobilised Protein A. Protein A is a 56kDa protein 
derived from the cell wall of the bacterium Staphylococcus Aureus which is able to bind 
immunoglobulins (Ig) from many different mammalian species [109]. Protein A binds 
effectively to human IgG (though not to IgG3 as will be discussed further later), so is a 
highly effective method for removing antibody prior to transplantation. Following 
passage through a protein A column only the antibody molecules are removed leaving 
all other plasma proteins unaffected which makes this a very well tolerated treatment 
modality, with treatment volumes of up to 40 litres in a single session possible [110]. 
Figure 1.19 shows the increased effectiveness of protein A immunoadsorption 
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compared to standard plasma exchange or DFPP. The major disadvantage of protein A 
immunoadsorption is the high cost associated with protein A column. In addition 
protein A does not bind to the potent complement fixing IgG3 isotype; the 
immunological significance of this molecule will be discussed in chapters 6 and 7. 
 
Selective adsorption of ABO antibodies. 
 
Plasma is passed through a commercially produced column containing 
immobilised blood group antigen, either blood group A or B depending on the blood 
group of the potential donor. Therefore the only component removed is the ABO blood 
group specific antibody that is bound to the column, everything else in the patient 
plasma passes back into the patient. As with protein A columns, this makes this 
procedure very well tolerated with up to 10 litres of plasma treated in a single session 
reported [111]. Despite the high cost associated with this treatment, these columns are a 
very attractive choice for clinicians to use in their ABO-incompatible transplant 
programs as the columns are highly specific and have a large capacity to deplete even 
high titre antibody. 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  David	  Lowe	  PhD	  Thesis	  2013	  	  
	   58	  
 
Figure 1.19: Single treatment effectiveness of three main approaches to reduce 
total IgG concentration in plasma. Protein A is by far the most effective method of 
antibody reduction, and combines removal efficacy with longer treatment duration. 
 
The same approaches can also be used to remove antibody post-transplantation, 
although the clinical value of post-transplantation antibody removal is questionable and 




1.10 Laboratory techniques for defining risk in AIT 
 
 
 The ability to understand the degree of immunological incompatibility between 
donor and recipient is crucial in defining the level of risk prior to AIT. This can be 
determined in the laboratory by measuring the strength of anti-donor reactive antibodies 
using both highly sophisticated solid phase assays and traditional serological assays. 
The ability to measure the blood levels of donor-specific antibodies before and after the 
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 The three commonly used methods for measuring HLA antibody levels are the 
complement dependant cytotoxic crossmatch (CDC), the flow cytometry crossmatch 
(FC), and HLA microbead analysis. The fundamental principle of each assay will be 
described here followed by a review of the potential clinical significance of each 
technique. For a conventional antibody compatible transplant donor/recipient 
compatibility is characterized by negative CDC and FC crossmatches and no detectable 
donor-specific antibodies (DSA) by microbead analysis. However, in the case of 
antibody incompatible transplantation these techniques can be used in combination to 
determine the risk to graft survival, when the transplant is performed in the presence of 
circulating DSA [91]. 
 
The Complement Dependent Cytotoxic Crossmatch (CDC) 
 
 The CDC crossmatch was first described by Terasaki and colleagues in the 
1960s and was shown to be an accurate predictor of hyperacute rejection prior to 
transplantation [25]. Donor lymphocytes are typically separated into T and B cell 
compartments, and patient serum is mixed with the lymphocytes. A source of 
complement (typically rabbit serum) is added. If donor-specific antibody is present it 
will bind to donor cells and the complement cascade will be activated via the classical 
pathway and lysis of the donor lymphocytes will result. This can be assessed 
microscopically by comparing the percentage of dead to live cells, higher percentages of 
dead cells mean more lysis, which in turn means a higher titre of donor specific 
antibody. Highly cytotoxic patient sera can be tested at a range of dilutions to better 
determine the titre. The sensitivity of the CDC assay can be increased by the addition of 
anti-human globulin (AHG) which binds to the lambda light chains of the donor 
specific antibody resulting in an increased density of available Fc receptors which are 
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able to associate with complement component C1q and initiate the classical pathway 
[112].  
 The CDC crossmatch can give false positive results, either as a result of 
technical error or more likely the presence of autoantibodies in the recipient serum. To 
determine the presence of autoantibodies a separate crossmatch should be performed 
against the recipients own lymphocytes. In addition, autoantibodies tend to be IgM 
rather than IgG so the crossmatch should be routinely performed with test wells treated 
with dithiothreitol (DTT) a reducing agent to which IgM is particularly sensitive. Also, 
it is often the case that a CDC crossmatch can be negative in the presence of donor-
specific antibody of low titre which is too low to reach the threshold required for 
complement activation. Additionally if the donor specific antibody is comprised of poor 
complement fixing ability isotypes (IgG2 or IgG4) then a negative result can be 
observed. 
 
The Flow Cytometry Crossmatch (FC) 
 
 The introduction of the FC crossmatch in the 1980s successfully addresses the 
issue of complement fixing isotype composition and lower sensitivity encountered with 
CDC [113].  In this technique, patient sera is once again mixed with donor 
lymphocytes. Fluorescently labeled anti-human IgG monoclonal antibody is added to 
the mixture and will bind to any antibody bound specifically to donor cells. T cells and 
B cells can be distinguished by the addition of fluorescently labeled CD19/20 (B cells) 
or CD3 (T cells). Antibody negative blood group AB serum is used routinely as a 
negative control and positivity is determined by shift in median channel fluorescence 
away from the negative control. This technique has added sensitivity compared to CDC 
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and also directly detects all bound donor-specific IgG and is not reliant upon a 




 This is a recently developed tool, which has made it much more practical to 
measure DSA on a daily basis. Unlike CDC and FC crossmatching, microbead analysis 
does not rely upon a constant supply of fresh donor lymphocytes to allow for daily 
monitoring. Instead, target HLA proteins are purified and attached to polystyrene beads 
[114, 115], the beads themselves are individually labeled with specific ratios of 
fluorescent marker dyes. The beads are incubated with patient sera and any HLA-
specific antibody present will bind to the HLA protein coupled to the microbead. A 
fluorescently labeled anti-human IgG antibody is then added and then both the bead sets 
and the bound antibody are classified by two colour lazer analysis on the Luminex™ 
platform (Figure 1.20). 
 The beads shown in figure 1.20 are commonly referred to as phenotype beads as 
they carry entire HLA haplotype profiles. More recently microbeads have become 
commercially available that only express a single HLA antigen (for example a specific 
bead within an assay set may express HLA-B7 and no other HLA specificity). This has 
increased the specificity of the assay markedly.  
 In addition to the fact that microbeads negate the need to constantly source fresh 
donor cells, they also allow the laboratory to monitor other HLA antibody specificities 
that may not be present on the graft. This helps to distinguish between a general 
upregulation of the immune response, such as that which may be associated with an 
inflammatory response, and a specific anti-graft response [116].  
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Figure 1.20: Principle of microbead analysis as detected on the Luminex platform. 
Fluorescently marked microbeads are coated with HLA protein. The beads are 
incubated with patient sera and HLA-specific antibodies are detected using labeled anti-
human IgG. 
  
 Although the development of luminex-based technology has led to substantial 
progress in antibody detection compared with cell-based techniques, it soon became 
apparent that the assay did have technical issues, particularly when testing patients with 
high-titre antibodies. High-titre antibodies can exhibit a phenomenon known as the 
prozone effect, whereby high-titre antibodies can agglutinate in suspension and as a 
consequence can prevent themselves from binding to target antigen. This results in 
stronger antibody profiles within a patient sample being detected at reduced mean 
fluorescence intensity (MFI) levels, or in some cases not being detectable at all [117]. A 
similar effect whereby false low readout can be obtained in high titre samples is the 
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hindrance and is investigated further in chapter 3. The presence of prozone, or the high 
dose hook effect, has to be overcome by serially testing sera. In addition to the obvious 
cost implications to repeat testing of patient sera, it is not always obvious when 
analyzing screening data when bead reactivities are being detected at false low levels. 
One potential solution has recently been suggested to overcome the apparent prozone 
effect is to add a small amount of ethylenediaminetetraacetic acid (EDTA) to the serum 
prior to testing [117]. EDTA has the ability to chelate metal ions, most notably calcium 
ions (Ca2+). A suggested mechanism for the prozone effect is the binding of 
complement component C1 to the Fc portion of IgG1 and IgG3 and the addition of 
EDTA disrupts this Ca2+ dependent process. The presence of C1 bound to the HLA 
specific antibody is then thought to prevent the binding of the anti-human IgG labeled 
secondary detection antibody resulting in a lower detectable level of fluorescent marker. 
Further support for this hypothesis was gathered by addition of C1 inhibitor (C1INH) 
also leading to a marked reduction in the prozone effect. 
Similarly, the presence of HLA-specific antibodies of IgM isotype have been put 
forward as a possible cause of reduced IgG binding in the luminex assay [119, 120]. It 
is hypothesized that the presence of HLA-specific antibodies of both IgM and IgG 
isotype within the same serum can lead to competitive inhibition and reduced binding of 
IgG antibodies. Therefore some laboratories recommend the routine treatment of all 
sera with DTT in order to reduce IgM binding capacity.  
Modifications of the luminex assay have also been developed so that antibodies 
can be defined into those that fix complement and those that do not, with many of the 
early studies appearing to indicate that the presence of donor specific complement 
fixing anti-HLA antibodies is associated with increased risk of rejection and graft loss 
compared to non-complement fixing antibodies. Studies performed in renal transplant 
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and cardiac transplant setting has so far concluded that complement fixing antibodies 
confer increased risk of rejection [121-125].  
 Another technical issue surrounding the use of HLA antigen coated beads has 
recently emerged. During the manufacturing process there appears to be a significant 
proportion of HLA protein coupled to the microbeads that has been denatured to some 
extent. The presence of denatured antigen on the bead surface can lead to the 
presentation of a number of non-native HLA epitopes due to altered conformation of the 
protein. These novel epitopes appear able to bind to a number of common antibodies 
that may have arisen in response to a previous viral or bacterial infection. Literature is 
available describing the presence of HLA-specific antibodies in previously untransfused 
and untransplanted male volunteers as detected by microbead analysis. These antibodies 
were previously explained as the presence of ‘naturally occurring’ anti-HLA antibodies, 
but it now seems that a much more likely explanation is that these reaction patterns 
would be due to binding to non-native epitopes presented by a proportion of denatured 
antigen found on the microbead [79]. Strategies to identify reactions caused by 
denatured antigen binding have been described, with the most common being to acid 
treat the microbead set to fully denature the beads’ protein repertoire. If it is suspected 
that all or part of an antibody profile is due to antibody binding to denatured protein, 
treating the bead set with an acidic buffer such as 100mM glycine pH2-3 will denature 
all the protein on the beads. If repeat testing with denatured beads gives the same 
antibody profile this confirms binding to disrupted HLA. Often, it is observed that the 
initial result is due to a combination of binding to both intact and denatured antigen, and 
that crucially antibody that recognizes non-native HLA epitopes are not to be 
considered clinically significant [126, 127]. 
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1.11 HLA Incompatible (HLAi) Transplantation: Overview 
 
Early attempts to reduce the levels of HLA specific antibody in highly sensitised 
patients prior to transplantation were made in the mid 1980s. Taube et al described a 
series of 5 patients who were transplanted following reduction of their anti-HLA titres 
following a protocol of pre-transplant plasma exchange and prednisolone and 
cyclophosphamide based immunosuppression [128]. Reduction of antibody reactivity 
lead to successful transplantation in four of the five cases reported. 
The Johns Hopkins University in the United States first developed a successful 
protocol for AIT in the late 1990s [129] which was a refinement of a number of earlier, 
less successful protocols [110, 128, 130]. This protocol involved the use of living 
donors which gave the added advantage that procedures could be planned well in 
advance providing an excellent opportunity to remove harmful antibody prior to 
transplant. Typically five sessions of plasma exchange were administered in the ten 
days leading up to the transplant with the aim being to reduce the level of DSA to that 
which would produce a negative crossmatch at time of transplantation. Interestingly this 
protocol also included the use of intravenous immunoglobulins (IVIg) on the basis that 
they may be able to block the action of any existing antibody and antibody that may 
resist plasma removal. 
The last decade has provided a number of studies which have indicated that AIT 
can be successful, and that not all components of the early Johns Hopkins protocol are 
required. During the recent advancements in AIT centres have adopted different parts of 
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The Local Experience 
 
A protocol for pretransplant antibody removal using plasmapharesis has recently 
been developed at the University Hospital of Coventry and Warwickshire (UHCW) to 
overcome this barrier [91].  After nearly ten years, the results of the programme are 
proving to be very good [90, 107, 108, 116, 132].  One of the key features of the 
protocol is daily monitoring of DSA during the early post-transplant phase.  This allows 
guided patient management, such as immunosuppression modification, as we have been 
able to recognise early signs of a rejection response in terms of rapid re-synthesis of 
prior DSA in the early post-transplant phase; we believe we are the only transplant 
centre in the world using this approach and have the resulting data and sample archive 
[133].  From over 100 procedures to date we are beginning to understand the predictive 
nature of the DSA response. Thus we have observed in certain cases, particularly those 
who undergo a rejection process, that after a rapid rise in DSA the antibody response is 
not sustained and following treatment and resolution of the rejection, the DSA is rapidly 
modulated [134].  Rejection in these cases has been successfully treated in all but one 
case, and the most effective treatment appears to be using the T-cell inhibitor OKT3 
[90].  This whole process, from first rise in antibody, onset and resolution of rejection to 
antibody modulation takes about two-three weeks, as shown in figure 1.21. One further 
feature of this observation is the rapid loss of serum DSA which is far quicker than that 
predicted by the half-life of serum IgG; ie this is probably an active process.  In 
contrast, with the absence of a rejection process following an early response there is 
usually sustained circulating antibody levels  (figure 1.21). 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  David	  Lowe	  PhD	  Thesis	  2013	  	  
	   67	  
 
Figure 1.21: Daily monitoring of DSA levels- examples from our local cohort. The 
top graph shows DSA bead MFI levels in a patient who developed rejection at day 11. 
Pre-transpant levels show reduction following successive plasma exchange treatments. 
Post-transplant (day 0), DSA is seen to rise from day 7 and fall from day 10. The 
bottom graph shows DSA changes in a patient who did not experience a rejection 
episode despite a much more rapid onset rise in DSA levels followed by sustained 




Figure 1:  The graph on the left (a) shows donor specific antibody (total IgG) levels as bead MFI (y 
axis) in a patient who developed rejection at day 11.  Pretransplant levels show reduction following 
successive plasma exchanges.  Post transplant (from day 0) DSA rises from about day 9.  Graph (b) 
shows DSA IgG changes in a patient who did not undergo rejection with a more rapid DSA onset 
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The daily monitoring of DSA in antibody incompatible transplantation has 
allowed us to observe three fundamental immunological phenomena; (1) an early 
humoral response which is damaging in some cases but not others, (2) antibody 
modulation as a result of the rejection process or its treatment, (3) active IgG removal 
from circulation. The identification of factors that may predict rejection is crucial, as 
rejection cannot be predicted based upon changes in DSA levels alone.  
	  
   
1.12 Hypothesis / aims  
 
Organ  transplantation has always been one of the major service areas of the 
Birmingham Histocompatibility and Immunogenetics (H&I) laboratory which has 
supported the West Midlands organ transplant programmes for over thirty years. The 
development and growth of renal transplantation in this region has always been 
accomplished by the laboratory working in partnership with the clinical units. Antibody 
incompatible transplantation requires a particularly close working relationship between 
laboratory and transplant unit in order to control the risks associated with this form of 
treatment and develop it further. The expansion of the programme of HLA incompatible 
transplantation nationwide requires the rapid development of UK H&I laboratories in 
order to provide a high level of service support to such schemes. At the University 
Hospital Coventry and Warwickshire NHS Trust programme we are leading the way in 
HLA antibody incompatible transplantation and have undertaken over 100 cases to date. 
The project will use soluble HLA proteins (sHLA), produced via collaboration 
with Dr William Hildebrand at the University of Oklahoma, USA, to investigate the 
means by which the epitope specificity of anti-HLA antibodies can be determined using 
current screening methodologies. In addition the definition of exact epitope specificity 
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will facilitate attempts to quantify the exact concentration of HLA-specific antibody in 
the circulation, something which has hitherto not been achieved. 
I  will explore the potential influence of IgG subclass distribution on the 
pathogenicity of the anti-HLA response. Using our unique archive of daily samples 
from over 100 HLA incompatible transplants performed to date, I will investigate how 
the subclass specific IgG profile may alter through the course of a HLA incompatible 
transplant and assess whether any changes correlate with clinical outcome. 
The project will also explore the possibility of developing a device to selectively 
remove HLA specific antibody from the patient prior to transplantation. Current 
technologies do not provide the specificity and often remove antibodies to other targets 
which may compromise patient immunity. Therefore we aim to develop a device in the 
form of  a column containing HLA antigen bound onto a substrate, through which the 
patient’s plasma will be passed and the HLA antibodies removed. 
The competing solutions most frequently used are plasma exchange; double 
filtration plasmapheresis; immunoadsorption with columns containing polyclonal 
antibodies against human immunoglobulins and with columns containing 
staphylococcal protein A. These solutions have several shortcomings: (a) all are non-
specific, removing antibodies against all antigens, rather than just against the donor 
kidney, resulting in increased infection rate, (b) effective removal of HLA antibodies by 
treatment of high volumes of plasma is not possible with plasma exchange and 
plasmapheresis, (c) double filtration plasmapheresis is frequently associated with 
complications such as fluid shift, hypotention and perioperative bleeding; d) in columns 
that remove just immunoglobulins, removal may be incomplete, especially in the case 
of Protein A, which does not remove IgG3 and IgM effectively. The competitive 
advantage will be specificity, tolerability, safety and effectiveness of the proposed 
columns containing HLA antigen. The device is designed to remove only antibodies 
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against HLA, leaving the remaining humoral immunity intact. The device will be well 
tolerated, reducing the likelihood of fluid shifts, hypotension and perioperative 
bleeding, as one would expect from experience with the Glycorex immunoadsorption 
columns for blood group antibodies. This allows larger volumes of plasma to be treated 
than possible with conventional plasmapheresis. This will both make HLA antibody 
incompatible treatments more effective and safer, opening kidney transplantation to 
patients currently ineligible for antibody incompatible transplantation, such as those 
without living donors, restricted to waiting for a deceased donor transplant, and those 
with significant comorbidity factors. 
 The ability to isolate HLA-specific antibody from patient serum using a HLA 
protein column will provide a novel means with which to study these antibodies. 
Purified antibody preparations will be used to investigate the epitope specific nature of 
antibody binding, and also to define the factors that may be involved in determining the 
functional capacity of these antibodies, and the implications upon graft survival. 
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2.1 BACKGROUND 
 
 This project used a range of standard protein chemistry techniques to purify  
proteins for further analysis. The following sections describe all of the techniques used 
in detail. In addition, the project employs a range of standard assays used in the 
Birmingham Histocompatibility and Immunogenetics laboratory, the techniques given 
here represent those used in the clinical laboratory. 
 All commercially available kit-based assays were performed as according to 
manufacturers’ recommendations, with the exception of microbead assays for HLA-
specific antibody determination which were modified to use reduced reagent volumes in 
order to abrogate the high costs of the assays. 
Blood samples and other human fluids used in this thesis were obtained from 
patients undergoing HLA antibody-incompatible renal transplantation at the University 
Hospital Coventry & Warwickshire. An informed consent was obtained from all 
patients and the study met with local ethics committee approval (Coventry Local 
Research Ethics Committee ref 055/10/03).  
 
 
2.2 HLA PROTEIN PRODUCTION AND PURIFICATION 
 
 The use of highly purified soluble HLA (sHLA) proteins form the basis of many 
of the methodologies used in this thesis. The two production methods which were used 
are described in detail below. These methodologies were kindly provided by Professor 
Paul Moss from the University of Birmingham [135] and Dr William Hildebrand from 
the University of Oklahoma in collaboration with the private biotechnology company 
Pure Protein LLC (Oklahoma City, USA)[136].  
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 Where sHLA is used to generate data, the exact source of the protein will be 
indicated in the relevant methods section. 
   
 
2.3 SOLUBLE HLA (sHLA) PROTEIN PRODUCTION AND PURIFICATION: 
BIRMINGHAM PROTOCOL 
 
All buffers used are listed in Table 2.1: 
 
2.3.1 Expression of sHLA (MHC class1 heavy chain and β2M in E.Coli) 
 
To make competent cells a single E.Coli colony was used to inoculate 5ml Luria 
Broth (LB) and then agitated at 37°C overnight. The cells were then transferred into 
200ml LB and grown at 37°C until the OD600 = 0.48. The OD600 reading is a measure of 
bacterial growth within a suspension. The preparation was then incubated on ice for 15 
minutes. Preparations were then centrifuged at 6000 rpm for 10 minutes at 4°C then re-
suspended in TFB1 buffer and incubated on ice for one hour.  Preparations were 
centrifuged once more at 6000 rpm for 10 minutes then re-suspended in 8ml TFB2 and 
incubated on ice for one hour. Samples were then distributed into 100-200µl fractions 
and stored at -70°C.  
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Table 2.1: Production of sHLA. The full list of buffers used in the production of 





Luria Broth (LB) 10g/l Trytone
5g/l Yeast
10g/l Sodium Chloride
TFB1 Buffer 30mM Potassium Acetate
100mM Rubidium Chloride
10mM Calcium Chloride
pH to 5.8 50mM Manganese Chloride
15% (v/v) Glycerol
TFB2 Buffer 25mM Calcium Chloride
10mM Rubidium Chloride
pH to 6.5 15% (v/v) Glycerol




Triton Wash 0.5% Triton X-100
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Transformation of Competent Cells 
 
To transform competent cells, 1-2µl of plasmid were added to 100-200µl of 
competent cells (use plasmid PGM17 for HLA-B*07:02 and PET23 for HLA-A*0201, 
as kindly provided by Professor Moss) and left on ice for one hour. Samples were then 
heat shocked in a water bath set to 42°C for exactly 45 seconds. Following the addition 
of 200µl LB, cells were shaken and incubated at 37°C for 1 hour. 200µl of cell 
preparation were put onto agar plates containing 0.02mg/ml Ampicillin and incubated at 
37°C overnight. 
 
2.3.3 Expression of MHC Class 1 and β2M. 
 
Sufficient LB was prepared and autoclaved in advance (typically four 2 litre 
flasks). Overnight cultures of transformed bacteria were prepared by pouring out 2 x 
40ml LB and adding 40µl Ampicillin stock (100mg/ml) and 1 colony from the 
transformed agar plate to each 40ml aliquot. This was done in duplicate in the event that 
one tube fails to grow. Incubated, shaking, at 37°C overnight.  
Subsequently, 1ml Ampicillin (100mg/ml) stock was added to each litre flask of 
media, 1ml of media was taken as a blank control for the spectrometer, and 10ml of 
overnight culture was added to each flask. Samples were incubated, shaking at 37°C for 
two hours until the OD600 = 0.3 – 0.6. Next, 0.5ml was taken for the pre induction 
sample protein gel analysis (see section 2.1.3 for protein gel protocol). Protein induction 
was instigated by adding 0.5ml 1M isopropyl-beta-D-thiogalactopyranoside (IPTG) to 
each flask (IPTG is a synthetic analogue of lactose which induces expression of cloned 
genes under the control of the lac operon), followed by incubation for a further 4-5 
hours. Another 0.5ml sample was taken for the gel, post induction sample (Figure 2.1). 
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The bacteria were then transferred into plastic containers and centrifuged in a 
pre-cooled centrifuge at 4000 rpm for 20 minutes. The supernatant was discarded and 
the pellet was re-suspended in 2ml cold PBS. The bacteria were kept on ice and 
transferred to a 50ml centrifuge tube. The container was rinsed with a further 2ml cold 
PBS. The bacteria were stored at -70°C at this stage until required. 
 
Figure 2.1: Protein gel image showing addition of IPTG has induced bacteria to 
produce MHC heavy chain. The pre-induction sample shows no protein band, whereas 
post-IPTG induction a protein band of approximately 40kDa is clearly visible and 
corresponds to induction of MHC class I heavy chain production. 
 
2.3.4 Purification of Protein Containing MHC Class I from Inclusion Bodies. 
 
The bacteria were allowed to thaw for a couple of hours at room temperature, 
and once thawed were kept on ice. Triton wash and Re-suspension buffer were prepared 
and placed on ice. The bacteria were then transferred to a glass beaker and placed on 
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ice. More PBS (up to 50% v/v) was added if required – this enabled more rapid 
sonication. Sonication was performed on ice, as it is vital the sample should not 
overheat. The next step was to add 0.1mM protease inhibitor (PMSF) and lysozyme 
(1.075ml of 10mg/ml per litre of bacteria) and incubated on ice for 30 minutes or until 
the sample had a gloopy consistency. Using the appropriate titanium horn, the bacteria 
were sonicated in bursts of 45 seconds, followed by 1 minute (between every 2 bursts) 
on ice to allow the sample to cool down. This was repeated at least 5 times until the 
sample was completely lysed. The sample was stored on ice again for 30 minutes to 
allow the lysozyme to completely breakdown any non-protein material. 
The sonicated sample was then spun in a pre-cooled (4°C) centrifuge at 15000 
rpm for 10 minutes. The supernatant was discarded and 4ml per litre of Triton wash was 
added. The sample was transferred into a glass homogeniser using a disposable loop or 
re-suspended with a pastette and transferred to the homogeniser. The sample was 
homogenised until it was completely re-suspended then transferred into plastic 
containers and centrifuged at 15000 rpm for 10 minutes at 4°C. The supernatant was 
removed and this procedure was repeated twice i.e. a total of 3 washes. Whilst washing, 
if a green/brown scum was seen on the top of the pellet this was removed and discarded.  
After the final wash the supernatant was discarded and 2ml per litre of re-suspension 
buffer was added. The sample was transferred into a clean glass homogeniser and spun 
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2.3.5 Urea Solubilisation of Proteins Containing MHC Class 1 
 
 
To the pellet, 20ml (for 4 litres of bacteria) of freshly prepared Urea solution 
was added and re-suspended by vortexing. The pellet was incubated at 4°C overnight, 
rotating to allow the protein to solubilise completely. MHC class I heavy chain protein 
samples were centrifuged at 15000 rpm for 5 minutes at 4°C to remove any insoluble 
material. The protein was now suspended in the supernatant. The protein concentration 
was measured and dispersed into aliquots of 10mg/ml fractions in Eppendorf tubes and 
stored at -70°C. The protein should be stable for up to a year. 
 
2.3.6 Refolding MHC Class 1 and β2M in vitro 
 
Prior to refolding, 1 litre of the refolding buffer was prepared (table 2.1) and 
allowed to cool to 4°C for 1 hour, whilst being constantly stirred. Once chilled, the pH 
was adjusted to 8.3 and 1ml of 0.1M PMSF was added prior to the addition of the 
protein. 5mg peptide of choice (e.g. NLV, VTE) dissolved in 500ul DMSO, was then 
added to the refolding buffer. 10mg of β2M was thawed and transferred to a 50ml tube. 
Slowly, the refold buffer was added to the 50ml tube drop-wise. A total of 10-15 ml 
refold buffer was added slowly to avoid protein precipitation. Finally this mixture was 
added slowly into the 1 litre refold buffer with constant stirring allowing the β2M to 
refold in the absence of heavy chain for 30 minutes. One quarter of the total amount of 
heavy chain required (7.5mg at this stage) was thawed and diluted in 5M urea (to a 
concentration of 1mg/ml) and transferred to a 50ml tube. Slowly, the refold buffer was 
added to the 50ml tube drop-wise. After adding a total of 10-15 ml refold buffer this 
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mixture was slowly incorporated into the 1 litre refold buffer with constant stirring, as 
before. 
 The mixture was then left to refold overnight, with constant stirring. The refold 
was repulsed with heavy chain only using the method employed for previous additions. 
The refold was pulsed up to 4 times in a period of 24 hours until all 30mg were added. 
 
2.3.7 Concentration of Refolded MHC Class I Complexes. 
 
Before concentration, the refold was passed through 0.45uM filter to remove any 
aggregates. Next the refold mixture was added to a Millipore Amicon stirred cell Model 
8400 filter, fitted with a 10,000 MW polyethersulfone (PES) membrane and 
concentrated under 50psi pressure with Nitrogen gas. The procedure was repeated until 
all the refold mixture was concentrated. The refolded protein was captured on the 
membrane so it was not allowed to dry out. The refold was concentrated from 1 litre to 
5-10ml and filtered through a 0.45 syringe filter prior to buffer exchange (see protein 
concentration and buffer exchange protocol in section 2.5.2).  
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2.4 SOLUBLE HLA (sHLA) PROTEIN PRODUCTION AND PURIFICATION: 
OKLAHOMA PROTOCOL 
 
The following protocol is used to create soluble class I and II HLA proteins and 
is in routine use in the research laboratory of Dr William Hildebrand at the University 
of Oklahoma. The proteins are also produced commercially by this same method by 
Pure Protein LLL (Oklahoma City USA). I received training and experience of the 
technique described here whilst on secondment to the University of Oklahoma and Pure 
Protein LLC in April 2011. The majority of the proteins produced for use in this project 
were supplied directly by Pure Protein LLC under the terms of an official collaborative 
agreement between University of Oklahoma, Pure Protein LLC, University of Warwick, 
and University Hospital Coventry and Warwickshire NHS Trust. 
 
 
2.4.1 Soluble Class I HLA Protein Production 
 
 
To produce secreted HLA Class I, α-chain cDNA of HLA-A, B, or C was 
modified at the 3' end by PCR mutagenesis to delete codons encoding the 
transmembrane and cytoplasmic domains and to add the VLDLr purification epitope 
(Figure 2.2). 
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Figure 2.2: Schematic representation of the cDNA use to produce the α-chain 
domains of secreted HLA class I. The codons encoding the transmembrane (TM), and 
cytoplasmic domains (C) were deleted, and a VLDL expression tag was incorporated. 
 
The resulting construct was cloned into the mammalian expression vector 
pcDNA3.1(-) that contained a geneticin resistance cassette. Class I HLA deficient 
human cell line 721.221 [137] was transfected with this expression construct and drug 
resistant clones were selected in growth media containing G418, an aminoglycoside 
antibiotic [138], at a concentration of 0.8mg/ml (see figure 2.3A), in addition β2m 
protein was added from glycerol stock at a concentration of 0.5mg/ml. sHLA 
production was measured using a capture ELISA where W6/32 was the capture 
antibody and anti-β2m was the detecting antibody. sHLA producing clones were sub-
cloned into 96 well plates by limiting dilution and high producing sub-clones were 
expanded and seeded in AccuSyst-Maximizer hollow fibre bioreactor (Biovest 
International, Tampa, USA).  
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Figure 2.3: Overview of sHLA class I production. A) HLA constructs are first cloned 
into HLA class I deficient human cell-line 721.221. B) High sHLA producing clones 
were seeded into large hollow fibre bioreactors and the secreted sHLA was hervested. 
C) sHLA is purified by passage through a W6/32 affinity chromatography column. 
 
Approximately 500 mg of sHLA was harvested from the sub-clones on the 
bioreactor (figure 2.3B). Supernatant containing sHLA was loaded on a W6/32 
immunoafffinity column and washed with 40 column volumes of 20mM phosphate 
buffer pH 7.4. Class I sHLA molecules were eluted from the affinity column with 
50mM DEA at pH 11.3, neutralized with 1M TRIS pH 7.0, and buffer exchanged and 
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2.4.2 Class II sHLA Protein Production.  
 
To produce secreted Class II sHLA molecules, α-chain cDNAs of HLA-DRA1, 
DQA1, DPA1 and HLA-DRB1,DRB3,DRB4,DRB5,DQB1,DPB1 were modified at the 
3' end by PCR mutagenesis to delete codons encoding the transmembrane and 
cytoplasmic domains and to add the leucine zipper domains. For DRA1,DQA1 and 
DPA1 a 7 amino acid linker (DVGGGGG) followed by leucine zipper ACIDp1 was 
added. For DRB1, DQB1, DPB1 the same linker was used, followed by leucine zipper 
BASEp1 sequence. The addition of the leucine zipper enables the α and β chains of the 
class II molecule to maintain native conformation (Figure 2.4). The HLA class II 
molecule exists as an alpha/beta heterodimer and replacing the transmembrane and 
cytoplasmic domains with the complemenatary leucine zipper domains ACIDp1 and 
BASEp1 produces the correct conformational structure. 
The class II sHLA-DRA1, DPA1, DQA1 was cloned into the mammalian 
expression vector pcDNA3.1(-) (Geneticin, Invitrogen, CA, USA) and sHLA-DRB1, 
DQB1, DPB1 was cloned into pcDNA3.1(-) (Zeocin, Invitrogen, CA, USA).   The HLA 
class II deficient mouse B-LCL cell line NS1 (ATCC # TIB-18) was transfected by 
electroporation simultaneously with sHLA-DRB1 and DRA1, DQB1, and DQA1, 
DPB1 and DPA1.   
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Figure 2.4:  Diagrammatic representation of the cDNA constructs used to produce 
the HLA class II proteins. The transmembrane domains (TMD) were removed and 
two complementary leucine zipper domains (LZA, LZB) were added to each chain to 
maintain the structural stability of the sHLA class II protein. 
  
 
Two days post-electroporation, cells were transferred into selective growth 
media containing antibiotics G418 (0.8 mg / ml) and zeocin (1mg/ml). Drug resistant 
stable transfectants were tested for production of sHLA class II molecules by sandwich 
ELISA using L243 (Leinco Technologies, St Louis, USA) as a capture and a 
biotinylated anti-HLA class II commercial antibody for detection (Product number 
FH0002, One Lambda Inc, CA, USA). Positive cells were sub-cloned into 96 well 
plates by limiting dilution. Individual wells with clonal cell populations were tested for 
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the production of sHLA class II by ELISA and high producers were expanded in an 
AccuSyst-Maximizer hollow fiber bioreactor (Biovest International, Tampa, USA).  A 
saturating capacity of approximately 200 mg of sHLA-DR11 was harvested from each 
bioreactor. sHLA-DR/DP/DQ containing supernatant  was loaded onto L243 or anti-
leucine zipper immuno-afffinity columns and washed with 40 column volumes of 
20mM phosphate buffer pH 7.4. Class II sHLA molecules were eluted from the affinity 
column with 50mM DEA at pH 11.3, neutralized with 1M TRIS pH 7.0, and buffer 
exchanged and stored at 1 mg/ml in sterile PBS.  
 
 
2.4.3 sHLA Purity Analysis 
 
 The purity of the sHLA complexes were assessed and analysed using mass 
spectroscopy (MS). Ten microgrammes of sHLA was reconstituted in 30µl 25mM 
ammonium bicarbonate in ultrapure water. The protein samples were then reduced by 
the addition of 1.5µl of 100mM DL-Dithiothreitol (Sigma-Aldrich, UK), to give a final 
concentration of 5mM. The samples were immediately incubated at 95°C for five 
minutes to allow sample reduction. Proteins were then alkylated by adding 3µl of 
100mM iodoacetamide (Thermo-Scientific, Loughborough, UK) to give a final 
concentration of 10mM followed by incubating in the dark for 1 hour at room 
temperature.  A two-step protein digestion was then performed by first adding 1µl of 
100ng/µl MS grade L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK) treated 
trypsin (Thermo Scientific, Loughborough, UK) for a 1:100 w/w enzyme protein ratio 
followed by incubation at 37°C for three hours. The same amount of trypsin was then 
added again to adjust the w/w enzyme/protein ratio to 1:50 and the samples were 
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incubated at 37°C overnight.  The protein digestion was then stopped by adding 20µl 
1% trifluoroacetic acid (TFA) followed by drying in the speed-vac (Eppendorf, UK) 
without heat. The digested tryptic peptides were then reconstituted in 30µl of 30% 
acetic acid / 70% ultra-pure water and 5µl was then loaded onto the UltiMate 3000 
HPLC system (Dionex, CA, USA) using a PepMap100 C18 75µm x 15cm, 3µm 100Å 
reverse phase column. Peptides were eluted using H2O/acetonitrile (20:80v/v), 0.08 
formic acid as the solvent at the following gradient: 2% for 4 minutes, 2-10% for 1 
minute, 10-35% for 45 minutes, 35-70% for 10 minutes, 70-80% for 3 minutes, hold at 
80% for 2 minutes, then 80% reducing to 2% in 2.5 minutes. The gradient was then held 
at 2% for 20 minutes. Peptides were analysed on a QTOF Qstar Elite mass spectrometer 
(ABI MDS Sciex, Framingham, USA) and analysed with Mascot software. Figures 2.5 
and 2.6 show the MS analysis of sHLA-A2 and DR11 constructs. 
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Figure 2.5: Mass spectroscopy analysis of sHLA-A2 proteins. Top panels represent a 
close-up view of the bottom panel broad purity analysis and show the minimal protein 
contamination in either the β-2 microgolublin or α-chain fractions. 
Mass$(da)$ Mass$(da)$
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Figure 2.6: Mass spectroscopy analysis of sHLA-DR11 proteins. Top panels 
represent a close-up view of the bottom panel broad purity analysis. Glycoforms of both 
the DRBα and β chain show minimal protein contamination. 
Mass$(da)$ Mass$(da)$
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2.5 PROTEIN CHEMISTRY TECHNIQUES 
 
 The following section describes the techniques used to handle proteins for use in 
various sections of the study. The ability to correctly identify, analyse, and quantify 
specific protein preparations underpins many of the practical elements of the study. 
Where applicable the names of kit manufacturer’s are given and the detailed 
composition of proprietary buffers has also been provided.   
 Values given to represent protein concentration will have been determined by 
either the BCA assay method, or by direct nanodrop OD280  measurement. This will be 
stated in the text where required. In some instances where both techniques have been 
used to quantify a specific protein concentration, a composite concentration value will 




2.5.1 Protein Gel Electropheresis. 
 
 This technique uses SDS-PAGE (sodium dodecyl sulfate - polyacrylamide gel 
electrophoresis) to separate proteins according to their size, and no other physical 
feature. SDS denatures the proteins into a linear conformation and coats the protein with 
a negative charge [139]. 
Prior to protein gel electropheresis sample buffer stock for reducing or non-
reducing conditions was prepared as required to the recipe given in table 2.2. Generally, 
20µl each sample was added to 20µl loading buffer. If reducing conditions were 
required, for example to break down the IgG molecule into its constituent heavy and 
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light chain components, samples were incubated at 60oC for 10 minutes following 
addition of reducing agent as outlined in table 2.2.   
 
Table 2.2: Sample buffer stock preparation for protein gel electrophoresis. 




NuPAGE 4-12% Bis-Tris gradient gel (Invitrogen, CA, USA) was removed 
from the packaging and the adhesive strip was removed to expose the electrode. 
Holding the sides of the gel cartridge firmly, the comb that protects the wells of the gel 
was carefully removed taking care not to damage the wells. Preservative was thoroughly 
rinsed from the wells with ddH20. The gel was placed in the central chamber of the 
electropheresis chamber and locked into place. The gel chamber was filled with either 
MES or MOPS buffer as detailed in table 2.3 ensuring that the top portion of the gel 
was fully submerged. MES and MOPS buffer can be used interchangeably distinguished 
by a slight difference in the alkaline pH of each buffer. 
  
Sample Buffer Stock Reducing Non-Reducing
4X NuPage LDS sample buffer (Invitrogen CA, USA) 200ul 280ul
(70% Glycerol, 10% Lithium dodecyl sulfate
ddH20 120ul 200ul
10X NuPage Sample Reducing Agent (Invitrogen CA, USA) 80ul 0ul(500mM&dithiothreitol)
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Samples were then loaded into the wells of the gel. In lane 1 of the gel 5µl of 
appropriate protein size ladder was loaded to assess size of protein product in sample 
well. The most commonly used protein size marker ladder was the Seeblue plus2 
protein standard (Invitrogen CA, USA), which consists of 10 pre-stained protein bands 
in the size range 4-250kDa (figure 2.8). 20µl of sample/loading buffer mixture was 
loaded into the other wells of the gel as required.  The lid was then placed on the gel 
tank and electropheresis was performed at 200V for 35 minutes.  
 Following electropheresis the Bis-Tris gel was removed from the gel cartridge 
and placed into a gel-washing basket. The gel was then submerged in double-deionsied 
water (ddH20) and microwaved at full power (850W) for 10 seconds. The ddH20 was 
then exchanged for fresh ddH20 and the wash procedure was repeated twice more. The 
gel was then submerged in Coomassie blue stain (Invitrogen CA, USA) and placed on a 
rotary stirrer until protein bands were clearly visible. 
  
MES Buffer MOPS Buffer
30ml 20X MES SDS (Invitrogen CA, USA) 30ml 20X MOPS (Invitrogen CA, USA)
(5% Sodiumdodecyl Sulphate) (20% 4-Morpholinepropanesulfonic acid, 10% TRIS Base, 5% sodium dodecyl sulfate)
570ml ddH20 500ml ddH20
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Figure 2.9: Invitrogen Seeblue Plus2 protein marker. A range of protein markers of 
various sizes are provided with the approximate molecular weight values given for a 
range of sample buffers including MES and MOPS. 
 
 
2.5.2 Protein Concentration and Buffer Exchange 
  
 This project relies heavily upon the production of purified sHLA proteins and 
HLA-specific antibodies selectively isolated from patient samples (see sections 2.8.3 
and 2.8.4). The protocols required to isolate these proteins often leads to a protein eluate 
that is high in buffer volume and consequently the concentration of the desired protein 
is often low. In addition the buffers required to elute specific proteins are often of 
extreme pH (acidic or alkaline depending on the nature of the protein being eluted), and 
unsuitable for long-term protein stability. Therefore it is important to have a robust 
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protocol in place to be able to concentrate the protein down to a usable concentration, 
whilst at the same time exchanging the elution buffer for a more physiologically stable 
storage buffer, such as phosphate buffered saline (PBS) pH7. 
Soluble HLA (sHLA) protein and HLA-specific antibody preparations were 
concentrated and buffer exchanged using 3000 molecular weight cut-off (MWCO) 20ml 
centrifugal spin concentrators (Vivaspin 20, Sartorius Stedim, UK).  
 To prepare the concentrator, 15ml PBS pH7.4 was added to the concentrator 
then centrifuged at 3000g for 30 minutes. The filtrate was then discarded and the 
concentrator was topped up with up to 15ml of protein sample solution then centrifuged 
again at 3000g for 30 minutes. The filtrate was then saved into an appropriately labelled 
500ml bottle and stored to guard against loss of protein at this stage. The entrapped 
concentrate was topped up with 15ml fresh PBS pH7.4 and centrifuged at 3000g for 45 
minutes (figure 2.10).  
 
 
Figure 2.10: Protein concentration using a 3000 MWCO spin concentrator. 
Proteins larger then 3000MW are retained in the upper filter capsule, whilst smaller 
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 The procedure was then repeated three more times so that complete buffer 
exchange can occur. The entrapped concentrate was then carefully removed using a fine 
tipped pipette. The concentrator was flushed with 200µl fresh PBS pH7.4 and this was 
combined with the concentrated protein sample. The sample was then prepared for 





2.5.3 Protein Quantification using BCA Assay 
  
Bicinchoninic acid (BCA) protein assay kit was used to determine the 
quantitation of total protein (Thermo Scientific, Loughborough, UK). The BCA assay 
relies on the reduction of Cu2+ to Cu1+ by protein in an alkaline medium with the 
highly sensitive and selective colorimetric detection of the cuprous cation (Cu1+) 
by bicinchoninic acid. Via a two-step process in which protein is chelated with 
copper, BCA invokes a colour change upon reaction with the reduced (cuprous) 
cation that was formed in step one [140]. 
Protein concentrations are generally determined in reference to standard 
dilutions of a common reference protein such as bovine serum albumin (BSA). Addition 
of BCA assay working reagent provides a colourimetric reaction, the intensity of which 
is detected by absorbance at 562nm and displays a near linear relationship with 
increasing protein concentrations. 
 Albumin BSA standards were prepared in the range 0-2000µg/ml by dilution of 
stock concentration with PBS pH7.4. Test samples were prepared at neat and 1 in 10 
dilution and 100µl of each sample and diluted standard was added to  disposable 
cuvettes. Each sample was set up in triplicate. All test and standard samples were then 
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incubated at 22°C for 2 hours. Samples were tested for absorbance at 562nm using a 
Perkin Elmer Lambda 2 spectrophotometer (Perkin Elmer, Waltham, USA). A cuvette 
filled with ddH20 was used to zero the instrument. The 562nm absorbance value of the 
blank BSA reference was subtracted from the 562nm absorbance reading of all other 
individual standard and test sample replicates. The mean 562nm absorbance of the 
diluted standard triplicates were plotted to produce a standard curve (Figure 2.11). 
Protein concentrations of test samples were determined by comparing the mean of the 
test sample triplicates against the standard curve.  
 
 
Figure 2.11: Colour response standard curve for bovine serum albumin (BSA) 
prepared for determination of protein concentration using the BCA assay (Thermo 
Scientific, Loughborough, UK). Absorbances of test samples at 562nm can be read 
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2.5.4 Protein Quantification Using Nanodrop 
  
The NanoDrop 1000 spectrophotometer (Thermo Scientific, Loughborough, 
UK) will accurately measure protein samples in the range of 0.1-100mg/ml. The protein 
A280 function was used to measure absorbance at 280nm of purified protein. Proteins 
that contain tryptophan (Trp), Tyrosine (Tyr), or cys-cys disulphide bonds will absorb 
in the ultra-violet (UV) range (280nm is indicative). Based on the absorbance values of 
these residues it is possible to extrapolate and give an accurate estimation of total 
protein content within a sample [141]. 
 To assess protein concentration 2µl ddH20 was pipetted on to the sample 
pedestal to initialise the NanoDrop. A blank measurement was then taken using 2µl 
PBS pH7.4. Protein concentration of test samples was then determined by subtracting 
blank absorbance from the measured absorbance at 280nm of each sample. 
 
 
2.6 HISTOCOMPATIBILITY AND IMMUNOGENETICS TECHNIQUES 
 
 The following section describes various techniques used in the 
Histocompatibility and Immunogenetics department at NHSBT Birmingham. The 
evolution and clinical relevance of these techniques have been discussed in the 
introduction section, this section describes how the tests are performed and interpreted 
in greater detail. 
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2.6.1 Isolation of Lymphocytes from Peripheral Blood 
  
Lymphocytes are isolated from human peripheral blood samples using density 
gradient separation medium (Lympholyte-H, Cedarlane Labs, Burlington, Canada). The 
cell population resulting from the following protocol is enriched for viable human 
lymphocytes and monocytes [142]. The use of purified lymphocyte populations is 
integral to accurate cytotoxic and flow cytometry crossmatch procedures.  
 Human blood was collected in a suitable tube containing anticoagulant (usually 
EDTA) and diluted 50:50 with cell culture medium (RPMI 1640, Gibco, UK). Diluted 
blood was then layered slowly over Lympholyte-H in a 2:1 ratio i.e 14ml diluted blood 
layered over 7ml Lympholyte-H, keeping mixing at the blood/Lympholyte-H interface 
to a minimum. Samples were then centrifuged at 1000g for 20 minutes at room 
temperature. This results in a clear lymphocyte/monocyte layer, with red cells clumped 
below the lympholyte-H layer (Figure 2.12). 
The lymphocyte/monocyte layer was then carefully removed with a 2ml pasteur 
pipette and transferred to a clean tube. The cell suspension was then topped up with 5-
10ml PBS pH7.4 and centrifuged at 300g for 10 minutes to clear platelet contamination. 
The supernatant (containing the platelets) was then discarded and the sample was again 
re-suspended in 5-10ml PBS pH7.4 and centrifuged at 200g for 5 minutes. The resulting 
supernatant should be clearer at this stage as platelets are removed with each wash. 
Centrifugation at 200g for 5 minutes was repeated 2-3 times until the supernatant was 
clear and free of contamination. Cell preparations were then suspended in culture 
medium prior to use.  
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Figure 2.12: Density gradient centrifugation for leukocyte isolation. Following 
centrifugation at 1000g for 20 minutes the leukocytes form a distinct layer above the 
density gradient medium that can then be removed for further processing. 
 
 
2.6.2 T And B Lymphocyte Separation 
  
In the case of cytotoxic crossmatching it is often necessary to further delineate 
enriched lymphocyte populations into its separate T and B lymphocyte subsets due to 
the differential expression of MHC class I and II (T lymphocytes express only class I, 
whereas B lymphocytes express class I and II). Partition of lymphocyte preparations 
into T and B lymphocyte subsets was achieved using HLA Class I/II dynabeads 
(Invitrogen, CA, USA). Dynabeads are magnetic particles coated with monoclonal 
antibody; T-cell specific dynabeads are coated with an anti-CD8 monoclonal antibody 
and B-cell specific dynabeads are coated with a monoclonal antibody specific for a 
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 Purified lymphocyte preparations were re-suspended in 1ml PBS pH 7.4 
containing 0.6% citrate and chilled at 4°C for 5 minutes. Next, 15µl either HLA-class I 
or class II dynabeads were added and the sample was incubated for 5 minutes at 4°C. 
The sample was placed on a tube roller at this point to ensure complete mixing of cells 
and dynabeads. Samples were then topped up with 4ml cold PBS pH7.4 containing 
0.6% citrate and tubes were placed into a magnetic particle concentrator (MPC) for two 
minutes. The supernatant was then decanted into a fresh tube and labelled as a B/T-cell 
depleted fraction, ensuring that the sample tube remains in place inside the MPC at this 
point or isolated beads and cells will be lost. The original sample tube was then 
removed from the MPC and the beads were re-suspended in 4ml chilled PBS pH7.4 and 
returned to the MPC for 1 minute. The supernatant was then discarded, again ensuring 
that the tube remains inside the MPC. The bead/cell suspension was then suspended in 




2.6.3 Complement Dependant Cytotoxic (CDC) Crossmatch 
 
  
Complement dependant cytotoxicity (CDC) is an assay used to determine 
immunological compatibility between potential organ donor and recipient prior to 
transplant [25]. Binding of immunoglobulin to HLA molecules on the donor cell surface 
leads to effective cross-linking of IgG by C1q resulting in activation of the classical 
pathway of the complement cascade and subsequent cell death. 
 Preparations of separated T and B lymphocytes (see section 2.6.2) were 
standardised to 2x106/ml in RPMI using a Neubauer counting chamber. CDC plates 
were first prepared by adding 20µl of mineral oil to each well. The plate was then 
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prepared with 2µl sample sera, positive and negative control sera into the appropriate 
wells. 
 One µl dithiothreitol (DTT) was added to specific wells to differentiate between 
CDC positivity caused by IgM and IgG. DTT disrupts the inter and intra-chain 
disulphide bonds prevalent in immunoglobulin structure (refer back to figure 1.13). The 
concentration of DTT was optimised to 20µM to disrupt the disulphide bond structure 
of pentameric IgM leaving IgG intact. The plate was then incubated at 37°C for 30 
minutes. To each well, 1µl of standardised cells (B or T cells as required) were added 
and the plates were incubated at 22°C for 60 minutes. Lyophilised rabbit serum 
(Cedarlane, UK) was reconstituted using 2ml distilled water and 5µl was added to each 
well as a source of complement. The plates were once again incubated at 22°C for 60 
minutes. Fluoroquench (One Lambda Inc, CA, USA), a cocktail of fluorescent dyes to 
stain lymphocytes and quench background fluorescence, was added to each well (5µl). 
Cells were then visualised using ultra-violet microscopy. Live cells stain green and dead 
cells stain red, positivity is determined by calculating the ratio of live/dead cells (figure 
2.13). 
 
Figure 2.13: Electron microscope images depicting examples of negative and 
positive cytotoxic crossmatch positive sera. Dead cells stain red under UV light due to 
ethidium bromide staining of nuclear DNA in ruptured cells. 
  
!!!!Pre%column! !!!!Post%column! !!!Peak!Elu1on!!Pre%colum !!!!Post%column! !!!Peak!Elu1on!CDC Negative CDC Positive 
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2.6.4 Flow Cytometry (FC) Crossmatch 
  
Flow cytometry crossmatching (FCXM) provides additional sensitivity 
compared to CDC. The method relies upon direct detection of donor specific IgG 
binding to lymphocyte subsets, and is therefore able to detect all bound IgG not just 
those that are capable of complement fixation [113]. 
 Purified lymphocyte preparations from the potential donor were standardised to 
12x106/ml in PBS pH7.4 containing 2% BSA. A negative control serum consisting of a 
pool of five blood group AB male blood donors previously shown to be negative for 
anti-HLA reactivity was prepared, as well as a positive control serum which was a pool 
of ten highly sensitised renal transplant waiting list patients. 
 Sample tubes were prepared by adding 25µl cells to 25µl serum. Control and 
test samples were set up in duplicate and then incubated at 22°C for thirty minutes. 
Samples were then washed three times in PBS pH7.4.  To each tube 100µl fluorescein 
isothiocyanate (FITC) conjugated goat anti-human IgG (working dilution 1:100) was 
added. Tubes were mixed thoroughly and incubated at 4°C for 15 minutes. Samples 
were then washed once more in 4ml PBS pH7.4. Then for B cell FCXM 100µl 
phycoerythrin (PE) conjugated mouse anti-human CD19 (working dilution 1:20) was 
added. For T cell FCXM 100µl phycoerythrin (PE) conjugated mouse anti-human CD3 
(working dilution 1:20) was used. Samples were incubated once more at 4°C for 15 
minutes then washed again in 4ml PBS pH7.4. Samples were re-suspended in 200µl 
PBS pH7.4 containing 2% BSA and 0.01%NaN3 ready for analysis. 
 Tests and controls were then analysed on a BD FACSCanto II flow cytometer 
(Becton Dickinson, UK).  For each sample 10,000 individual cells, or events, were 
counted and the median fluorescence values of controls and test samples were 
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determined. Figure 2.14 shows examples of negative and positive control samples when 
analysed using the T-cell specific (CD3) FCXM.  
The definition of positivity regarding the flow cytometry crossmatch varies 
between laboratories and is often dependant upon local policy based upon clinical 
outcomes. In the Birmingham Histocompatibility and Immunogenetics laboratory 
crossmatch positivity is calculated as the median fluorescence of the IgG FITC detector 
divided by the median fluorescence of the negative control sample to provide a ratio 
termed the relative median fluorescence (RMF). In our laboratory RMF>2.3 denotes a 
positive crossmatch.  
 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  David	  Lowe	  PhD	  Thesis	  2013	  	  




Figure 2.14: Flow cytometry crossmatch histograms. Negative crossmatch (top 
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2.7 LUMINEX MICROBEAD ANTIBODY SCREENING AND 
IDENTIFICATION 
 
 As outlined in the introduction, the development of recombinant HLA proteins 
coupled to microbeads has revolutionised the way in which laboratories are able to 
define HLA-specific antibodies [114]. At present these microbead preparations are 
supplied by two manufacturers, One Lambda Inc, (CA, USA), and Gen-Probe, (CA, 
USA). Although the principle underpinning both manufacturers’ assays is the same 
there are a number of subtle differences in the way in which each assay is prepared and 
tested. The detailed protocols for each assay is described in this section. It is also 
important to note that both of these assays were developed purely as a qualitative tool 
only, the use of these assays to monitor the changes in antibody titre has been outside 
the scope of the original assay design. 
 
2.7.1 Sample Preparation  
 
 Serum samples were taken using BD Vacutainer (Becton Dickinson, UK) 5ml 
blood collection tubes containing silicone and micronized silica particles which act as a 
clot activator. All samples were given with full informed and written consent from 
patients participating in the HLA incompatible transplant programme at University 
Hospital Coventry and Warwickshire (UHCW), and ethical approval for these studies 
was applied for and obtained (Coventry Research Ethics Committee- CREC 055/01/03). 
Serum fractions were taken and frozen in 100µl aliquots until required.  
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2.7.2 Antibody Screening and Identification- One Lambda Assays 
 
Prior to testing samples were centrifuged at 13,000rpm for ten minutes. The 
required number of wells was prepared in a 96 well filter microplate (Millipore, UK) by 
the addition of 200µl One Lambda wash buffer. The wells were then applied to a 
vacuum to draw the wash buffer through the wells. Finally 20µl buffer was dispensed 
into each well. 
One tube of each required microbead preparation tubes (One Lambda Inc, CA, 
US) were placed into an ultra-sonic bath and subjected to ultrasonic agitation for five 
minutes in order to disperse any aggregated beads. The sonicated bead tubes were 
briefly centrifuged at 13,000rpm for ten seconds then vortex mixed for thirty seconds. 
To each well, 2µl of microbead preparation was added followed by 8µl of serum. One 
well containing HLA-specific antibody negative control serum, and one well containing 
multi-specific HLA antibody positive control serum was set up with each batch of 
testing. Test plates were then incubated between 18 and 22ºC in the dark for thirty 
minutes. Following incubation the wells were washed by adding 200µl wash buffer to 
each well. The plate was then applied to a vacuum to draw through the wash buffer and 
remove any non-specific binding. The wash step was repeated a further three times to 
give a total of four washes.  
A 1mg/ml stock concentration of phycoerythrin (PE) conjugated goat anti-
human IgG is supplied with each One Lambda kit. This reagent is light sensitive and 
must be stored and used with minimal exposure to natural light. This antibody was then 
diluted 1in100 with wash buffer to obtain the correct working concentration of 10µg/ml. 
To each well 40µl of diluted antibody was added and the plates were once again 
incubated between 18 and 22ºC in the dark for thirty minutes. Following the second 
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incubation the plates were washed four times as before using the vacuum filtration 
method, reactions were then re-suspended in 85µl wash buffer. Plates were then 
analysed using the Luminex™ Xmap 100 platform (Luminex Corp, US) and antibody 
data was analysed using the HLA Fusion software (One Lambda Inc, US). 
The assay set-up was outlined in figure 1.20. Figure 2.15 shows an example of the 
luminex antibody profile data. 
 
Figure 2.15: Example data from One Lambda single antigen microbead analysis. 
Class I HLA specific antibody positive profile, the patient reacts positively with beads 
specific for HLA-A2, A68, A69, B57, and B58. Positivity is determined by increased 
detection of fluorescently labelled human IgG specific secondary antibody, measured on 
the y axis as MFI (Mean fluorescence intensity). The principle of the assay is described 
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2.7.3 Antibody Identification- Gen-Probe Assays 
  
 Prior to testing samples and plates were prepared as for the One Lambda assay 
protocol. Gen-Probe bead preparations were also sonicated, centrifuged, and vortex 
mixed as for One Lambda bead sets. 
 To each microplate well, 20µl of microbeads were added, followed by 5µl of 
patient serum, negative and positive controls as required. Test plates were then 
incubated between 18 and 22ºC in the dark for thirty minutes. Following incubation, 
100µl of wash buffer was added to each well and then drawn through by application of 
a vacuum. Two further washes were then performed by adding 250µl wash buffer to 
each well followed by vacuum filtration.  
 Phycoerythrin conjugated anti-human IgG as supplied by the manufacturer was 
diluted 1 in 10 with wash buffer, then 20µl is added to each test well. Samples were 
then incubated for a second time between 18 and 22ºC in the dark for thirty minutes. 
Following second incubation samples were suspended in a further 100µl wash buffer 
and analysed on the Luminex™ Xmap 100 platform (Luminex Corp, US). Data were 
analysed using LifeMatch Quicktype analysis software version 2.2. 
 
 
2.7.4 IgG Subclass Specific Luminex Microbead Assay 
 
 Immunoglobulin G (IgG) can be present in any of four distinct isotypes (IgG1-4, 
see table 1.5), the presence of each of which confers a distinct set of functional 
characteristics upon a patients’ antibody repertoire. To investigate this we modified the 
standard microbead analysis method outlined in section 2.7 as follows. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  David	  Lowe	  PhD	  Thesis	  2013	  	  
	   108	  
The subclass specific luminex bead assay was carried out using exactly the same 
protocol as that given above for the use of One Lambda assays. Phycoerythrin (PE) 
conjugated goat anti-human IgG is substituted with each subclass specific phycoerythrin  
(PE) conjugated mouse monoclonal antibody (IgG1, clone 4E3; IgG2, clone 31-7-4; 
IgG3, clone HP6050; IgG4, HP6025, Southern Biotech, Birmingham, AL, USA).  The 
final concentration of each subclass specific antibody was 0.25µg/µl. Samples were 
analysed as before using the Luminex™ Xmap 100 platform (Luminex Corp, US) and 
antibody data was analysed using the HLA Fusion software (One Lambda Inc, US). 
This modified subclass detection assay was validated by preparing a panel of 
microbeads with each one coated with a separate IgG subclass anibody derived from the 
serum of multiple myeloma patients. The full details of this validation exercise are 
given in chapters 7 and 8. The method by which these proteins were coupled to 
microbeads is given below. 
 
 
2.7.5 Coupling Protein to Luminex Microspheres 
  
 To validate the modified assay to detect IgG subclass binding to microbeads a 
validation set of beads was prepared. Fresh microbead populations were activated and 
then coupled with IgG proteins of known IgG subclass. These had been isolated from 
the serum of patients with multiple myeloma. These antibody samples were kindly 
provided by Dr Mark Cobbold and Dr Margaret Goodall from the University of 
Birmingham, UK. 
 All buffers used in the process of coupling protein to luminex microspheres are 
listed in Table 2.4. 
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PBS, activation, wash, and storage buffers were prepared as listed in table 2.4. 
The region numbers of the microspheres were chosen such that there would be no 
coincidence with other microsphere regions, this is particularly important when 
designing multiplex analysis. Each isolated protein was coated onto its own unique 
microsphere region. The luminex analyser is able to sort individual beads within a set 
by virtue of unique fluorochrome ratios with which the beads are impregnated. Each 
ratio corresponds to an individual detection region, which the luminex analyser is able 
to discriminate. 
 Each region specific container of microspheres were vortex mixed for two 
minutes then centrifuged at 13,000 rpm followed by sonication for five minutes in order 
to fully disperse the microsphere pellet. Two hundred microlitres of each microsphere 
(approximately 2.6 x106 microspheres/ ml) were dispensed into separate wells of a 96 
well filter plate (Millipore, MSVHHTS00), this provided enough beads for around 50 
tests. The fluid was aspirated from each well using a Millipore vacuum manifold 
leaving the microspheres on the plate filter mesh. The beads were then washed once by 
Buffer Composition
Luminex Buffer 1L PBS
2g BSA (Sigma A4503)
500μl Tween20 (Sigma P.1379)
5ml 10% NaN3
Filter through 0.2μm and store at 2-8°C
Activation Buffer 3g NaH2PO4 (Sigma S0751)
250ml distilled water
adjust pH to 6.2 with 1M NaOH
Wash and Storage Buffer 200ml PBS
2g BSA (Sigma A4503)
100μl Tween20 (Sigma P.1379)
2ml 10% NaN3
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adding 200µl activation buffer to each well followed by vacuum filtration. Wells were 
then re-suspended in 200µl activation buffer. 
 Bead activation cocktail was then prepared by first dissolving 5mg N-
hydroxysulfosuccinimide sodium salt (Sulpho-NHS, Sigma, UK #56485) in 100µl 
activation buffer to give a 50mg/ml solution. Similarly, 5mg of 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hyrdrochloride (EDC, Sigma, UK #6383) was 
dissolved in 100µl activation buffer to give a 50mg/ml solution. Final coupling buffer 
was prepared by adding 10µl sulpho-NHS and 10µl EDC to 80µl activation buffer per 
microsphere (scaled up for coupling more than one microsphere region).  
 The activation buffer was aspirated from the microplate using the vacuum 
manifold. To each well of microspheres 100µl coupling buffer was added. The plate 
was then agitated gently in the dark at room temperature for 30 minutes. Excess 
coupling buffer was then removed by vacuum filtration. 
 Proteins to be coupled, in this case individual IgG preparations derived from 
multiple myeloma patients, were prepared by diluting in PBS to a concentration of 
1mg/ml and 100µl of each protein suspension was added to the appropriate microsphere 
well. The plate was then incubated in the dark for 3 hours at room temperature and 
under constant agitation. Wells were then washed three times using 200µl storage buffer 
and vacuum filtration. Microspheres were then re-suspended in 200µl storage buffer by 
vigorous vortex mixing and transferred to sterile 2ml microtubes. This process was 
repeated twice more to ensure no microspheres were left in the wells.  There was then 
600µl of microspheres at a concentration of 4x106 microspheres/ ml ready for use. 
Beads can be stored at 2-6°C for up to 6 months. 
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2.7.6 C1q Screen Assay 
 
 
 The ability of antibody to fix complement via the classical pathway is dependent 
upon the isotype of the antibody. As discussed earlier IgG1 and IgG3 are potent 
activators of complement whereas IgG2 and IgG4 are less so. To distinguish between 
complement and non-complement fixing anti-HLA antibodies One Lambda developed 
the C1qScreenTM assay, which uses microbeads to identify the specificities of anti-HLA 
antibodies capable of crosslinking with C1q and initiating the classical complement 




Figure 2.16: Principle of the One Lambda C1qScreenTM assay. The test allows the 
direct identification of those anti-HLA antibody specificities which have the capacity to 
bind human C1q and thus initiate the classical pathway of complement activation. 
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One Lambda C1qScreenTM assay was used to determine the presence of 
complement binding HLA specific antibodies in human serum [122-124]. To prepare 
the serum for analysis 40µl serum was transferred to a fresh 1.5ml Eppendorf tube and 
incubated in a water bath at 56ºC for thirty minutes in order to inactivate endogenous 
complement present in sera. The sample was then centrifuged at 13,000rpm for 10 
minutes and the clear serum supernatant (approximately 30µl) was decanted into a fresh 
1.5ml Eppendorf tube and then kept chilled on ice. 
 Human C1q protein was reconstituted in 10mM HEPES pH7.2 at a volume of 
1µl per test sample. The reconstituted C1q was then diluted a further four fold in 10mM 
HEPES pH7.2, thoroughly mixed via vortex and kept on ice prior to use.  
 Next, 5µl of the diluted human C1q was added to designated separate wells of a 
96 well microtitre filter plate, and 5µl of heat inactivated serum sample was added to 
each appropriate well. The plate was gently mixed before 5µl of class I or class II single 
antigen coated beads (LS1A04 / LS2A01, One Lambda Inc) was added to each well. 
The plate was then gently mixed by vortex mixing and incubated at room temperature 
for 20 minutes. The plate must be constantly agitated and protected from light during 
the incubation period. 
 Following incubation, 5µl of PE-conjugated anti-C1q as supplied by the 
manufacturer was added to each test well and thoroughly vortex mixed. Again the plate 
was incubated in the dark at room temperature for 20 minutes under constant agitation. 
To each well, 80µl of PBS pH7.4 was added and the supernatant was removed by 
vacuum filtration. A further 80µl of PBS pH7.4 was added to each well and the plate 
was then analysed on the Luminex™ Xmap 100 platform (Luminex Corp, US), and 
antibody data was analysed using the HLA Fusion software (One Lambda Inc, CA, US). 
A positive reaction threshold of >500 MFI was applied to all assays. 
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2.8 PROTOCOLS TO MANUFACTURE COLUMNS WITH BOUND sHLA 
 
 Current methods to remove HLA-specific antibody from patient blood both prior 
to and following solid organ transplantation are both inefficient and non-selective. 
Therefore humoral immunity of the patient is often compromised leading to increased 
risk of secondary complication such as infection. In order to remove anti-HLA antibody 
in a highly effective and specific manner we sought to design antibody removal 
columns using sepharose as a carrier matrix and soluble HLA proteins as the 
immobilised target antigen over which patient plasma would be passed. We have 
abbreviated the name of this column to soluble HLA antibody removal column 
(SHARC). Figure 2.17 shows both the mini- and clinical scale SHARC columns, the 
production and use of each of these is detailed in the following section.  
 
Figure 2.17: Examples of SHARC columns used in this project. The left panel show 
a 1ml column used to deplete small volume patient samples of HLA-specific antibody. 
The right panel shows a 50ml clinical scale SHARC column (circled) used to deplete 
larger volume patient samples. 
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2.8.1 Mini HLA-column Coupling Protocol 
 
The term mini HLA-column is used to describe sepharose coupled with HLA 
protein which is then packed into 2ml chromatography columns for the purpose of 
selectively depleting small volumes of patient serum or plasma samples of HLA-
specific antibody. Typically mini-HLA columns contain between 100µg and 1mg of 
sHLA protein coupled to up to 1ml of activated sepharose.  
To hydrate the sepharose, 200mg cyanogen-bromide (CNBR) activated 
sepharose (Sigma-Aldrich, UK) was resuspended in 2ml of 1mM hydrogen chloride 
(HCl) and chilled on ice for 30 minutes. The sepharose was centrifuged at 3000rpm for 
10 minutes then the supernatant was decanted. The sepharose was resuspended in 
suspension buffer consisting of 50mM HEPES pH7.8, and 100mM NaCl (Sigma-
Aldrich, UK) then centrifuged again at 3000rpm for 10 minutes. This stage was 
repeated twice more for a total of three washes. Next, 500µl suspension buffer was 
added to a clean 1.5ml Eppendorf tube and the CNBR resin was transferred into this to 
give an approximate total volume of 1ml and an approximate sepharose concentration 
of 2mg/ml. 
Soluble HLA (sHLA) was added to the sepharose at a concentration of 2mg per 
1ml of sepharose (for example add 200µg of sHLA to 100µl of activated sepharose). 
The sHLA/sepharose mix was incubated at 4oC for two hours whilst rotating constantly. 
The sepharose was centrifuged gently at 500rpm for 5 minutes then the supernatant was 
decanted into a fresh eppendorf tube. The A280 reading of the supernatant by nanodrop 
analysis (see section 2.5.4) was used to determine the amount of sHLA bound to the 
sepharose, aiming for >80% coupling efficiency. If <80% coupling was observed, the 
sample was incubated again for two hours at 4oC, then centrifuged at 500rpm for 5 
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minutes then protein concentration in the supernatant was determined. If required the 
steps were repeated again until >80% coupling efficiency was achieved. 
To deactivate the sepharose 1ml of 1M ethanolamine was added to the sepharose 
pellet and incubated at 4oC overnight whilst constantly rotating. The sample was then 
centrifuged at 500rpm for 5 minutes and the supernatant was then carefully discarded. 
The pellet was then resuspended in 1ml PBS pH7.4 and centrifuged at 500rpm for 5 
minutes. The supernatant was again discarded and the pellet was rinsed once more in 
PBS pH7.4 by addition of 1ml followed by centrifugation at 500rpm for 5 minutes. The 
pellet was then resuspended in an approximate equal volume of PBS pH7.4 and spiked 
with 0.02% sodium azide (NaN3) to act as a preservative. 
HLA protein coupled sepharose was then packed into a 2ml affinity 
chromatography column (Bio-rad Laboratories, CA, USA). To prepare the column filter 
mesh, 2ml of PBS was dispensed into the column. The flow tap was opened and the 
PBS was allowed to flow through the column and fully hydrate the filter. Up to 1ml of 
HLA coupled sepahrose was then added to the column, ensuring that the flow tap was in 
the closed position. The sepharose was then allowed to settle for up to one hour at room 
temperature. The flow tap was then opened and the excess PBS from the sepharose was 
allowed to flow through. The flow tap was closed before the PBS level dropped below 
the level of the sepharose, under no circumstances should the sepharose be allowed to 
dry out. A further 2ml of PBS was then added and allowed to flow through to the same 
level as before. The column was then resuspended in 2ml PBS containing 0.01% NaN3 
and stored at 4oC until ready for use. 
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2.8.2 Clinical Scale HLA-column Coupling Protocol 
 
  
 We define the term clinical scale HLA-column as being the required volume of 
HLA protein coupled to sepahrose to effectively deplete 2-3 litres of patient plasma of 
HLA-specific antibody. The calculations to determine the required protein 
concentration to achieve this were determined via extrapolation of mini-HLA column 
data and subsequent empirical testing using larger scale HLA-columns. The details of 
these validation experiments is provided in chapter 8, but a 60ml sepahorose column 
containing 50mg sHLA was used for clinical scale depletion experiments. 
For clinical scale protein coupling the same protocol was used as for mini-
column coupling, with one minor amendment being the addition of sHLA at a reduced 
concentration of 1mg per 1ml of swollen matrix. All other incubation times and wash 
steps were kept the same but volumes were scaled up accordingly.  
 Column packing was also performed as per the mini-column protocol but wash 
volumes were scaled up to take into account the 50ml volume capacity of the clinical 
scale column.  
 
 
2.8.3 Affinity Columns: HLA Specific Antibody Depletion using SHARC 
  
Up to 5ml of patient sera was loaded into the column reservoir and allowed to 
drip through by gravity by releasing the flow tap at the bottom. Fractions were collected 
drop wise into 96 well ELISA plates so that microbead analysis could be performed 
retrospectively (3 drops per well which was the approximate equivalent of 150µl). Flow 
taps were closed when the sample reached the upper limit of the protein coupled resin 
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inside the column chamber. The column was then washed with up to 7ml of PBS pH7.4 
with fractions taken once more into ELISA plates.  
 HLA specific antibodies bound to the protein/sepharose matrix were then eluted 
by introducing an alkaline pH to the column. Acid elution of HLA-specific antibodies is 
unsuitable as sHLA is denatured at a pH of 6 or below. An elution buffer of 100mM 
glycine pH11.0 was added, typically in the volume range 8-10ml. Elution fractions were 
collected as before, with 35µl 1M tris pH7 pre-loaded into each well to assist in 
neutralising the antibody fractions. Each fraction was retrospectively tested by 
microbead analysis for presence of purified HLA specific antibodies. 
 HLA columns were then re-equilibrated by addition and flow through of up to 
10ml PBS pH7.4, followed by a long-term storage buffer of 5ml PBS pH7.4 containing 
0.01% NaN3. Columns were then stored at 4oC.  
 Column integrity following repeated rounds of antibody depletion and elution 
was assessed by repeated depletion of a standard concentration of the HLA-class 
specific monoclonal antibodies W6/32 and anti-β2M.  
 
 
2.8.4 Antibody Depletion and Isolation using clinical scale SHARC 
 
 For clinical scale HLA columns between 2 and 3 litres of diluted plasma effluent 
were run through the column at a flow rate of 50ml/min using a Watson Marlow 501H 
peristaltic blood pump (Watson Marlow, Portsmouth, UK). Pressure monitors were set 
up both proximally and distally to the HLA column in order to monitor the fluid 
pressure through the column and potentially identify any build up in pressure indicative 
of column blockage (figure 2.18).  
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Figure 2.18: Circuit Design for Clinical Scale HLA-Specific Antibody Removal. 
The circuit was designed to incorporate pressure monitor sensors both proximally and 
distally to the SHARC. The circuit can be diverted such that post depletion samples and 
eluted antibody preparations can be collected separately. 
 
 
Following the run through of patient material the circuit was switched to allow 1-2 litres 
of PBS pH7.4 to run through and remove any non-specific binding to the HLA column. 
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To neutralize the antibody preparation at this stage 20% w/v 1M Tris pH7 was added. 
The column was then re-equillibrated using 2 litres PBS pH7.4 , then 2 litres of PBS 
pH7.4 containing 0.01% NaN3 for long-term storage. 
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SINGLE ANTIGEN LUMINEX BEADS- 
PRACTICAL CONSIDERATIONS. 
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3.1 INTRODUCTION 
 
The central dogma that pre-existing donor-specific (HLA and ABO) antibodies 
(DSA) are a bar to renal transplantation is steadily being dismantled.  It is becoming 
apparent that quantity in addition to specificity is a critical factor in determining whether 
to transplant a patient with HLA-specific antibodies.  On this basis pretransplant 
antibody removal or reduction can eliminate hyperacute rejection.  Despite this there 
remains increased risks of graft damage and acute rejection and these are likely to be 
dependent on the amount of antibody present at the time of transplantation and post-
transplant resynthesis of DSA.  For these reasons accurate and reproducible 
measurement of HLA specific antibody together with a strategy of antibody monitoring 
is required. 
The ability to measure circulating levels of DSA, in both the pre- and post-
transplantation phase is critical to understanding the patient’s immunological status.  
The number of removal cycles (e.g plasma exchange cycles) will depend on the amount 
and rate of re-synthesis of the pre-existing DSA.  During antibody removal the 
effectiveness of the procedure can be determined by specific measurements, ideally 
before and after each treatment, finally reaching a level which is considered safe and 
manageable.  Post transplant monitoring identifies the status of the patient’s response, 
for example, early immunological signs of rejection, and can be used to guide treatment 
where appropriate [91].  Complement dependent cytotoxicity (CDC) and later flow 
cytometry (FC) were first used to monitor HLA-specific antibody levels.  In comparison 
to microbead assays, both lack sensitivity and require viable donor or third party 
lymphocytes and are cumbersome to perform on a daily basis.  These are also difficult 
to standardise because of variability seen with cells from different individuals [115].  
More recently assays based on purified HLA are in widespread use, and of these the 
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bead-based assays are the most used.   Bead assays are a development of FC but use 
antigen coated beads instead of lymphocytes as targets for HLA-specific antibody 
detection [114].  These are standardised, quality controlled reagents which have enabled 
us to monitor AiT on a real-time basis.   However, the use of this assay for antibody 
quantitation rather than detection has not been validated.  There are many variables 
which need to be considered, such as different antigen coating levels between beads 
(specificities), the linearity of dose response, and the level at which the assay saturates.  
In this chapter I show how these factors determine antibody measurement so that the 
bead based assay can be standardised, and monitor changes in DSA levels to inform 
effective transplant management. 
 
3.2 PATIENTS AND METHODS. 
  
3.2.1 Microbead Assays.     
 
HLA class I and class II specific antibodies were analysed using recombinant 
single antigen microbead assays manufactured by OneLambda Inc. (Canoga Park, CA) 
and analysed on the Luminex Xmap 200 platform.  Antibody binding was measured as 
raw fluoresence to avoid differences in background binding seen with different sera 
which disproportionately influences relative fluorescence, a particular problem 
associated with plasma exchange [91, 116]. 
 
3.2.2 Maximum antibody binding capacity.   
 
The relative density of HLA antigen bound to each bead was determined using 
monoclonal anti-HLA antibodies (Mab).  For class I, PE-conjugated W6/32 monoclonal 
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antibody (Cedarlane Labs, Ontario, Canada) and PE-conjugated polyclonal Beta-2- 
microglobulin (β2M) specific antibodies (AbCam, Cambridge, MA) were used.   For 
class II we used separate PE conjugated anti-HLA-DP, DR, and DQ monoclonal 
antibodies (AbCam, Cambridge, MA). All monoclonal antibodies were tested against 
each single antigen bead assay and standard curves were constructed to determine the 
maximum antibody binding capacity (ABC) for each bead (dilutions used were 1, 0.5, 
0.25, 0.125, 0.031, 0.016mg/ml). The distribution of mean channel fluoescence intensity 
(MFI) values corresponding to the maximum ABC of all beads was used to normalise 
subsequent serological measurements to the 75th percentile. 
 
3.2.3 Binding characteristics of human antibodies.  
 
 All assays were performed using serum/bead ratios in accordance with the 
manufacturer’s instructions.  Raw MFI values were used to track changes in DSA and 
TPA levels over the course of the transplant as previously described [91, 116]. 
The binding capacity of each patient’s serum was investigated by testing serial 
dilutions of patient sample (tested at neat then dilution with AB serum at 1:5, 1:10, 





Patients were selected for HLA antibody incompatible transplantation if they 
displayed current reactivity with donor specific HLA antigen as measured by CDC 
crossmatch, flow cytometry crossmatch, or by luminex single antigen microbead assay. 
Patients were treated prior to transplant with alternate day sessions of double filtration 
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plasmapheresis (DFPP). The number of sessions administered was dependant upon 
starting levels of DSA with five being the most frequent. Immunosupression was given 
as previously described [91, 116]. 
Post transplant samples were tested for DSA and TPA levels daily for the first 
two weeks then three times a week for the following two weeks. All antibody analysis 
was carried out on a real-time basis as the results were used in acute patient 





3.3.1 Saturation of the binding capacity of the single antigen bead assay. 
 
Maximum antibody binding capacity (ABC) of the OneLambda HLA class I 
single antigen bead assay was standardised by the use of PE conjugated anti-HLA class 
I (w6/32) and also anti-beta-2 microglobulin (B2M). HLA class II ABC was determined 
using anti HLA-DR, DP and DQ PE conjugated monoclonal antibodies (AbCam, UK). 
Standard curves were constructed by testing against serial dilutions of each monoclonal 
antibody in order to standardise ABC across all beads (Figure 3.1).  
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Figure 3.1: Typical standard curve showing the standardisation of HLA class I 
single antigen beads.  This example uses the rabbit polyclonal antibody specific for 
β2M. Saturation of available binding sites can be seen by the flattening out of the 
standard curve at higher concentrations of antibody. 
 
 
3.3.2 Binding characteristics of human sera. 
 
At higher concentrations of antibody, binding capacity may appear reduced as 
all available antibody binding sites are occupied and the excess antibody competitively 
inhibits binding, this observation can be referred to as the ‘high dose hook effect’[118].  
To demonstrate the high dose hook effect in a clinical situation figure 3.2 shows 
the standard curve constructed using serial dilutions of a post-transplant sample from 
patient 039. At neat concentration the DR4 DSA in the patient saturates the available 
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false low MFI reading. The standard curve indicates that at a dilution factor of 1in10 the 
DSA is measurable within the linear region of the binding curve and accurate MFI 
readings can be obtained. The importance of the linear region of the antibody binding 
curve is discussed in greater detail in chapter 5. 
 
 
Figure 3.2: Standard curve constructed using serial dilution of a post transplant 
serum sample. DR4 DSA (colour) displays saturation of binding sites at neat dilution 
(green)- and in the case of one bead a false low reading: the ‘high dose hook effect’ 
(red). The linear binding region, the area of the curve in which MFI increases in 
correlation with antibody concentration, is also highlighted for the DR4 positive beads. 
 
 
Failure to recognise the presence of the high dose hook effect may have serious 
implications on patient management particularly in the post transplant period. Figure 3.3 
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confirmed rejection with rise in serum creatinine and fall in urine output. Antibody 
levels appeared to have fallen sharply at onset of rejection. Re-testing of patient sera at 
a dilution factor of 1in10 revealed a steady rise in DSA levels from day 5 onwards in 





Figure 3.3: The impact of the high dose hook effect on the interpretation of 
changes in antibody level.  Testing without dilution appears to show a sharp fall in 
antibody levels, however testing at 1 in10 dilution revealed a steady rise in DSA level 
consistent with deteriorating graft function. The points between which the high dose 
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The high dose hook effect can be observed most markedly during the initial 
rounds of pre transplant DFPP. In the case of high titre DSA saturating bead capacity, 
DFPP results in a false rise in MFI. This can be corrected by dilution of patient serum as 
shown in figure 3.4. 
   
 
Figure 3.4: The impact of the High Dose Hook Effect in the pre-transplant 
monitoring period. With each round of DFPP the MFI rises when tested using 
undiluted serum suggesting ineffective antibody removal. Testing at 1 in10 serum 
dilution reveals the presence of the HDHE masking the true fall in antibody level. 
 
3.3.3 Effect of correcting for variation in antigen density. 
 
Local studies performed which identify the variation in antigen expression on 
single antigen beads have shown there can be a large variation in expression level 
between beads (figure 3.1). By saturating the available binding sites with the use of 
monoclonal antibodies we have shown that with the One Lambda single antigen assay 
























	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  David	  Lowe	  PhD	  Thesis	  2013	  	  
	   129	  
density beads. The variation in antigen density that is inherent in the single antigen 
assay has a profound effect upon maximum ABC.  
This knowledge is vital when monitoring accurately the changes in MFI 
readings in transplant recipients. Figure 3.5 shows the effect of correcting for antigen 
bead density for patient 035 involved in our HLA antibody incompatible transplant 
scheme. Although in this case both corrected and uncorrected antibody profiles follow 
the same general pattern, correction for antigen density reveals that both DSA and TPA 
were of very similar level. DSA levels appear to be higher than TPA levels until 
application of correction factors reveals the true titre profile. 
 
Figure 3.5: Effect of correcting for antigen density. When corrected MFIs are used 
(bottom panel) we can observe that 3rd party specificities were not of higher level than 
DSA pre-transplant. 
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3.3.4 Use of saturation ratios to reveal confounded antibody specificities.   
 
The use of monoclonal antibodies to obtain bead saturation MFI values as an 
indicator of antigen density also provides a means by which antibody specificities 
which are confounded by the presence of other specificities can be positively identified. 
This is particularly apparent when dealing with DSA and TPA directed against the 
HLA-DP protein. The polymorphism displayed by HLA-DP is unique amongst HLA 
loci, with almost all known polymorphism attributable to combinations of several 
different amino acid motifs at six sequence positions [144, 145]. These common 
epitopes are outlined in table 3.1. As a consequence of this, single antigen microbeads 
are not always able to conclusively define DSA in the presence of other TPA directed 
against HLA-DP locus specificities.  
 
Table 3.1: HLA-DP Polymorphic epitopes. Polymorphism is limited to six key amino 
acid positions. 
 
DPB1* .8(11 33(36 55(57 65(69 76 84(87
01:01 VY&G E&YA AAE I&&K V DEAV
02:01 LF&G E&FV DEE I&&E M GGPM
02:02 LF&G E&LV DEE I&&E M GGPM
03:01 VY&L E&FV DED L&&K V DEAV
04:01 LF&G E&FA AAE I&&K M GGPM
04:02 LF&G E&FV DEE I&&K M GGPM
05:01 LF&G E&LV EAE I&&K M DEAV
06:01 VY&L E&FV DED L&&E M DEAV
08:01 LF&G E&FV DEE I&&E V DEAV
09:01 VH&L E&FV DED I&&E V DEAV
10:01 VH&L E&FV DEE I&&E V DEAV
11:01 VY&L Q&YA AAE L&&R M DEAV
13:01 VY&L E&YA AAE I&&E I DEAV
14:01 VH&L E&FV DED L&&K V DEAV
15:01 VY&G Q&YA AAE L&&R M VGPM
16:01 LF&G E&FV DEE I&&E M DEAV
17:01 VH&L E&FV DED I&&E M DEAV
18:01 VY&G E&FV DEE I&&K M VGPM
19:01 LF&G E&FV EAE I&&E I DEAV
20:01 VY&L E&FV DED L&&K M DEAV
21:01 VY&L E&LV EAE I&&K M DEAV
22:01 LF&G E&LV EAE I&&E M DEAV
23:01 LF&G E&FV AAE I&&K M GGPM
Epitope5amino5acid5position
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In our transplant program so far there are 5 patients whose sole DSA is directed 
against HLA-DP. The example shown in figure 3.6 highlights the antibody profile of a 
renal patient who appears to have raised antibodies via a previous mismatched renal 
allograft to the 84-87 DEAV motif. This motif is present in 
DP1,3,5,6,8,9,10,11,13,14,16,17,19,20,21, and 22 antigens, and the patient reacts 
against all of these specificities (figure 3.6A). Presence of antibody specific for this 
motif will potentially mask antibodies specific for many other immunogenic motifs, for 
example both 8-11VY-L and 55-57DED would be confounded. By dividing the sample 
MFI by the previously determined saturation MFI for each bead a saturation ratio is 
obtained which can be used to accurately define reactivity between patients (figure 
3.6B,C). If the antibody level is high it may be necessary to dilute the patient sample to 
negate the high dose hook effect. Application of these factors provides clear ‘groups’ of 
saturation ratios which correlate to exact antibody specificities (figure 3.6D).  
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Figure 3.6: The use of saturation ratios to define epitope specific reactivity 
patterns. A) Positive HLA-DP specific reactions with undiluted and 1 in 10 diluted 
serum broadly corresponding to the 84-87 DEAV epitope. B) Levels at which the HLA-
DP specific beads saturate using a HLA-DP specific monoclonal antibody. C) 
Saturation ratios of the serum from 3.6A shows the emergence of a 55-57 DED motif. 
D) The 55-57 DED epitope is clearly indicated when the sample is diluted thus 
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3.4 DISCUSSION. 
 
 The use of single recombinant HLA antigen coated polystyrene microbeads has 
revolutionised the way in which the transplant laboratory is able to monitor the HLA 
antibody status of transplant recipients. Fulfilling the early promise of the technology, 
daily monitoring of patient serum is now possible without the use of cumbersome 
crossmatching methods [91, 116]. Through analysis of the DSA and TPA profiles of a 
series of patients transplanted as part of HLA antibody incompatible programme we 
have been able to identify distinct MFI values that correspond with both the pre-
transplant crossmatch results and the likelihood of rejection post-transplant [91, 116]. 
The determination of such cut-off values relies heavily on the correct analysis and 
interpretation of the readouts obtained from the microbead assay, addressing in 
particular the points outlined in this study.  
  
3.4.1 Maintaining binding capacity within the assay- avoiding the high dose hook 
effect. 
 
 When monitoring patient antibody levels intensely, particularly in the early post 
transplant period, it is of vital importance to identify the points at which the binding 
capacity of the assay has been exceeded. In order to avoid the high dose hook effect it is 
absolutely crucial to maintain daily MFI readouts at a level which remains within the 
linear region of the binding curve. The most effective way to manage this is to apply a 
suitable dilution factor to the patient serum (see figure 3.2). This dilution factor may 
need to be adjusted through the clinical course, for example a continual sustained 
increase in DSA titre may necessitate a further increase in dilution factor. This is 
demonstrated by case 069 in our HLA incompatible transplant program who displayed a 
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HLA-DR9 DSA which was measurable at 1in10 dilution up until day 7 post transplant 
whereafter a dilution of 1in100 was required to effectively measure any further changes 




Figure 3.7: Monitoring of DSA at three dilutions. Sustained rapid rises in DSA levels 
are undetectable from day 7 onwards unless serum is diluted. Further dilution to 1 in 
100 was required to accurately determine decline in antibody around day 24 post-
transplant.  
 
 This suggests that the construction of a standard curve for antibody binding is 
required for each patient transplanted in our scheme to provide an indication prior to 
pre-transplant antibody reduction therapy as to the parameters required for accurate 
daily antibody monitoring. In those patients whose post transplant antibody titres 
exceed those measured pre-treatment it may be necessary to construct new binding 
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3.4.2 Correcting for variation in antigen density. 
 
 The variation in antigen density on the microbeads can have major implications 
when comparing changes in titre levels between DSA and TPA. As shown in figure 3.5 
the use of uncorrected antibody levels can give misleading results. It is of great 
importance when monitoring patient antibody profiles to be able to distinguish a donor 
specific response from that of third party. For example, in figure 3.5 the uncorrected 
data indicates a fall in DSA immediately post-transplant. However it is only when this 
data is corrected for antigen density variation that it becomes truly clear that DSA fell 
much more rapidly than TPA. 
 Corrected data is also a useful way of maintaining continuity when the bead 
manufacturer’s change kit batches during important phases of patient monitoring. By 
standardising the MFI values to allow for variation in antigen density accurate patient 
monitoring could continue despite the change in kit batch. 
 
3.4.3 Saturation ratios to confirm HLA-DP antibody specificity. 
 
 Due to the unique nature of the polymorphism of HLA-DP locus, saturation 
ratios provide a novel method of determining individual specificities in the presence of 
other confounding specificities. There are currently five patients in our program whose 
sole DSA is directed against the HLA-DP locus. By comparing the saturation ratios we 
are able to correlate the putative amino acid motif against which the DSA is directed. In 
these instances the saturation ratio can be monitored closely and changes in DSA can be 
distinguished from those of TPA at the HLA-DP region. 
Despite the undoubted advantages given by single antigen beads, problems may 
arise during testing that, if not compensated for thoroughly, may give misleading results 
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which could potentially impact on patient care. The use of single recombinant HLA 
coated microbeads and the constantly evolving use of the data provided by this 
technology has allowed us to constantly refine our transplant protocols and pre-emptive 
therapy strategies. 
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4.1 INTRODUCTION 
 
 The presence of human leukocyte antigen (HLA) specific antibodies represents 
one of the major obstacles to successful solid organ transplantation. Recent advances in 
laboratory testing, most notably the introduction of microbeads coated with single HLA 
antigens has allowed us to define HLA antibody specificities to new levels.  However, 
many of the anti-HLA reactivity patterns seen in patient allosera are highly complex and 
require skillful interpretation from the laboratory scientist. This is particularly 
significant when we consider the mechanisms by which antibodies interact with their 
target antigen. HLA-specific antibodies recognize small clusters of non-self amino acid 
residues, which form epitopes. Specific epitopes are shared amongst many different 
HLA antigens, such that a given HLA protein can express many different immunogenic 
epitopes and potentially any of these epitopes, if not present on self-HLA, can illicit a 
humoral response. The in silico analysis of epitope reactivity has been possible with the 
use of the HLA Matchmaker algorithm [81, 82, 146] which can predict potential 
immunogenicity between HLA types by comparing the differences between individuals 
in terms of distribution of epitopes. Recent studies using mouse monoclonal antibodies 
and adsorption with single antigen cell lines has lead to the elucidation of over 100 
immunogenic epitopes on HLA Class I [80, 147]. However, this approach is costly and 
time consuming.  
As the methods for synthesising large repertoires of highly purified HLA 
proteins improve, they can be used in other modes than coupled to microbeads. One 
new application would be to better define the specificities of HLA antibodies. An HLA 
molecule may be capable of stimulating the production of multiple HLA specific 
antibodies, and an antibody directed against an epitope on one HLA protein should react 
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with the same epitope on other HLA proteins. In addition, a common problem 
encountered when using single antigen microbeads, are false positive reactions caused 
by antibody binding to denatured antigen found on the bead. By using an intact HLA 
protein molecule to inhibit antibody binding to native HLA epitopes we can recognize 
those positive reactions likely to be due to binding to denatured antigen. 
Described here is a method of identifying multiple epitope specific antibodies 
within allosera by inhibiting the sera with selected specificities of soluble HLA (sHLA) 
then analyzing the remaining reactivity by microbead analysis.  
 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 sHLA Production 
 
To create soluble class I HLA protein a modified cDNA of HLA-class I alpha 
chain was cloned into a mammalian expression vector pcDNA3.1(-) that contained a 
geneticin resistance cassette. Class I HLA deficient cell line 721.221 was transfected 
with the expression construct and drug resistant clones were selected in growth media 
containing G418 (0.8mg/ml). sHLA production was measured using a capture ELISA 
where W6/32 was the capture antibody and anti-β2m was the detecting antibody. sHLA 
producing clones were sub-cloned into 96 well plates by limiting dilution and high 
producing sub-clones were expanded and seeded in AccuSyst-Maximizer hollow fibre 
bioreactors (Biovest International). Approximately 500 mg of sHLA was harvested 
from each bioreactor. sHLA containing supernatant  was loaded on a W6/32 
immunoafffinity column and washed with 40 column volumes of 20mM phosphate 
buffer pH 7.4. sHLA molecules were eluted from the affinity column with 50mM 
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diethylamine (DEA) at pH 11.3, neutralized with 1M TRIS pH 7.0, and buffer 
exchanged and stored at 1 mg/ml in sterile PBS. 
 
 
4.2.2 Patient Allo anti-sera 
 
 Patient sera were chosen from our panel of over 100 HLA antibody 
incompatible (HLAi) transplant recipients, and all showed extensive HLA-class I 
specific antibody reactivity by microbead analysis with complex patterns of 
alloreactivity. In addition a panel of sera for whom high resolution HLA typing had 
been performed and were positive for HLA-specific antibody were analysed to 
determine the number of epitopes that could be elucidated. 
 
4.2.3 sHLA Inhibition 
 
 Sera were incubated at 22°C for 30 minutes with selected sHLA. A sHLA 
concentration of 0.1µg/µl was deemed optimal in terms of efficacy of inhibition and 
minimizing the effect of sample serum dilution (see section 4.3). An identical reference 
sample was tested in parallel diluted to the same degree by using PBS instead of sHLA 
preparation. Single antigen bead analysis was carried out using Labscreen single antigen 
beads (LS1A04, One Lambda, Inc, Canoga Park, CA) in accordance with the 
manufacturers instructions. Data generated from the LABScan 100 Luminex platform 
were analysed using Excel spreadsheets taking trimmed mean fluorescence values from 
the output (.csv) files produced by the luminex analyser. Data were adjusted for 
background noise by subtraction of the negative control bead. Normalisation of the 
antigenic load for each bead was not required for this analysis as inhibition of mean 
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fluorescence intensity (MFI) signals were calculated as a percentage of the uninhibited 
MFI value.  
The patterns of reactivity of all beads where initial MFI values were reduced by 
>80% following soluble inhibition were compared with those listed for epitope specific 
reactivity by El-Awar et al [80, 147], and where these corresponded epitope specific 
reactivity was determined.  
Figures 4.1, 4.2, and 4.3 show a summary of the epitopes and the corresponding 
beads on which they are expressed derived from El-Awar[79, 80] et al. These maps are 
used to aid the definition of epitope specificity. Note that some epitopes (e.g 253Q) 
specificities are present on antigens of more than one HLA-locus and are therefore 
listed on multiple epitope maps. 
 
Results for soluble inhibition are given as a percentage absorption for each antibody 
using the following formula: 
 
         Percentage Absorption= Raw MFI following sHLA Inhibition      x100 
                                                   Raw MFI diluted reference sample 
 
 Positions of epitopes are shown using Cn3D Viewer software using the three-
dimensional structure of the HLA-A02:01 molecule (accessed 13th July 2012 from 
http://www.ncbi.nlm.nih.gov). 
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Figure 4.1: List of HLA-A locus epitope specificities and the broad HLA antigen 
specificities on which they are expressed. 
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Figure 4.2: List of HLA-B locus epitope specificities and the broad HLA antigen 
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Figure 4.3: List of HLA-Cw locus epitope specificities and the broad HLA antigen 
specificities on which they are expressed. 
 
 




 The use of the correct nomenclature makes describing the sHLA specificites and 
the bead specificities difficult in this context. For example the sHLA that is the product 
of the HLA-A*02:01 gene is too cumbersome a description to be used repeatedly and 
therefore will be referred to as HLA-A02:01 only. Similarly, the HLA microbead which 
carries the protein encoded by the HLA-A*66:02 gene will henceforth be referred to as 
HLA-A66:02 and so on. These differences are important to clarify as this study is 




4.3.1 Optimisation of Soluble Inhibition Conditions 
 
 Patient 065 was selected for determination of optimum soluble inhibition 
condition. This patient had significant microbead activity (7000-11000MFI) with the 
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following single antigen bead specificities; HLA-A66:02, B07:02, B13:01, B13:02, 
B27:05, B27:08, B47:01, B48:01, B40:01, B40:02, B73:01, B81:01. Analysis of 
previously published HLA class I epitopes [147], and the use of HLA Matchmaker 
indicated that this pattern of reactivity was due to antibody recognition of a single 
epitope designated 163E+166E/163E+167W, where ‘/’ represents the possible 
alternative sites that may be responsible for antibody recognition. Therefore, HLA-
B07:02 soluble HLA protein was added at a range of concentrations with the aim of 
inhibiting reactivity against all beads carrying the correct epitope. Figure 4.4a shows the 
reduction in MFI levels for all beads carrying the 163E+166E/163E+167W epitope, 
where more than one bead is specific for the same broad HLA antigen the mean of the 
combined MFI values was used. Effective inhibition was seen across the range of 
concentrations, 0.1µg/µl was chosen as a reduction of over 80% from starting MFI was 
observed across all beads. To support this initial observation that the pattern of 
microbead reactivity was due to the recognition of a single defined epitope, the 
experiment was repeated using an alternative sHLA specificity, HLA-B13:01, which 
should also absorb this antibody specificity. To rule out the possibility that our sHLA 
specificities were somehow pan-reactive, we also ran the experiment using a third party 
sHLA specificity, HLA-A02:01, which does not carry the 163E+166E/163E+167W 
epitope. Figures 4.4b and 4.4c show the results of this analysis. Inhibition with sHLA-
B13:01 shows epitope specific reduction of reactivity comparable to that of sHLA-B7 
confirming earlier observations. sHLA-A2 inhibition did not result in reduction of 
binding reactivity to any microbeads specific for the 163E+166E/163E+167W epitope 
thus confirming the specificity of inhibition. 
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Figure 4.4: Optimisation and key examples of the epitope specific inhibition 
protocol. a) Determination of optimum concentration of sHLA required for effective 
depletion of epitope specific reactivity. b) Specific depletion of 
163E+166E/163E+167W epitope specific reactivity using sHLA-B1301 protein. c) 
Lack of depletion following inhibition with sHLA-A0201 which does not express the 




















































HLA Microbead Specificity 
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4.3.2 HLA-A2 Epitope Analysis 
 
Next, we sought to investigate the epitope composition of a number of allosera 
that were highly reactive against HLA-A2. There are a number of highly immunogenic 
epitopes that have been elucidated recently that correspond to the original cross-reactive 
groups (CREGS) that were originally identified by serological analysis [148-150]. The 
most common examples are reactivity to HLA-A2, B57, and B58 which is due to the 
recognition of a glycine (G) residue at position 62, and the 127 lysine (K) substitution 
shared between HLA-A2,23,24,68,69. There are a number of other HLA-A2 associated 
epitopes that will be discussed further later.  
Three HLA-A2 reactive patient sera taken from waiting list patients were first 
inhibited using sHLA-A2 to determine the extent of HLA-A2 associated epitope 
reactivity. The HLA specificities substantially inhibited (>75% reduction in MFI) for 
each patient are listed in table 4.1.  
 
Table 4.1: Single antigen bead specificities for each patient significantly inhibited 





Epitope specific inhibition of sera from patient LT66 using soluble HLA-B57:01 
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reactivity (figure 4.5). This reveals the presence of antibody specific for 62G epitope 
(HLA-A2/B57/B58). The residual A2 reactivity is most likely due to antibody directed 
against the epitope listed as 43Q/62G/62G+66K/62G+76V/62G+79G by El-Awar et al 
[147]. The position of the 62G residue that is crucial in both of these epitopes on the 




Figure 4.5: Epitope specific inhibition of sera from patient LT66. Epitope specific 
inhibition of sera from patient LT66 using soluble HLA-B57:01 reveals the presence of 
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 The initial reaction pattern of sHLA-A2 inhibition for patient LT68 was 
identical to LT66, however figure 4.6 clearly shows that specific inhibition using 
sHLA-B57 was enough to eliminate all reactivity allowing epitope specificity to be 




Figure 4.6: LT68- Epitope specific inhibition. Epitope specific inhibition using 
soluble HLA-B*57:01 shows almost 100% reduction in HLA-B57/58 reactivity and 




Soluble Inhibition (sInh) of LT79 using sHLA-A69 resulted in a total reduction 
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reactivity suggesting that multiple epitope specific antibodies are present (figure 4.7). 
HLA-A69 and A2 depletion can be attributed to antibody binding to a tryptophan 
residue (W) at position 107, which is not present on HLA-B57 and B58, hence the lack 
of reduction following sHLA-A69 treatment. SI with HLA-B57 reduced HLA-B57 and 
58 reactivity substantially and gave a slight reduction in HLA-A2 MFI. This indicates 
the probable presence of both 62G (HLA-A2,57,58) and  
43Q/62G/62G+66K/62G+76V/62G+79G (HLA-A2 only) specific antibodies. The latter 
appears to be the dominant epitope specific antibody population in this allosera mix. 
 
 
Figure 4.7: Soluble Inhibition of LT79 antibody using sHLA-A69. Total reduction of 
HLA-A69 specific reactivity and partial depletion of HLA-A2 reactivity suggests 
multiple epitope specific antibodies presents, sHLA-B57 reduced HLA-B57,58 
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4.3.3 Class I Epitope Determination 
 
 A panel of class I HLA-specific antibody positive sera were characterised by 
luminex single antigen bead assay, then based upon these antibody profiles soluble 
inhibition analysis was carried out to determine the number of epitopes that could be 
elucidated in each case. Table 4.2 shows the individual cases, the epitope specific 
antibodies that could be identified, and the specificity of the sHLA used to determine 
the identified epitopes. 
In the eight sera tested, twelve distinct patterns of epitope specific reactivity 
could be identified. In each case there were a number of reactions that could not be 
accounted for using the present repertoire of recognised epitopes. Potential reasons for 
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4.4 DISCUSSION 
 
 The use of purified intact soluble HLA proteins can be extremely useful in 
gaining insight into the complex nature of HLA-specific antibody recognition. The use 
of soluble inhibition in this study has highlighted the epitope specific nature of the anti-
HLA response and has supported previous work that demonstrated how patterns of 
reactivity in the single antigen bead assay can be attributed to distinct patterns of amino 
acid substitutions [80, 147]. Soluble inhibition can also be used to support in silico 
analysis of the mismatches between potential donor and recipient pairs [81]. Antibodies 
specific for potential epitope mismatches between donor and recipient can be assayed 
directly by soluble inhibition analysis simply by choosing one or more sHLA sharing 
the mismatched epitope, and depleting the reactivity of the patients’ HLA-specific 
antibody profile accordingly. 
 The analysis of HLA-A2 specific reactivity has indicated that the humoral 
response to HLA-A2 is highly complex and often individuals will produce antibodies to 
more than one epitope specific to the HLA-A2 protein. This is likely to have clinical 
implications, in particular in those cases where MFI reactivities are being monitored 
post-transplant. This data shows that the reported MFI values are often a sum of two or 
more antibodies competing for binding sites located very closely together on the same 
HLA molecule. It is entirely feasible that these competing antibodies will differ not only 
in their specificity, but also in affinity, and functional properties (complement, non-
complement fixing). This competition may result in inhibition of binding and false low 
MFI values (the high-dose hook effect). In such cases it may be prudent, once epitope 
specificities have been identified, to monitor other bead specificities that carry one or 
other of the HLA-A2 epitopes individually. For example if we were to consider patient 
LT79, monitoring the changes in MFI of the HLA-A2 specific beads may not be the 
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best indicator of changes in antibody titre as there are at least three separate epitope 
specific antibodies competing for tightly clustered epitopes on the same molecule 
(Figure 4.7). By analysing the changes in the HLA-A69 bead specific for the 107W 
epitope and the HLA-B57 or B58 beads specific for the 62G epitope a much clearer 
picture of antibody level changes may emerge. 
 The nature of epitope specific binding and the fact that in a high proportion of 
cases there appears to be multiple antibodies binding to the same HLA molecules may 
have more fundamental implications. The ability of a given serum to activate 
complement via the classical pathway may not necessarily only require there to be 
sufficient levels of suitable HLA-specific IgG, but may also be reliant on the 
composition of the antibodies in the serum. A mixture of separate antibody populations 
specific for different epitopes on the same molecule may potentially be a very potent 
activator of complement via the classical pathway as this mechanism requires the co-
localisation of IgG molecules such that C1q can be incorporated to form the first stage 
in complement activation. Given that in HLA incompatible transplantation, complement 
dependant cytotoxic crossmatch (CDC) positive transplants have much higher rates of 
antibody mediated rejection [91, 116] a more detailed understanding of the factors 
determining serum cytotoxicity would be of great clinical benefit.  
 Analysis of further samples allowed the identification of 12 specific epitopes 
from eight sera (table 4.2). This did not account for the total repertoire of HLA-reactive 
microbeads in each case, and many positive reactions were unexplained following 
sHLA inhibition. There are a number of possible reasons for this; firstly, the panel of 
sHLA specificities, although extensive, may not be broad enough to cover all epitopes 
at this stage. Secondly, antibody reactivity specific for any antigen may be a composite 
of many different epitope specific antibodies. The extensive sharing of epitopes 
between different HLA proteins can make the potential positive identification of 
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individual epitopes very difficult in complex sera such as those where there is likely to 
be high numbers of individual epitope specific antibodies in the same serum. Thirdly, 
there is a growing body of evidence which shows that many of the ‘positive’ reactions 
seen in the microbead assay are false and that the antibody profiles indicated are due in 
large part to the non-specific binding of serum immunoglobulin to denatured HLA 
antigen [126, 127].  These studies suggest that antibodies direct against denatured HLA 
or ‘crytpic’ epitopes are not likely to be significant to transplantation. Therefore the 
identification of these non-HLA antibodies is crucial, a prospective study using sHLA 
to determine ‘true positives’ in the single antigen microbead assay is indicated. 
 In summary, by using soluble HLA in the standard single antigen microbead 
assay it is often possible to identify the specific epitopes against which HLA-specific 
antibody is produced. Also, antibody to very common HLA antigens are often 
composed of a mixture of more than one epitope specific antibody and that this 
complexity may be crucial both to the accurate interpretation of MFI titre levels but also 
to the understanding of factors governing serum cytotoxicity. Finally, sHLA inhibition 
may help to address the problem of recognising antibodies directed against denatured 
HLA antigen.  
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5.1 INTRODUCTION 
  
The recent advances in HLA antibody detection methodology, most notably the 
recent prominence of bead based assays, has provided the clinical transplant laboratory 
with valuable tools with which to rapidly and accurately monitor the changes in HLA 
specific antibody levels [114, 115]. The recent increase in centres with active HLA 
antibody incompatible (HLAi) transplant programmes has come about, at least in part, 
due to the emergence of these new assays[91, 116]. Indeed in our experience the data 
provided by these assays is vitally important in the clinical management of these 
transplants with changes in donor specific anti-HLA antibody (DSA) levels often 
preceeding the clinical signs of antibody mediated rejection (AMR) [91, 116].   
 The one major drawback of these assays however, is the fact they provide semi-
qualitative data only. The output of these assays is given only as units of detectable 
fluorescence, usually referred to in the literature as mean fluorescence intensity (MFI). 
At best these MFI values can be considered as comparative; they enable the change in 
antibody levels relative to previous antibody levels to be estimated. MFI values given 
by these assays can be sum totals of more than one antibody which may recognise 
separate epitope determinants co-expressed on the same recombinant HLA molecule, as 
shown in chapter 4. In practice this may often mean that MFI values given for a 
particular antibody reactivity may be over-estimated. Conversely, these assays may 
often ‘saturate’ at higher levels of antibody as discussed in chapter 3. In addition, these 
assays are only detecting specific IgG levels, with data suggesting that presence of 
antibody of IgM isotype may inhibit assay sensitivity[119]. 
 The adaptation of these widely used assays in such a way as to provide data on 
serum concentration of HLA specific antibody would be of clinical utility. The normal 
ranges of serum concentration of HLA specific antibody is currently unknown but 
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knowledge of this would be extremely useful particularly in understanding the 
requirements of antibody depletion in HLAi transplantation. Direct interpretation of 
MFI data and conversion to a clinically defined concentration has been hitherto absent 
due to the lack of an available standard reagent. The National Institute for Biological 
Standards and Controls (NIBSC) defines as biological standard reagent as ‘a batch of a 
substance that has been assigned units of activity and is used as a benchmark’. Here it is 
shown that by using human monoclonal antibodies with HLA reactivity defined to the 




Human monoclonal antibodies (Mab) of IgG isotype were obtained from Leiden 
University Medical Centre. Clone SN607D8 showed single epitope reactivity 142T 
present on HLA-A2 and HLA-A28. Clone WK1D12 showed specificity for the 
163E+166E/163E+167W epitope expressed on HLA-A*66:02, HLA-
B7,B13,B27,B40,B42,B47,B48,B73,B81 and outlined in detail in chapter 4.  Samples 
were supplied as culture supernatants, figure 5.1 shows the protein gels derived from 
these culture supernatants. IgG was then purified by affinity chromatography using 
protein G sepharose columns. Antibody was then eluted from protein G columns by the 
addition of 100mM glycine pH3.0, and immediately neutralised in 1M Tris pH7.0. 
Samples were then concentrated and dialysed into phosphate buffered saline (PBS) 
pH7.4. Antibodies were then quantified using a bicinchoninic acid (BCA) protein 
quantification assay (ThermoFisher, USA). 
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Figure 5.1: Protein gel showing HLA-specific IgG monoclonal antibody 
preparations run in reducing conditions. The IgG heavy chain (45 kDa) and light 
chain (23 kDa) bands can be seen in the boxed area. Human serum albumin (66-67kDa) 
are the prominent serum proteins in each sample. A protein marker ladder is shown on 
the left-hand side (refer to figure 2.9).  
 
 
Each monoclonal antibody was then ‘spiked’ into pooled AB serum previously 
shown to be negative for HLA-specific antibody (data not shown) by single antigen 
bead assay (OneLambda Inc, CA, USA). A dynamic concentration range of 0.1-
200µg/ml was used to construct a standard curve of HLA reactivity using single antigen 
beads. Bead MFI values corresponding to the presence of epitope specific reactivity 
were plotted. Due to variability in the level of antigenic expression on single antigen 
beads, assays were standardised by assessing the HLA expression density using W6/32 
pan HLA-Class I specific MAb. MFI values were normalised to the bead representing 
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Selected sera from sensitised renal transplant patients were taken and HLA 
specific reactivity was determined to the epitope level. This was achieved by 
competitive inhibition of bead assay binding using soluble HLA protein (full details 
given in Chapter 4). For example in patient 065 addition of HLA-B*07:01 protein at 
0.05µg/µl resulted in inhibition of all specificities carrying the 163E+166E/163E+167W  
epitope. This was confirmed by 163E+166E/163E+167W  inhibition using HLA-
B*13:01 and HLA-A*66:02 soluble protein (refer to figure 4.4a-c). 
Standard curves were constructed and interpreted using Prism 4 analysis 
software. MFI reactivity was then converted to a defined serum concentration by 




 Initially, HLA specificity of the MAbs was confirmed using single antigen 
microbead analysis. Identical epitope specific reactivity was also confirmed in two renal 
transplant patients using epitope specific inhibition prior to microbead analysis 
(outlined in chapter 4).  
 Standard curve of antibody reactivity for each MAb were constructed at the 
following concentrations: 200, 100, 50, 25, 10, 5, 1, 0.1 µg/ml. For each curve all 
primary epitope specific beads were used to construct the curves, the mean HLA-A2 
bead reactivity for SN607D8, and HLA-B7 bead reactivity for WK1D12. The 
microbead assay reached a plateau or point of saturation at MAb concentration of 
100µg/ml, this is consistent for both clones tested (figure 5.2).  
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  David	  Lowe	  PhD	  Thesis	  2013	  
	   161	  
 
 
Figure 5.2: Standard concentration curves for the HLA-A2 epitope specific MAb 
SN607D8, and the HLA-B7 epitope specific antibody WK1D12. The linear 
relationship between bead MFI and antibody concentration is lost over 6000 MFI for 
WK1D12 and 8000 MFI for SN607D8. This implies a ‘working range’ of detectable 
antibody of up to 25-35µg/ml. 
 
 
 A serum sample for patient QE01 (142T epitope specific antibody) was then 
tested by single antigen microbead assay and the mean MFI of the A2 beads was read 
off to give an estimate of serum concentration. A mean A2 bead MFI of 6200 
corresponded to a serum concentration of 31.7µg/ml. This patient is active on our local 
waiting list and consistently produces a HLA-A2 reactive MFI in the region of 5000-
7000 indicating a stable antibody. 
 We then analysed patient 065 who received a HLA antibody incompatible 
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during a period of antibody mediated rejection marked by a rapid increase in donor 
HLA-B7 (163E+166E/163E+167W) specific reactivity. When tested at neat dilution 
this sample gave an estimate of 163E+166E/163E+167W specific serum concentration 
of 93.1µg/ml which equated to an initial MFI reading of 10,600. However, due to the 
fact that 93.1µg/ml is close to the 100µg/ml estimated saturation point of the assay it 
was felt that this concentration gave a significant under-estimate of the true antibody 
level. Thus the sample was re-tested at 1in10 dilution and gave an MFI corresponding to 
18.5µg/ml, equating to an overall estimated serum concentration of 185µg/ml. To test 
the robustness of this approach, the concentration of the original MAb (WK1D12) was 
adjusted to 185µg/ml and tested again with single antigen microbeads. Figure 5.3 shows 
that the MFI values obtained for each bead specificity was directly comparable and that 
any differences observed could be attributable to normal assay variation. 
 
Figure 5.3: Microbead analysis of patient 065 and MAb WK1D12 with sample 
concentration adjusted to 185µg/ml.  Serum from patient 065 was estimated to have a 
serum concentration of 185µg/ml, monoclonal antibody WK1D12 was adjusted to 
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 In the case of patient 065 the peak antibody concentration post-transplantation 
was estimated to be 185µg/ml. Samples taken from this patient at specific time-points 
pre and post-transplantation were retrospectively analysed and a serum antibody 
concentration for each specific time-point was derived. This data is given in Table 5.1 
and the time-course is plotted in terms of reactive MFI and estimates of serum 
concentration in figure 5.4.  
 
Table 5.1: Estimated serum concentration of 163E+166E/163E+167W specific 
antibody through the course of HLAi transplantation. A serum concentration of 0 
denotes MFI dropping below the sensitivity threshold of the standard curve. *sample 





This analysis indicates that this approach utilising standard curves of defined 
epitope reactivity is sensitive down to a serum concentration in the region of 1-2µg/ml, 
the lower threshold of MFI reactivity which could be quantified is in the region of 800. 
The estimated upper limit of quantifiable MFI reactivity is in the region of 40-50µg/ml 
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with dilution analysis required to accurately quantify HLA-specific responses above this 
concentration range (figure 5.2). 
 
 
Figure 5.4: Comparison of MFI values with serum concentration of antibody. It 
can clearly be seen that when the antibody concentration exceeds the dynamic upper 
limit of the assay (days 13-24), the MFI and actual serum antibody concentration show 






 This study provides a simple method to estimate serum concentration of epitope 
specific anti-HLA antibodies. For the first time this gives us a valuable insight into the 
range of levels at which circulating anti-HLA specific antibody can be found in a 
patient population. The individual patient sera used here were chosen both for their 
epitope reactivity but also to represent different cycles of a patients’ response to foreign 
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consistently gives a HLA-specific MFI in the region of 5000-7000. In this study this 
was calculated as a HLA epitope specific serum IgG concentration of 31.7µg/ml. As 
this is a simplified example of single epitope reactivity we would expect the anti-HLA 
specific fraction of circulating IgG to typically be a multiple of this amount as many 
patients carry a range of HLA-specific antibodies. Based on examination of normal 
ranges of total IgG in serum a concentration of 31.7µg/ml would constitute around 0.05-
0.2% of total circulating IgG. 
 Patient 065 provides an example of a dynamic antibody response in the 
immediate pre and post-transplantation period in HLA antibody incompatible 
transplantation. Analysis showed a pre-transplant HLA-specific antibody starting 
concentration of 12.8µg/ml, which was reduced below quantifiable level by five rounds 
of pre-transplant double filtration plasmapheresis (DFPP) therapy. Antibody levels rose 
in conjunction with an episode of biopsy proven antibody mediated rejection (AMR) 
around 10 days post-transplant rising to a peak antibody concentration of 185µg/ml on 
day 17 post-transplant. This peak response level equates to approximately 1% of the 
total serum IgG being specific for the donor kidney at this stage. Subsequently, levels of 
donor reactive antibody fell to 29.3µg/ml at post-transplant day 24, then to sub-
quantifiable levels at day 55. These falls in serum antibody concentration were 
consistent with resolution of AMR and restoration of renal function. 
 Knowledge of the serum quantification of anti-HLA antibody has clinical utility 
when monitoring the changes in antibody titre, with particular benefit to centres 
supporting HLAi transplant programmes. These measurements may assist in the 
assignment of immunological risk prior to transplant, with the potential assignment of 
critical cut-off values of antibody concentration above which increased risk of AMR 
could be expected. 
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 It is also important to note the limitations of this approach. At present this 
method allows the accurate quantification of single epitope specific antibodies. The 
examples given here are common epitope specific reactivities seen in a number of 
patients in our transplant cohort. It is not yet known the effect of multiple epitope 
specific antibodies in a given patient serum. Also it is labour intensive to define the 
exact epitope specificities present in a sample serum, requiring extensive soluble phase 
absorption experiments and expensive microbead analysis. 
 The microbead assays in use in virtually all modern transplant laboratories are 
themselves not well suited to this application. As noted earlier these assays are easily 
saturated at higher antibody concentrations (data suggests 100µg/ml), therefore it is of 
paramount importance to recognise when a particular sera is likely to have saturated the 
assay and to dilute the sample accordingly. The subsequent dilution of patient sample 
may then lead to a larger degree of error when converted back to pure concentration, 
although the data shown in figure 5.2 suggests this degree of variation is not 
unacceptable. Other studies have suggested that other immunoglobulin isotypes such as 
IgM may inhibit the accurate measurement of IgG by these assays[119] so sample pre-
treatment with specific reducing agents such as dithiothreitol (DTT) may be worthy of 
further investigation. 
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6.1 INTRODUCTION 	  
Donor HLA-specific antibodies are not always an obstacle to organ 
transplantation: a complete understanding of the heterogeneity of these antibodies and 
the circumstances which cause this to vary is therefore important in the development of 
strategies to safely transplant across antibody barriers.  Hyperacute rejection mediated 
by HLA-specific antibodies seems to be dependent on a cytotoxic pretransplant 
crossmatch but non-cytotoxic levels of antibodies are not always associated with 
immediate graft failure, whether detected by flow cytometry [151, 152] or by solid-
phase assays [153].  The specificity of alloantibodies in terms of the HLA isotype 
recognised is also a significant factor; pre-formed HLA class I-specific antibodies are 
considered to be more harmful to kidney transplants than those against Class II HLA 
[154].  Therefore both qualitative as well as quantitative factors determine the 
pathogenicity of HLA-reactive antibodies. 
A third factor likely to determine alloantibody pathogenicity is immunoglobulin 
isotype.  IgG is the predominant HLA-specific antibody; HLA-specific IgA is variously 
thought to be protective or not directly harmful to allogeneic grafts [155], and donor 
HLA-specific IgM is generally considered of limited, direct clinical significance [156].  
There are four subclasses of IgG which are functionally distinct as a result of different 
heavy chain gene usage.   The germ-line IgG heavy chain genes are in the order Cγ3, 
Cγ1, Cγ2, Cγ4 with subclass switching being sequential, in this order, and antigen 
driven, under T cell control.  In order to evaluate the role of IgG subclasses in 
transplantation we must have a reliable method to detect and characterise each type of 
IgG specific for individual antigens in a patient’s serum.  Single antigen bead assays 
(SABA) provide a system to do this.  Lobashevksy et al [157] and Honger et al [158] 
each used bead assays to investigate the significance of pretransplant HLA-specific IgG 
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subclasses but with seemingly contradictory conclusions. IgG subclass distribution is 
likely to influence the pathogenicity of HLA-specific sera.  However, it is not known if 
there is a characteristic distribution of IgG subclasses for HLA specific antibodies, 
whether this is a property of the individual or of the antibody specificity, and if this is 
dependent on the type of immunising event.  In this study we have optimised a standard 
HLA SABA for IgG subclass characterisation and describe the distribution and relative 
levels of IgG subclasses of 148 HLA antibody specificities in sera from highly 
sensitised, prospective renal transplant patients.  We found a range of subclass profiles 




6.2 METHODS  
 
6.2.1 Study samples 
 
Sera from fifty-one patients were studied and were selected primarily on the 
basis of their recruitment into our HLA antibody incompatible transplant (AiT) 
programme [91]; pretreatment sera were used.  These cases are therefore characterised 
by a relatively high level of HLA-specific sensitisation.  All sera were shown to contain 
donor-specific (DSA) and third party-specific  (TPA) antibodies using single HLA 
microbead assays for class I (HLA-A/B/C) and class II (HLA-DR/DQ/DP), (One 
Lambda Inc, CA, USA) and analysed on a standard luminex platform (X-MAP 100).  
These kits use a polyclonal goat anti-human IgG-specific antibody and therefore detect 
total IgG binding to the HLA on each bead. 
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Selected antibody specificities were tested for the presence of IgG1-4 using 
individual HLA coated beads (Labscreen Singles, One Lambda Inc, CA, USA).  The 
bead specificities chosen corresponded to the DSAs for each subsequent transplant plus 
the highest level TPA if present.  There was therefore no intended bias of particular 
specificities.  The specificities tested are listed in Table 6.1. Note that from the 148 
selected specificities determined by total IgG, there were 10 specificities that were not 
detectable using IgG subclass-specific monoclonal antibodies.  This is described further, 
in table 6.2. 
 
Table 6.1: HLA specificities tested and number of sera containing each specificity.  
All antibodies were primarily characterised using a pan IgG-specific secondary 
antibody.  Ten specificities were below critical threshold values using subclass-specific 
secondary antibodies and these are indicated by the lower numbers in brackets. 
 
HLA$Class$I Number HLA$Class$II Number
Bead$Specificity of$sera Bead$Specificity of$sera
A1 7 $ 1
A11 3 DP2 2
A2 13(12) DP4 2
A24 6 DQ2 4
A25 2 DQ4 1
A3 5(4) DQ5 4
A30 1(0) DQ6 4
A32 1 DQ7 7(6)
A33 2(1) DQ8 2
A34 1(0) DQ9 1
A66 1 DR1 2
A68 2 DR10 1
B13 2 D103 1
B27 1 DR11 5
B35 3 DR13 2
B44 2 DR14 1
B53 1 DR15 1
B57 4 DR17 3
B60 3 DR4 13(11)
B62 5 DR52 2
B65 1 DR53 1
B7 6 DR7 5
B8 4(3) DR8 3(2)
C3 1 DR9 3
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Table 6.2: Ten cases with subclass-specific MFI values below the pos-neg threshold 
of 5 times the negative bead average. (IgG3 62.7, IgG1 120.6, IgG2 72.0, IgG4 17.2).  
*Pan IgG MFI determined using multiple antigen beads and confounding specificities 




6.2.2 HLA-specific IgG subclass assay 
 
Assay conditions followed the manufacturers instructions in that bead to serum 
ratios were adhered to but the pan-IgG reactive secondary antibody was replaced by 
subclass specific phycoerythrin  (PE) conjugated mouse monoclonal antibody (IgG1, 
clone 4E3; IgG2, clone 31-7-4; IgG3, clone HP6050; IgG4, HP6025, Southern Biotech, 
Birmingham, AL, USA).  The final concentration of each subclass specific antibody 
was 0.25ug/ul.  Negative and positive control sera were supplied by the manufacturer.  
Each assay was finally resuspended in 85ul luminex wash diluent for analysis on the 
Luminex100TM analyzer. Subclass specific monoclonal antibodies were validated by 
coating individual microbeads with IgG subclasses purified from sera from four human 
myeloma patients.  Analysis of reactivity patterns showed that potential cross-reactivity 
Specificity IgG3 IgG1 IgG2 IgG4 Pan3IgG
A34 17 118 6 8 2200
DQ7 15 114 11 8 2000
A33 15 111 11 11 *
A33 58 83 16 10 *
A30 43 81 12 1 193
DR4 7 75 1 1 1300
B8 17 63 28 11 781
DR4 27 5 4 4 2700
DR8 18 7 11 4 *
A2 5 13 3 1 1600
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between subclass specific monoclonal antibodies represents <5% for all monoclonal 
antibodies as shown in Table 6.3. 
 
Table 6.3: Monoclonal antibodies binding to IgG subclass coated beads.  Values are 
raw MFI.  Specific binding levels are in shaded boxes, non-specific (cross-reaction) 
levels are given with percentage of specific binding in brackets.  Note, no case of non-




The incidence of antibody specificities of each subclass were determined on the 
basis of a critical threshold value for each subclass.  There are no existing controls or 
standard sera for HLA specific antibodies because of the complexity and individual 
nature of each HLA-specific antibody as discussed in chapter 5. We therefore used a 
stringent assessment of positivity relative to background binding to the negative control 
bead.  This was set at greater than 5 times the average negative control bead mean 
fluorescence intensity (MFI) of all tests for each subclass.  This reduces the risk of false 
positives at the expense of potentially increasing false negatives but is justified given 
that higher levels of HLA specific antibodies are likely to be clinically more significant 
than lower levels.  Relative levels of each antibody between individuals and groups 
were compared using bead MFI values [91]. 
 
  
IgG1 IgG2 IgG3 IgG4
4(E(3 IgG1(specific 6950 2261(3.13%) 141(0.2%) 91(0.13%)
37(171(4 IgG2(specific 2481(4.42%) 5342 101(0.18%) 111(0.19%)
HP6050 IgG3(specific 661(1.7%) 381(0.99%) 3854 81(0.21%)
HP6025 IgG4(specific 371(1.42%) 181(0.61%) 111(0.37%) 2936
Monoclonal1Antibodies
Bead1Specificity
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6.2.3 Assignment of sensitizing event to antibody specificity 
 
Where possible, each antibody specificity was assigned a sensitizing event based 
on historical records, as follows.  Sensitisation arising from pregnancy was assigned if 
the antibody specificity corresponded to the partner’s mismatched HLA and if the 
timing of the antibody appearance was consistent with the dates of the pregnancy.  
Similarly, sensitisation due to a previous transplant was assigned if the antibody 
specificity corresponded to a graft HLA mismatch and the timing of the appearance of 
the antibody was consistent with rejection of the graft.  Blood transfusion stimulated 
antibody was assigned for cases with a known transfusion history, the absence of a 
temporal relationship with other sensitising events containing the relevant HLA and the 
exclusion of specificities corresponding to any previous pregnancy or transplant 
mismatch.  In certain cases this allowed assignment of different specificities to different 
sensitising events in single individuals. 
 
 
6.2.4 Statistical analysis 
 
Statistical analysis was performed using SPSS for windows, version 19.0 (SPSS 
Institute, Chicago, IL).  Frequency differences were assessed using the Chi Squared test, 
and quantitative comparisons were assessed using the Wilcoxon Rank test.  The level of 
statistical significance was set at p<0.05. 
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6.3 RESULTS 
 
6.3.1 Detection of HLA-specific IgG subclasses 
 
HLA-specific IgG subclasses were detected and measured in 148 separate sets of 
bead assays and raw MFI values recorded.  Figure 6.1 shows these MFI values (y axis) 
for assays of all the specificities each arranged in the same order, ranked by the 
corresponding IgG1 level.  This illustrates that the patterns of IgG2, IgG3, and IgG4 
subclass detection are not due to crossreactivity with the IgG1-specific antibody as the 
rankings are clearly different, thus confirming earlier validation data provided in table 
6.3.  Linear regression analysis comparing MFI values between all the paired subclass 
MFI values in each set of assays gave no significant correlations.  The ranked MFI 
values of all subclasses form a smooth curve with no obvious step between a negative 
and a positive threshold. 
Each isotype-specific antibody gave different control bead values, so the 
positive threshold MFI values used for each HLA specific IgG subclass were different, 
as follows:  IgG1 120.6, IgG2 72.0, IgG3 62.7, IgG4 17.2.  In ten of the 148 antibody 
specificities tested, the MFI values of all subclasses were below the chosen positive 
threshold (details given in Table 6.2). Certain examples of these specificities have MFI 
levels that are less than 1x the negative control beads despite the specificity being 
detected using the pan-IgG antibody with single antigen beads.  Others have MFI close 
to our threshold values but, although it is probable that these sera contain some 
corresponding HLA reactivity, they were excluded from the qualitative analysis as we 
could not determine which subclass did or did not contribute to the pan-IgG reactivity.  
Together these data indicate that;  (1) Detection of HLA specific IgG using pan-IgG 
polyspecific secondary antibodies is more sensitive than using subclass-specific 
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monoclonal antibodies. (2) The pan-IgG assay may detect antibodies other than IgG1-4.  
(3) The chosen 5x negative bead value threshold is likely to exclude some specific 
antibodies. 
 
Figure 6.1: Distribution of MFI levels of all HLA specificities for the four IgG 
subclasses.  Each vertical bar represents the result of a serum tested against one specific 
bead.  The data in all graphs are sorted by IgG1-specific MFI level so that the position 
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6.3.2 Subclass distribution 
 
The term specificity is used to refer to the HLA on the bead against which an 
antibody was detected.  Antibody refers to the particular immunoglobulin and thus we 
can refer to a specificity being comprised of one or more antibodies (IgG1 or IgG1 and 
IgG2, etc).  Subclass profile will be used to describe the mixture of subclass antibodies 
for a given specificity. The frequencies of the IgG subclasses amongst the 138 HLA 
specificities are shown in Table 6.4. 
 
Table 6.4: Incidence of each IgG subclass amongst 138 HLA-specific antibodies.  
The incidence of each IgG subclass is analysed in total, and separately for HLA class I 




All subclasses were detected but IgG1 was the most prevalent followed by IgG2, 
then IgG3, with IgG4 being the least.  The prevalence of each subclass is similar for 
both HLA Class I and Class II specific antibodies.  Twelve of the 138 (9%) specificities 
do not have IgG1 levels above our cut-off threshold.  Of these twelve antibodies, eleven 
have IgG3 (nine exclusively), and one IgG2 only.  No specificities had only IgG4.  Of 
the 126 specificities which include IgG1, 38 have IgG1 exclusively, the remainder have 
a mixture of subclasses but none with IgG4 only.  Most specificities (90/138) are 
comprised of mixtures of IgG subclasses.  The distributions of these IgG subclass 
n % n % n %
IgG3 71 51.4 38 53.5 33 49.3
IgG1 126 91.3 64 92.1 62 92.5
IgG2 78 56.5 43 60.6 35 52.2
IgG4 55 39.9 30 42.3 25 37.3
Class5I5specific5antibodies Class5II5specific5antibodiesAll5Antibodies
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profiles for the 138 specificities are shown in Figure 6.2A.  This shows that for both 
HLA Class I and Class II specific antibodies there are two predominant IgG profiles; 
one restricted to IgG1, the other with all four subclasses detectable.  The subclass 
profiles are given as the presence or absence of each subclass in the order IgG3, IgG1, 
IgG2, IgG4 (ie the germ-line heavy chain gene sequence). 
 
6.3.3 Sensitising events and IgG subclasses 
 
Unequivocal identification of sensitising events was possible in 38 of the 51 
sera, allowing the cause of antibody stimulation to be assigned to 109 of the 138 
specificities.  In these 109 specificities, subclass MFI values were above the cut-off 
thresholds in 106 (as described in Table 6.1) and could therefore be analysed 
qualitatively as follows and shown in Table 6.5a.  IgG1 was found to be the dominant 
subclass of HLA-specific antibodies for all causes of sensitisation.  While IgG2 is 
second most prevalent in blood transfusion and kidney graft sensitisation antibodies 
(48% and 68%, respectively). Amongst the pregnancy stimulated specificities IgG3 is 
the second most prevalent antibody at 68% (p=0.052) with IgG2 at 50%.  IgG4 is of low 
frequency in our transfusion sensitised cases (26%) compared with this antibody in the 
combined two other groups (47%) (p=0.046).  Comparisons of bead MFI values as an 
indicator of relative antibody amount (and not dependant on an arbitrary cut-off) also 
show differences due to the route of sensitisation. Median MFI values were found to be 
higher in transplant stimulated IgG1, IgG2, and IgG4 antibodies compared with the 
other routes of sensitisation (statistics for all comparisons are given in Table 6.5b).  The 
median IgG3 MFI value was highest in the pregnancy group but overall there are no 
significant differences in the distribution of IgG3 MFI levels between the three modes 
of sensitisation. 
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Figure 6.2: Distribution of IgG subclass profiles, shown in 138 HLA specificities 
indicating the presence (subclass number) or absence [-] of each subclass.  The 
combinations of each four are given in germ-line heavy chain gene order. A)  Frequency 
of profiles for HLA class I and Class II antibody specificities with no significant 
differences.   B)  The distribution of the profiles according to mode of sensitisation.   
The distribution of the profile containing IgG1 only (“-1--”) is significantly different 
than that expected (p=0.033); the distributions of the remaining profiles do not differ 
from expected. 
The distribution of HLA-specific IgG subclass profiles in the three sensitisation 
groups is shown in Figure 6.2B.  This illustrates general differences associated with 
sensitisation route. IgG1 only dominates antibodies resulting from transfusion 
!
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(p=0.033), while for both pregnancy and failed graft sensitisation the most prevalent 
profile is that comprising all subclasses.  For the failed transplant cases the IgG1 only 
profile is third in order of prevalence.  Consistent with the raised frequency of IgG3 in 
the pregnancy cases, the IgG3 only profile is more common in this group (23% vs 8% 
in the non-pregnancy cases, p=0.052). 
 
Table 6.5: a) Incidence of each HLA-specific IgG subclass in the three sensitisation 
groups. (* p=0.046 compared with the the non-transfusion cases; no other significant 
differences). b) Quantitative differences between type of sensitisation for each IgG 
subclass.  Median MFI values in bold, interquartile values in brackets. 
 
 
We found no subclass to be associated with any particular HLA type or isotype.  
However, we did see a higher frequency of DQ-specific IgG4 amongst the transplant 
stimulated antibodies (7/8) compared with IgG4 non-DQ specificities (9/26) (χ2=6.87, 
a)
n"(50) % n"(34) % n"(22) %
IgG3 20 40 20 59 15 68
IgG1 46 92 32 94 15 77
IgG2 24 48 23 68 11 50
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p=0.009).  In contrast to this, only 3/12 non-transplant stimulated DQ specificities 
contained IgG4 (compared with the 7/8 transplanted DQ specificities, χ2=7.5, p=0.006). 
 These observations indicate that the route of sensitisation influences IgG heavy 
chain usage in the response against HLA.  Thus within a single, multi-specific serum we 
might see different distributions of IgG subclass for each specificity.  Examination of 
sera containing multiple specificities allowed us to investigate whether the HLA 
specific IgG subclass profile is a property of the specificity or the serum.  In each of 40 
of the 51 sera analysed, multiple specificities were present which were considered not 
due to cross-reactions (because of temporal separation of the appearance of specificities 
and/or the absence of known cross-reactions).  In seven of these all the specificities 
within each serum had the same subclass profile.  In the remaining thirty-three sera, the 
clear majority, there was mixtures of different subclass profiles for the different 
specificities.  Examples of sera showing different patterns of IgG subclass profiles for 
different specificities are shown in Table 6.6. In Table 6.6a, the serum has five 
specificities all with the same profile (all 4 subclasses present) even though there are 
two separate sources of immunization stimulating distinct specificities.  This contrasts 
with the serum shown in Table 6.6b which has four specificities with differing profiles. 
The two specificities stimulated by graft mismatches, DR103 and DQ5, have the same 
subclass profile while the transfusion stimulated specificities, B57 and DR4, have their 
own peculiar subclass profiles (IgG1 and IgG2 only, respectively).  These latter two 
specificities are likely to have been the result of distinct immunisations as they appeared 
about 5 months apart.   
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Table 6.6: Complex patterns of HLA-specific IgG subclasses vary within 
individuals and depend on route of sensitisation and specificity.  Examples of 
antibodies in three sera from separate individuals (a-c).  Values given are the ratio of 
MFI for specific reactions to the average of the negative control beads for each subclass 
to allow comparisons between subclasses (ie >5 is positive, as indicated by shaded 
boxes).  The causes of each sensitisation is indicated by superscript (B-blood 
transfusion, T-failed kidney transplant, P-pregnancy). 
 
 
The serum described in Table 6.6c contains four specificities of differing 
subclass profile stimulated by a graft rejection.  The DQ7-specific reactivity has all four 
subclasses present including a relatively high level of IgG4.  In contrast the B7 
specificity is composed of IgG1 and IgG4, while those of both A1 and DR4 are limited 
Specificity IgG3 IgG1 IgG2 IgG4
a)
B57 P 7.5 112.7 24.1 11.9
A2 B 7.6 102.9 42.3 16.6
DR7 P 35.9 145.5 45.1 25.9
DR9 P 14.1 73.9 21.9 20.3
DR11 P 14.9 97.5 27.2 15.7
b)
B57 B 4.3 8.8 1.9 3.2
DR103 T 2.5 180.2 317.1 9.3
DQ5 T 2.7 152 340.7 132.6
DR4 B 0.6 2 128.2 3.2
c)
B7 T 3.2 44.1 3.8 5.5
A1 T 1.4 20.9 0.7 0.3
DR4 T 1.1 16.7 0.6 2.3
DQ7 T 9.1 112.8 6 62.5
DR1 B 2.1 34 1.3 4.1
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to IgG1.  A fifth specificity, DR1, in this serum appeared after a transfusion and is 




The complex nature of the HLA-specific humoral response has only really been 
possible to understand since the use of assays based on recombinant proteins.  We now 
know that each expressed HLA allele carries multiple epitopes [159] which can all 
stimulate antibodies such that a positive crossmatch against a single mismatch could be 
due to one or many epitope-specific antibodies.  Here we give a detailed description of a 
further layer of heterogeneity, that of IgG subclass distribution and the presence and 
relative level of each subclass as well as the mixture of subclasses.  Our analysis 
suggests a major factor underlying this heterogeneity is the type of immunising event, 
but following such an event individuals can also stimulate distinct specificities with 
different subclass profiles.  Failed transplant stimulated antibodies are characterised by 
both a wider range of subclasses and higher levels of each subclass.  We routinely 
observe the emergence of an HLA DQ-specific response associated with chronic graft 
failure (unpublished observations) and the dramatic skew towards IgG4 of these 
antibodies implies a specific quality of the immune response.  The combination of HLA 
DQ specificity and IgG4 therefore has the potential as a biomarker for chronic rejection. 
It has been shown previously that IgG1 is the predominant subclass of HLA-
specific IgG [158, 160] and in general this data agrees with this.  Other protein 
alloantigens, such as those on red cells are also biased toward IgG2 [161].  If one looks 
at individual responses against different types of immunisation then a more complicated 
picture emerges.  This is likely to be of direct relevance to transplantation, particularly 
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antibody incompatible transplantation, because of the different functional properties of 
each IgG subclass.  IgG1 and IgG3 are the more effective at complement activation via 
complement factor C1q and Fcγ receptor binding.  IgG1 only, IgG3 only, or both have 
indeed been shown to be the more pathogenic Rh-specific antibodies which cause 
haemolytic disease of the newborn[162].  Therefore the consequences of transplanting 
across a particular level of IgG1 or IgG3 may be different than the effect of an 
equivalent level of IgG2 or IgG4.  Lobashevsky et al [157] reported antibody-mediated 
rejection (AMR)-free transplants associated with IgG2/IgG4 donor-specific antibody.  
On the other hand, Honger et al [158] were unable to show this in terms of AMR 
diagnosis but the high prevalence and higher levels of IgG1 compared with the other 
subclasses may have limited the statistical power of their analysis.  However they did 
see a tendency towards increased AMR risk from the higher IgG1 levels and this is 
consistent with the findings of Griffiths at al [163].  Others have shown that differences 
in complement activation cannot always be explained by IgG subclass composition.  
While complement activation may not be the only pathogenic feature of HLA-specific 
antibodies this does illustrate that all the factors contributing to antibody heterogeneity 
are likely to be determinants of the pathogenicity of a recipient’s HLA specific 
antibodies. 
The presence or absence of each subclass indicates the degree of heavy chain 
class switching for each specificity.  As class switching is T cell dependent, progression 
from IgG3 to IgG4 suggests enhanced T cell activation while a subclass limited 
response implies limited T cell activation.  Thus, the tendency for multiple subclasses to 
be stimulated by graft rejection may be due to a greater degree of specific T cell 
activation compared with the response against a blood transfusion. The qualitative and 
quantitative characteristics of a graft rejection response may help to explain why re-
transplantation against a previous graft sensitisation is considered to carry a particularly 
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high risk.  This is in contrast to the impact of HLA specific antibodies stimulated by 
transfusion alone with a tendency towards lower levels and a bias towards IgG1 only.  
These can quickly decline after which transplantation against the same specificities does 
not carry high risk [164]. 
The description of subclass composition according to heavy chain gene order is 
useful as this clearly identifies class switching progression.  In certain cases we 
observed “skipping” of subclasses.  For example, in one individual we found the 
specificity HLA B7 with the IgG subclass profile “3-24” (MFI values 106;6;49;53, 
respectively).  However, we know there is no general IgG1 defect in this patient as the 
same serum had IgG1 specific antibodies against three other HLAs, including B60 (MFI 
values 381;121;186;223) (which interestingly shares epitopes with B7).  We saw six 
individuals with specificities having the profile “-1-4” but in all cases other specificities 
in the same individuals include IgG2 (an example of this is seen in Figure 6.6c).  Thus 
such subclass skipping may be relatively common and seems to relate to processes 
peculiar to the response to an individual sensitising antigen rather than necessarily a 
general heavy chain gene defect. 
A general weakness in HLA-specific antibody quantification and 
characterisation is the lack of reagent standards for each specificity.  This is unlikely to 
be resolved because of the large number of possible epitope-defined specificities as 
discussed in chapter 5.  Even two sera with the same specificity are likely to have 
different combinations and proportions of immunoglobulin classes and subclasses 
competing for the same binding sites.   These problems are not peculiar to bead-based 
antibody characterisation, and cell based methods suffer the additional problem of 
lacking standardised levels of target protein.  The use of an arbitrary cut-off value is 
also a problem but currently unavoidable because of the lack of an obvious step in MFI 
values between positivity and negativity.  The position of the threshold is therefore the 
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issue and more studies will be needed before this could be standardised for each 
subclass.  Honger et al [158] used greater than mean+3 standard deviations to define a 
positive.  We used a cut-off based on the median values of control beads as the MFI 
values do not form a normal distribution and chose a relatively high cut-off value 
because of the greater clinical significance of higher antibody levels, although at the 
expense of increasing the chance of false negative assignments.  Our subclass assay is 
less sensitive than the pan-IgG assay and this was also seen by Honger et al [158]; the 
greater avidity of the polyclonal secondary antibody is probably why this gives more 
sensitive detection.  Despite these concerns, analysis of IgG subclasses is practical both 
for further quantitative and qualitative description of HLA specific antibodies and may 
help resolve why these are not always an obstacle to transplantation. 
In conclusion, we have been able to demonstrate a remarkable degree of 
heterogeneity between HLA specific antibodies between and within individuals.  
Subclass composition is an important characteristic of HLA-specific antibodies as this 
will be one of the factors contributing to their direct pathogenicity, hence the need for a 
systematic description of this parameter.  An understanding of pathogenicity of different 
combinations of antibody specificity and IgG subclass profiles may help interpret a 
positive pretransplant crossmatch.  Even when two antibody specificities are stimulated 
by the same event, they may have distinct subclass profiles and could be treated 
differently with respect to exclusion of potential donors carrying the corresponding 
HLA.  These latter two points will become increasingly relevant in the drive to 
overcome allo-antibody barriers in transplantation while improving outcomes.  Finally, 
the progression towards less functionally effective subclasses as a cause or consequence 
of graft rejection may seem paradoxical, but, as class switching is T cell-dependent, 
differences in subclass use implies differences in T cell responses and this might have 
value in guiding both anti-T cell as well as anti-B cell therapies.	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IMPORTANCE OF HLA-SPECIFIC IgG 
SUBCLASS ANTIBODIES 
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7.1 INTRODUCTION 
 
Renal transplantation is limited by a shortage of organs, but does offer the best 
quality of life for those with end stage renal failure.  Living donor transplantation (LDT) 
is more than an expedient deceased donor transplantation, and also offers a choice as to 
when transplantation is performed, in particular allowing transplantation before dialysis 
if required.  The Department of Health has provided targets to increase the rate of 
transplantation in the UK and because the number of deceased donor organs continues 
to decline, a rise in the rate of live donor renal transplantation will be the most effective 
way to meet the targets.  There are obstacles to transplantation and pre-formed donor-
specific antibodies have always been one of the major barriers. 
Patients previously exposed to foreign human leukocyte antigens (HLA) through 
transplant, blood transfusions or pregnancy often develop antibodies reactive to HLA. 
Such preformed antibodies are the cause of hyperacute rejection where the organ fails 
immediately following revascularization [21] because of complement-mediated damage 
to the kidney endothelium. 
Currently 25% of patients waiting for deceased donor transplant are sensitised to 
HLA antigens. Also, in the UK alone, about 400 living donor renal transplants fail 
work-up each year because of donor-specific antibodies.  Extracorporeal antibody 
removal to facilitate transplantation is being increasingly considered and a reasonable 
estimate of demand in the UK might be 50-100 cases per annum.  This estimate is based 
on the use of plasmapheresis (PP) based protocols for living donor transplants[165].  If 
it were possible to reduce HLA antibody levels in all of those awaiting transplantation, 
there would be in excess of 1000 sensitised patients on the UK transplant list who 
would potentially benefit.  Studies have shown that plasmapheresis and low-dose CMV-
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Ig combined with traditional immunosuppression is effective in producing a specific 
and durable elimination of antibody to donor HLA[166]. 
Our transplant unit at the University Hospital Coventry & Warwickshire  
(UHCW) NHS Trust has been pioneering the work in antibody incompatible (both 
HLAi and ABOi) transplants in the UK and has done over 100 such transplants with 
preformed antibodies in the last ten years [90].  The protocol we use involves plasma 
exchange to reduce donor specific antibody (DSA) between 3-7 times before transplant 
based on the regular measurement of antibody levels. 
Among the isotypes of HLA-specific immunoglobulin (Ig), IgG is considered to 
be the agent of humoral rejection with complement activation and Fc receptor (FcR) 
mediated activities being the effector mechanisms.  HLA-specific IgM is rarely found in 
the absence of cognate IgG (D Briggs, unpublished observations) and at low titre is 
probably harmless [156], and IgA DSA may be protective [167].  IgG subclasses (1-4) 
exhibit functional differences such as complement activation and Fc receptor binding.   
IgG1 and IgG3 are the most effective at complement activation. Interestingly although 
IgG3 has the greater binding efficiency to complement component C1q, IgG1 is the 
subclass most effective at complement dependent cell lysis [168]. Neither IgG2 or IgG4 
appear to bind to C1q although IgG2 can fix complement weakly, but IgG4 not at all. 
In normal human serum IgG1 predominates (65%), followed by IgG2 (23%), 
IgG3 (8%) and IgG4 (4%).  For specific antibodies these proportions can change as, for 
example, hyperimmunization can result in IgG4 restricted response [169]: IgG4 
predominance in factor VIII inhibitors exemplifies this [170].  There are few studies 
investigating IgG subclass distribution in HLA-specific antibodies, and none 
considering individual specificities or looking at specific responses.  From the limited 
number of relevant studies it seems that in HLA-specific sera (identified by lymphocyte 
binding) IgG1 predominates [160, 163], with recently published data suggesting that the 
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presence of non-complement fixing IgG2 and IgG4 donor specific antibody (DSA) do 
not correlate with antibody mediated rejection [157]. 
This chapter aims to explore the distribution and role of donor HLA specific IgG 
sublasses in the early pre and post-transplant period following HLAi renal 








Fifty one patients who received HLA antibody incompatible (HLAi) renal 
allografts between June 2003 and October 2008 at University Hospital Coventry and 
Warwickshire were included in the study. All recipients underwent flow cytometry (FC) 
and complement dependant cytotoxic (CDC) crossmatching prior to transplant. Initially, 
donor specific (DSA) and third party (TPA) antibody levels were monitored daily both 
pre- and post-transplant on the luminex platform using the Labscreen Single Antigen 
bead assay (One Lambda, Canoga Park, CA).  
Prior to transplant patients were treated with five alternate day sessions of 
double filtration plasmapheresis (DFPP) with the aim of achieving  FC crossmatch 
negative at the time of surgery. The number of DFPP sessions was adjusted up or down 
depending on the starting levels of DSA. In some cases the transplant was performed in 
the presence of CDC and or FC-positive crossmatch. 
Immunosuppression consisted of mycophenolate mofetil 1000mg twice daily 
beginning 10 days prior to transplant with dose reduction if white cell count fell below 
4.0x109/l. Tacrolimus commenced 4 days prior to transplant, 0.15mg/kg/day with a 
target trough level of 10-15mg/l. Prednisolone, 20mg once daily, was started at the time 
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of surgery. Methylprednisolone, 500mg, was given during the transplant operation. 
Post-transplant, two doses of basiliximab were given on days 0 and 4. 
Rejection was diagnosed by renal biopsy if renal function deteriorated, or 
clinically if rapid onset oliguria occurs with a concomittant rise in creatinine and DSA 
levels. The 51 patients included in the study were broadly divided into those who 
experienced an episode of acute rejection in the first 30 days post-transplant (n=26) and 
those who did not (n=25). Patient characteristics can be seen in Table 7.1. 
 
 
Table 7.1: Characteristics of patient cohort. Patients are grouped into those who 
experienced an episode of rejection in the first 30 days post-transplant and those who 
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7.2.2 Methods 
 
Crossmatching (CDC and FC) were performed as previously described [91]. 
Donor specific and third party antibody levels were monitored using the Lasbcreen 
Singles bead assay  (One Lambda, Canoga Park, CA). Single antigen bead specificities 
were selected for each patient to correspond with all DSA and transplant mismatch 
(TXMM) specificities, in addition selected TPA specific beads were included. All HLA-
specific antibodies were determined by testing at least two separate samples from each 
patient, and all antibody specificities were assigned following careful consideration of 
reactivity patterns and comparison with patterns of known epitope specific reactivity.  
Patient serum samples were chosen at specific time points in the transplant 
course; pre antibody removal therapy, 1 day pre-transplant, 1 day post-transplant, 
corresponding with peak post-transplant total IgG level, and 30 days post-transplant. 
Antibody analysis was carried out in accordance with manufacturers instructions 
as previously described [91], goat anti-human IgG1-4 isotype specific monoclonal 
antibodies (Southern Biotech, Birmingham, AL) were used to determine levels of IgG 
subclass reactivity.  Raw mean fluorescence intensity (MFI) values were used to denote 
positivity. Isotype specific monoclonal antibodies were validated by using luminex 
microbeads coated with IgG subclass specific human myeloma antibodies. Cross-
reactivity between isotypes was observed at <5% (table 6.3). Positive threshold MFI 
levels for each HLA specific IgG subclass were as following: 120.6 (IgG1), 72.0 (IgG), 
62.7 (IgG3) and 17.2 (IgG4). These values represent a value that is 5 times greater than 
the negative control bead incorporated into the assay. 
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7.2.3 Statistical Analysis 
 
Each individual is associated with one of the groups – rejectors (R) or non-
rejectors (NR) based on clinically identified outcome. Statistical Wilkinson rank test 
was performed in order to assess whether data from the different groups had similar 
median values. The null hypothesis of no difference was tested at the 5% level of 
significance, and this is presented by p-values.  
Values of MFI for each IgG subclass (i=1, 2, 3, 4) were normalised by 
corresponding threshold levels for each subclass: 
 
 
Index r means ratio. 
Δ denotes subclass specific positive threshold value. 
 
 
IgG subclasses were also grouped by their complement activating ability: strong ability 
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7.3 RESULTS 
  
7.3.1 Pre-transplant data  
 
MFIr values for IgG subclasses and for assigned groups of complement 
activating ability are presented in Table 7.2 and Figure 7.1.  It can be seen (Table 7.2) 
that IgG1 is a more prevalent subclass of DSA-HLA in both rejector (89%) and non-
rejector (72%) groups. In the non-rejector group, IgG1 (72%) is followed by IgG2 
(60%), IgG3 (56%) and finally IgG4 (36%) in order of frequency. This is in accordance 
with previous findings [158] and with the normal sequence of abundance of these 
subclasses of immunoglobulin in serum. In the rejector group the order is different: the 
percentage of IgG4 and IgG2 is 65% and they both follow IgG1. IgG3 is least 
represented with 54%. This means that concentration of IgG4, normally least presented 
in serum, is higher in patients who experienced an episode of AMR (65% vs 36%). 
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Figure 7.1: Box plots of pre-transplant MFIr values for IgG subclasses. All are 
grouped by allograft rejection status: N –non-rejected cases, R – rejected cases.  
+ Denotes outlying values. 
 
Another observation is that the range of antibody distribution shown in brackets 
in Table 7.2 for IgG4 and for joint IgG2 and IgG4 subclasses are extensive for the 
rejector group compared with non-rejector and with other subclasses, reaching relatively 
high maximal MFI values.  
 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  David	  Lowe	  PhD	  Thesis	  2013	  
	   195	  
 
Table 7.2:  Quantity and percentage (in brackets) of patients with presented IgG 
subclasses. Median MFI ratios and median ranges (in brackets) of IgG subclasses for 






P-values presented in Table 7.2 and Figure 7.1 show that for samples taken 
before antibody removal therapy there is no statistically significant difference in MFI 
values for the two groups, either individually by IgG subclass or in two combined sets 
related to complement activating ability (IgG1+ IgG1 vs IgG2+IgG4):  p-values 
calculated using Wilkinson rank test are all greater than 0.05. This is also in 
correspondence with previously published results [14].  
More detailed study of HLA class I and II DSA specificities was carried out for 
all IgG subclasses (Table 7.3) and did not show any statistically significant difference 
between R and NR groups either: p-values exceed 0.05. However, the calculated p-
value is small (p=0.08) for IgG4 class II HLA, and additionally we observed a 
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the rejector group than in non-rejector group. Another observation is that IgG4 is rarely 
seen in the non-rejector group: 3 out of 25 profiles (12%) compare with 46% (12/26) in 
the rejector group, indicating presence of this subclass in almost half of the profiles in 
the rejector group. This trend towards IgG4 is explored further. 
 
 
Table 7.3.  Quantity and percentage (in brackets) of patients with presented IgG 
subclasses. Median MFI ratios and median ranges (in brackets) of IgG subclasses for 




Rejectors)(n=26 Non0rejectors)(n=25) Rejectors)(n=26 Non0rejectors)(n=25)
IgG1 17)(65.4%) 11)(44%) 17)(65.4%) 10)(40%)
14.6)(1.60131) 40)(1.10101.2) 22.0))(1.3077.5) 20.3)(2.0090.2)
IgG2 12)(46.2%) 10)(40%) 11)(42.3%) 8)(32%)
5.3)(1.408.9) 7.5)(1.1066.2) 8.0)(1.20131.6) 4.6)(1.1042.9)
IgG3 9)(34.6%) 9)(36%) 10)(38.5%) 6)(24%)
1.8)(1.3015.7) 4.8)(1.2011.1) 14.4)(1.40378.2) 2.9)(1.207.8)
IgG4 11)(42.3%) 10)(40%) 12)(46.2%) 3)(12%)
2.3)(1.10140.4) 7.5)(1.1066.8) 144)(1.40378.2) 1.6)(1.101.9)
IgG1+3 16.2)(1.60134.4) 11.1)(1.60101.2) 26.6)(1.3095.5) 22.3)(2098)
IgG2+4 7.0)(1.10143) 19.4)(2.5072.3) 18.2)(1.40445.1) 6.0)(1.1044.5)
HLA)Class)I HLA)Class)II
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7.3.2 Post-transplant data. 
 
There were two time points of interest in the post-transplant antibody course: 
that which corresponded to the peak level of pan-IgG DSA (days 8-11) and antibody 
levels on the 30th day after transplantation where in most cases post-transplant IgG 
responses had normalised back down to baseline levels.  
Peak level distributions for all 51 patients are presented in Figure 7.2A. If there 
is a significant difference in median values between the two groups the values are 
marked by an asterix. The results are qualitatively similar to the pre-transplant data for 
IgG2, IgG3, and IgG4 subclasses (Figure 7.2A) However it can be seen that there is a 
significant increase in peak values in the rejector group of donor-specific IgG1 subclass 
with p-value equal to 0.01. Also, the proportion of the total IgG response associated 
with the complement fixing subclasses IgG1 and IgG3 is greatly increased in the R 
group (p=0.007) in comparison with the pre-transplant value (p=0.32). More detailed 
study of DSA-HLA specificities of class I and II carried out for all IgG subclasses 
showed that IgG4 class II (Figure 7.2B) associates with R group with the p-value 
further dropping to 0.04 compared to pre-transplant data (Table 7.3, p=0.08). The form 
of the distribution also differs from the others in that the spread of IgG4 MFI values in 
the rejector group is significantly higher and the maximum MFI value is higher than for 
all other groups/subclasses. 
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Figure 7.2: DSA subclass distribution at the peak post-transplant timepoint. A) 
Box plots of peak post-transplant MFI values for IgG subclasses. All are grouped by 
allograft rejection status: N –non-rejected cases, R – rejected cases. B) Box plots of 
peak post-transplant MFI values for IgG4 class I and II HLA grouped by allograft 
rejection status: N –non-rejected cases, R – rejected cases. + Denotes outlying values. 
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Next, we compared the amount of IgG subclasses presented in rejector and non-





Figure 7.3: Box plots of 30th day post-transplant MFI values for  IgG1,  IgG2, 
IgG3,  IgG4, IgG1+IgG3 and IgG2+IgG4. All are grouped by allograft rejection 
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There was no difference between rejector and non-rejector groups for presence 
of any individual subclass. However, the rejection group demonstrated a significant 
increase in donor specific IgG4 with p-value 0.03 (Figure 7.3). In addition, the 
proportion of the total IgG response associated with weak/no complement activating 
ability subclasses IgG2 and IgG4 increased in the rejector group (p=0.02). 




7.3.4 IgG4 Further Analysis 
 
 In order to fully investigate the observed association with AMR of increased 
levels of IgG4, a further cohort of 35 patients (19 rejector, 16 non-rejector) were tested 
at pre-transplant, peak post-transplant IgG4, and 30 days post-transplant time-points, 
specifically for presence and levels of IgG4 specific DSA. These additional patients are 
an extension of the original cohort and represent the next group of HLA incompatible 
transplant patients from our cohort.  
 Figure 7.4A shows the Wilcoxon rank test data from both cohorts individually 
and combined. The increased sample size allows us to identify a significant increase in 
class II DSA specific IgG4 both pre-transplant and also at the peak post-transplant IgG 
time-point. There is also a significant increase in 30 day post-transplant IgG4 when 
HLA class I and II are analysed together. Figure 7.4B shows the HLA class II donor-
specific IgG4 for the large sample group at each time-point.  The overall analysis of 
median reactivity for each subclass shows that the trend for IgG4 is atypical when 
compared to the other subclasses (Figure 7.4C), with IgG4 levels continuing to rise 
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even at the 30th day post-transplant at which point all other subclasses have reduced 





Figure 7.4: Kinetics of HLA-specific IgG subclasses. A) Differences in donor-
specific IgG4 between rejector and non-rejector groups. Significant differences between 
groups are highlighted in bold. B) Box plots to show differences in IgG4 level between 
rejector and non-rejector groups. C)  Median MFI value calculated over the group of 
rejectors (black line) and non-rejectors (grey line). 
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7.4 DISCUSSION 
 
 A recent study described the use of a modified single antigen bead assay to 
demonstrate that analysis of subclass specific DSA prior to transplantation did not 
provide any substantial additional value beyond the standard pan-IgG assay in the risk 
stratification of potential transplants [158]. This data set sought to confirm this 
observation, but also to investigate the nature of subclass specific responses post-
transplantation. Regarding pre-transplant risk assignment it was also initially observed 
that no individual subclass or combination of subclasses based on putative complement 
fixing ability was predictive of AMR in the early post-transplant period. However, a p 
value of 0.08 associated with the presence of IgG4 DSA directed against HLA-class II 
was observed. This was confirmed by the testing of an additional cohort of 35 patients, 
which strengthened this association (p=0.02). Due to the unusually high concentration 
and extensive range of MFI values of IgG4 subclass, and particularly HLA class II 
specific DSA, the presence of IgG4 specific for donor HLA class II in serum before 
antibody removal therapy and before transplantation could be an indicator of high 
rejection risk.  
 Analysis of subclass profile at the time of peak post-transplant pan-IgG donor 
reactivity showed two significant observations. Firstly that the levels of IgG1 specific 
DSA had risen considerably from pre-transplant levels for the rejector group (p=0.01), 
and secondly that the proportion of the DSA response that could be attributed to 
complement fixing subclasses (IgG1 and IgG3) had skewed heavily towards this strong 
complement fixing profile (p=0.007). Interestingly, IgG3 in isolation was not 
significantly increased in those who experienced AMR. This is in contrast to recent 
studies suggesting an association between IgG3 and rejection[171, 172]. These 
associations may be due to the fact that in these studies it appears that the IgG3 DSA 
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detected are de novo and implicated more in the chronic rejection setting. In our cohort 
we were able to identify these antibodies prior to transplant and in many cases we can 
assign them to a specific historical sensitising event. This implied memory response 
would lead us to suspect that class switching has long since progressed past IgG3, and 
given that the half-life of IgG3 is only around 9 days we would not have expected to see 
an over-representation of IgG3 in our cohort. Additionally the levels of IgG4 DSA were 
also increased at this point, although when class I and II DSA were combined this did 
not reach statistical significance in the original cohort (p=0.15). However, separate 
analysis of HLA class II specific DSA shows a significant shift towards IgG4 in the 
rejector group (p=0.04), and this observation was even stronger following the testing of 
an additional 35 patients (p=0.03). This observation suggests that antigen dependant T-
cell driven affinity maturation processes are active as a significant component of the 
DSA is shifting towards production of IgG4. 
 Analysis of the 30 day post-transplant sample also shows the increased 
contribution of IgG4 DSA in the rejector group. The analysis of median reactivity of all 
subclasses shows that the IgG4 response in the rejector cohort in particular continues to 
rise at least until 30 days post-transplant. All other subclasses show reduction from peak 
post-transplant levels by this point. This suggests that the process of affinity maturation 
is ongoing and that increasing numbers of memory B cells are switching toward IgG4 
production then maturing into subclass committed plasma cells. We believe this 
observation to be novel, and has been hitherto undetectable using the pan-IgG assay as 
the relative contribution to the overall DSA response by IgG4 would always be 
miniscule in comparison to other subclasses, in particular IgG1. The fact that this 
response is dominated by reactivity to HLA class II antigens is interesting and 
potentially sheds light on the way in which the humoral response contributes to chronic 
rejection. In our laboratory, and many others, it is a common observation that chronic 
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rejection episodes are often characterised by donor specific antibodies directed against 
HLA class II, in particular HLA-DQ. In this study the post-transplant subclass specific 
response is only analysed up to the 30 day post-transplant sample, a further analysis of 
patient samples following the transplant course for much longer is indicated to 
determine the extent and duration of the progressive class switching and affinity 
maturation. The association of increased IgG1 in the rejector group at peak IgG time-
point was lost at 30 days post-transplant as IgG1 levels fall back towards baseline 
levels, it is the dynamics of the IgG1 response that typifies the overall pan-IgG profile 
we observe routinely in these cases[91]. 
 The subclass specific microbead assay itself is robust, with each subclass 
specific monoclonal antibody validated using a panel of carefully prepared subclass 
specific human myeloma immunoglobulins. Acceptable levels of cross-reactivity were 
observed between all subclasses, although as reported in other studies the greatest 
degree of cross-reactivity was seen with the IgG2 subclass specific monoclonal 
antibody. Similar to other groups we noticed a decreased sensitivity of the subclass 
specific assay when compared to the pan-IgG standard assay. It should also be noted 
that in many cases multiple subclass specific antibodies recognising the same epitope(s) 
would be present in the same sera. In theory this may lead to competitive inhibition of 
binding to single antigen beads and may mean that certain subclasses with reduced 
affinity may have reduced binding in the assay. We have balanced this reduced 
sensitivity by altering our positive cut-off threshold accordingly, with a cut-off value of 
greater than 5 times the internal negative control bead deemed positive. This is a 
stringent way of determining positivity and as such provides a greater risk of assigning 
weakly positive samples as negative. Therefore it may be that many of the observations 
here have underestimated the number of positive samples and that in turn all positive 
associations carry greater weight for this. The use of a ratio of reactivity (number of 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  David	  Lowe	  PhD	  Thesis	  2013	  
	   205	  
times greater than the negative control bead), allows us to use a ranking analysis for 
most of the data, which has the added advantage of eliminating the need to define a 
positive/negative reaction cut-off.  
 In conclusion, this data strongly suggests that there is merit in determining the 
donor-reactive IgG subclass profile prior to transplantation, as increased presence of 
donor-reactive HLA class II specific IgG4 appears to be predictive of early AMR. In 
addition, the careful monitoring of IgG subclasses in the early post-transplant period is 
highly informative, with a skewing of IgG subclasses towards IgG1 and the strongly 
complement fixing IgG1+IgG3 combination strongly associated with AMR. The early 
identification of this shift in subclass composition may indicate clinical intervention and 
reduce the impact of AMR in these high-risk transplants.  
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SELECTIVE ANTIBODY DEPLETION 
USING HLA COLUMNS 
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8.1 INTRODUCTION 
 
HLA-specific antibodies have become a dominant problem in solid organ 
transplantation. Such antibodies cause early loss of renal allografts if present at the time 
of transplantation, and approaches to transplanting across anti-HLA antibodies are only 
partially successful [99, 105, 129]. HLA-specific antibodies cause long term graft 
failure in kidney and other solid organ transplants [24, 173]. Despite the realisation that 
these antibodies are of such importance, our ability to effectively suppress synthesise 
and remove these antibodies from the patient blood are limited. Clinical outcomes 
would be markedly improved if we were able to define antibody specificities and 
selectively control their synthesis, and also selectively remove large amounts of HLA 
antibodies from patients. 
The ability to synthesise and purify HLA proteins has recently transformed the 
ability to measure HLA antibody levels in patients’ serum, as the proteins have been 
coupled to microbeads and have allowed rapid measurement of multiple antibody 
specificities from small amounts of serum. Reproducible solid phase assays have not 
completely replaced cellular crossmatch techniques, but are now a mainstay of HLA 
antibody screening and monitoring [91, 174].  
One new application would be better to define the specificities of HLA 
antibodies. These are not related to HLA specificities per se, but to the epitopes and 
more specifically eplets on HLA proteins. An HLA molecule may be capable of 
stimulating the production of more than one anti-HLA antibody specificity, and an 
antibody directed against an epitope on one HLA protein may react with the same 
epitope on many other HLA proteins [81, 146]. Many HLA epitopes have been defined 
[80, 147] but it is not yet possible to use this understanding to define a patients’ HLA 
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antibody profile by epitope. It is still necessary to list HLA specificities, which is 
cumbersome, imprecise, and may prohibit transplantation unnecessarily. 
Methods currently available for the removal of HLA-specific antibodies from 
patients are sufficient to allow the successful transplantation of those with moderate 
levels of donor HLA specific antibodies (DSA)[90, 91, 107, 116, 129]. A commonly 
used method of antibody depletion is plasma exchange, where patient blood is passed 
through a plasma filter or is simply centrifuged. The plasma component, which contains 
the antibodies, is removed and discarded. However, along with the antibodies the 
plasma component also contains albumin and other clotting factors and these have to be 
replaced with fresh donor plasma. Depending on the size of the patient, only 3-4 litres 
of plasma can be treated per session.  Double-filtration plasmapheresis (DFPP) is a 
more refined approach whereby plasma is separated as for plasma exchange but is then 
passed through a second filter which operates via size exclusion. This filter traps larger 
molecules and consequently smaller plasma proteins which need to be replaced in 
standard plasma exchange such as albumin and lower molecular weight clotting factors 
are allowed to pass back into the patient. This approach is much better tolerated by the 
patient and typically DFPP treatment volumes can be 6-8 litres per session, usually only 
limited by fluid shift out of the vascular compartment [108].  A slightly more selective 
approach can be taken using protein A immunoadsorption. Once again plasma is 
separated  as for DFPP and is then passed through a column containing immobilised 
protein A. Protein A binds human IgG, with the exception of the potent complement 
fixing IgG3 isotype. It is therefore a highly effective method for removing antibody 
prior to transplantation. Following passage through a protein A column only the 
antibody molecules are removed leaving all other plasma proteins unaffected which 
makes this a very well tolerated treatment modality, with treatment volumes of up to 40 
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litres in a single session possible [110]. The major disadvantage of protein A 
immunoadsorption is its high cost and additional removal of essential, protective IgG 
However, these methods cannot remove sufficient antibody pre-transplant to 
allow safe transplantation of those with high levels of donor specific antibodies (DSA), 
and post-transplant the non-specific nature of current methodologies such as DFPP or 
Protein A columns means that all antibodies are depleted, leading to a significant 
infection risk, especially when antibody removal is performed in patients on intense 
immunosuppression. The ability to remove selectively large amounts of HLA-specific 
antibody before and after HLA antibody incompatible (HLAi) transplantation would 
make this treatment approach much safer and enable many more renal transplants to 
take place, and might also be useful for other organ transplants. Selective antibody 
removal has been possible for some time in the ABO incompatible transplant setting 
following the introduction of Glycosorb columns, where the only component removed 
is the ABO blood group specific antibody that is bound to the column, everything else 
in the patient plasma passes back into the patient. This makes this procedure very well 
tolerated with up to 10 litres of plasma treated in a single session being reported [111].  
In this study we set out to develop and test a method to selectively remove HLA 
specific antibody from human blood. 
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Serum samples were taken from our archive of 100 HLAi transplant patients. 
The study was approved by the West Midlands Research Ethics committee and written 
informed consent was obtained. The HLA specific antibody profiles of these patients 
have been elucidated to the highest available resolution by single antigen bead assay. 
Patients were chosen on the basis of having high reactivity (>5000 mean fluorescence 
intensity (MFI)) for the specific HLA antibody studies,  as measured by luminex single 
antigen bead analysis. 
For clinical scale column analysis larger volumes of plasma effluent, a by-
product of DFPP were used for analysis. Briefly, 500-600ml of patient specific plasma 
effluent was centrifuged at 4000g for 45 minutes and supernatant  filtered through 
0.45µM. The filtered plasma effluent was then diluted 1:4 with HLA-specific antibody 
negative fresh frozen plasma (FFP) to a final volume of 2 litres. A specific anti-HLA 
reactivity in the range 5-10,000 was determined by luminex single antigen bead 
analysis. 
 
8.2.2 Soluble HLA-A*02:01 / B*07:02 Protein Production 
 
To produce secreted HLA-A2, α-chain cDNA of HLA-A*02:01 or HLA-
B*07:02 was modified at the 3' end by PCR mutagenesis to delete codons encoding the 
transmembrane and cytoplasmic domains and the VLDLr purification epitope added. 
The resulting construct was cloned into the mammalian expression vector pcDNA3.1(-) 
that contained a geneticin resistance cassette. Class I HLA deficient cell line 721.221 
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was transfected with the expression construct and drug resistant clones were selected in 
growth media containing G418 (0.8mg/ml). sHLA production was measured using a 
capture ELISA where W6/32 was the capture antibody and anti-β2m was the detecting 
antibody. sHLA producing clones were sub-cloned into 96 well plates by limiting 
dilution and high producing sub-clones were expanded and seeded in AccuSyst-
Maximizer hollow fiber bioreactor (Biovest International). Approximately 500 mg of 
sHLA-A2 was harvested from the bioreactor. sHLA-A2 containing supernatant  was 
loaded on a W6/32 immunoafffinity column and washed with 40 column volumes of 
20mM phosphate buffer pH 7.4. sHLA-A2 molecules were eluted from the affinity 
column with 50mM DEA at pH 11.3, neutralized with 1M TRIS pH 7.0, and buffer 
exchanged and stored at 1 mg/ml in sterile PBS. 
 
8.2.3 Class I Single Antigen Bead Assay 
 
HLA class I specific antibodies were analysed using a recombinant single 
antigen microbead assay manufactured by One Lambda Inc. (Canoga Park, CA) and 
analysed on the Luminex Xmap 200 platform (Qiagen, UK).  Antibody binding was 
measured as raw fluorescence to avoid differences in background binding seen with 
different sera which disproportionately influences relative fluorescence, a particular 
problem associated with DFPP therapy. All assays were performed using serum/bead 
ratios in accordance with the manufacturer’s instructions.  Raw MFI values were used 
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8.2.4 HLA Protein Mini-column Coupling Protocol 
 
 
To prepare a 200µg HLA protein column, 200mg freeze-dried cyanogen 
bromide (CNBr) activated Sepharose-4 Fast Flow matrix (GE Healthcare, NJ,USA) was 
swollen and activated using 2ml 1mM HCl pH3.0 and chilled on ice for 30 minutes. 
The swollen matrix was then centrifuged at 2000g for 10 minutes and supernatant was 
discarded. Matrix was then resuspended in 2ml suspension buffer (50mM HEPES, 
pH7.8, 100mM NaCl), then re-centrifuged at 2000g for 10 minutes. Matrix was then 
resuspended in 500µl suspension buffer to give a final matrix concentration of 
approximately 2mg/ml. 
The starting concentration of HLA protein was determined using OD280 
absorbance measurement. 200mg of HLA protein was added to 100µl matrix and 
incubated for 2 hours at 4°C.  The matrix was centrifuged at 2000g for 5 minutes and 
the OD280 absorbance of the supernatant was determined to confirm coupling efficiency 
greater than 80%. Non-reacted matrix residues were then dectivated by the addition of 
1ml 1M ethanolamine and incubation at 4°C overnight. Supernatant was then removed 
and the matrix resuspended in 1ml PBS containing 0.05% sodium azide (NaN3) pH7.4. 
The protein coupled matrix was then packed into a 2ml affinity chromatography 
column. A negative control column was prepared in parallel using bovine serum 
albumin (BSA) as an alternative to HLA protein. 
 
8.2.5 Clinical Scale HLA Protein Column Coupling Protocol 
 
sHLA-A2 was covalently linked to Sepharose 4 Fast Flow using NHS activated, 
amine-based chemistry (GE Life Sciences). For the coupling reaction 1mg of sHLA was 
added per 1ml of swollen matrix in alkaline buffer (0.1N NaHCO3 pH8.3). After 1 hour 
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of coupling, the reaction was stopped. Uncoupled NHS groups were blocked with 0.1M 
TRIS pH8.3 for 2 hours. After blocking, the matrix was washed and stored in PBS, 
0.02% NaN3. For all matrix the used in this study, the coupling efficiency was ≥90%. 
 
8.2.6 Antibody Removal using HLA Protein Columns 
 
Mini-columns were tested for antibody binding capacity by treating repeated 
cycles of 1mg HLA-specific monoclonal antibodies W6/32 and Beta 2 microglobulin 
(B2M).  1ml of patient serum was  applied to the HLA protein column containing A2 
antibody specificity and allowed to run through by gravity. The negative control BSA 
column was run in parallel. The post-column serum fractions were then re-tested with 
class I single antigen beads. To analyse the characteristics of antibody eluted from the 
columns 5ml 100mM glycine pH11 was added to the column and the eluate was 
immediately neutralised in 1M Tris-HCl pH7. Eluted fractions were dialysed into PBS 
pH7.4 and analysed using single antigen bead assay. 
Clinical scale HLA columns were tested for  antibody binding capacity by 
treating with 25mg of class I HLA-specific monoclonal antibodies W6/32 and B2M. 
Columns were set up in a simple circuit which first allowed 1 litre of  NaN3 free PBS to 
be pumped through the column. Pressure monitors were set up proximally and distally 
to the HLA column in order to monitor the fluid pressure through the column and 
potentially identify any build up in pressure indicative of column blockage. The circuit 
was then switched to allow the diluted patient plasma to flow through the HLA column 
at a flow rate of 50ml/min used clinically with Glycosorb. 1ml aliquots of plasma were 
taken after flowing through the column for further analysis at specified timepoints. 
After the circuit was  switched back to NaN3 free PBS to fully flush the column clear of 
any unbound protein remaining from the patient plasma run. During the antibody 
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elution phase, 1 litre of 100mM glycine pH11.0 was passed through the column and 





8.3.1 Optimisation of Column Elution Conditions. 
 
 The soluble HLA (sHLA) proteins used to produce the mini-columns are 
sensitive to acidic pH’s below pH6.5. Therefore traditional acid elution would 
irreversibly damage the integrity of the sHLA. In order to re-use the HLA columns a 
suitable elution buffer which utilises an alkaline pH needed to be identified. A stock 
solution of 1M glycine was prepared, then a pH range of 8-12 was prepared in 100mM 
glycine. W6/32 was passed through a 1ml HLA-A2 column then eluted with each buffer 
in turn with rising pH. The combined elution profiles for each buffer is shown in figure 
8.1.     
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Figure 8.1: Optimisation of elution conditions. Solutions of 100mM glycine were set 
up at a range of pH values. pH11 was clearly shown to be most effective at HLA- 
specific antibody isolation  
 
 
Peak elution of W6/32 monoclonal antibody was seen at a pH of 11, with the 
total amount of eluted monoclonal as determined by OD280 absorbance of 250µl. 
Effective elution is observed between pH10 and 11.5. Long-term storage of eluted 
antibody fractions required a neutralisation of the pH with the addition of 1M Tris pH7.  
 
8.3.2 Mini-column Validation 
 
 Having determined the optimum conditions for antibody elution, HLA-A2 and 
B7 mini-columns were assessed for efficacy and reproducibility of elution conditions by 
running through the HLA-Class I specific monoclonal antibodies W6/32 and B2M at a 
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absorbance of the eluted fractions. Column performance was analysed for a minimum of 
3 cycles of each monoclonal. Performance trend for each column is given in figure 8.2. 
 
 
Figure 8.2: HLA-A2 and HLA-B7 mini-column validation. Capacity of 1ml mini-
column to isolate W6/32 or B2M monoclonal antibody was maintained following 
multiple absorption / elution cycles. 
  
 
Column efficiency was consistent over repeated cycles of antibody binding / 
column regeneration with a binding capacity in the region of 200-250µl of HLA 
specific antibody which was consistent after multiple elution cycles. Capacity of the 
1ml HLA column is therefore unaffected by the extreme alkaline pH required to elute 
antibody from the HLA column. 
 
8.3.3 Reduction capacity of 1ml mini-columns 
 
 Serum samples from patients who were included in our HLA incompatible 
(HLAi) renal transplant programme were selected if antibodies directed against HLA-













































	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  David	  Lowe	  PhD	  Thesis	  2013	  
	   217	  
HLA antibody reactivity (as shown by the mean fluorescence intensity [MFI] value) 
was determined by microbead analysis. Sera (typically 5ml) was then passed through 
the HLA-A2 or HLA-B7 mini-column and then re-analysed for HLA antibody reactivity 
by microbead analysis. Figure 8.3 shows the reduction in MFI post-column in six 
patients positive for anti-A2 and six HLA-B7 antibody positive patients. 
 
 
Figure 8.3: Reduction in MFI reactivity following antibody depletion using HLA-
A2 and HLA-B7 mini-columns. In all cases mini-column depletion resulted in a 
significant depletion of DSA reactivity measured by microbead assay. 
 
 Figure 8.3 clearly indicates that in all cases depletion of HLA-A2 specific 
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removal of 95.45% (range: 91.5-98.71%). HLA-B7 specific antibody removal was also 




8.3.4 Specificity of Antibody Eluted from the HLA-column 
 
The mini-column had shown excellent capacity to deplete HLA-specific 
antibody, with 1ml columns depleting up to 5ml patient sera. The antibody removed by 
the column was then eluted from the column for further analysis. Figure 8.4 shows the 
elution profiles of three patients whose sera was passed through a 1ml HLA-A2 mini-
column and three whose sera was passed through a 1ml HLA-B7 mini-column. 
Luminex microbead analysis was performed on fractions taken during the load phase 
(when patient sera was passed through the column), the wash phase (rinsing with 4ml 
PBS prior to elution), and the elution phase (antibodies released from the column by 
alkaline elution). 
The data in Figure 8.4 clearly indicates that the mini-columns elute HLA-
specific antibody in an epitope specific manner. Cases i and iii show that 3rd party 
antibody (i.e antibody that does not recognise HLA-A2 or B7 specific epitopes) passes 
through the mini-column in the load and wash phases. HLA-A2/B7 specific antibody is 
absorbed onto the column matrix, as supported by the excellent reduction in MFI values 
detailed in figure 8.3. Under appropriate alkaline elution conditions this HLA-specific 
antibody is released from the column and detected at a range of concentrations by 
microbead analysis. The antibody that is eluted from the column shows not only HLA-
A2 or B7 specific reactivity but also excellent reactivity against a range of antigens 
which share common epitopes with HLA-A2.  
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Figure 8.4: Epitope specific absorption using 1ml HLA Columns. Selected patients 
were passed though HLA-A2 of HLA-B7 1ml columns. Antibody was absorbed and 
eluted in an epitope specific manner   
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8.3.5 Effect of Mini-Column Depletion on Crossmatch Results. 
  
 The aim of antibody reduction therapies in renal transplantation is to achieve a 
negative crossmatch by the time of transplantation, although in practice current 
therapies are often unable to reduce antibody titres sufficiently to achieve this goal. The 
HLA mini-columns were able to reduce microbead MFI values by around 90% on 
average, this level of depletion should lead to a significant reduction in RMF in the 
FCXM. 
 Figure 8.5 shows the FCXM data on the six cases highlighted earlier which were 
passed through the HLA-A2 mini-column. Pre-column, post-column, and peak elution 
fractions for each case were crossmatched against two separate lymphocyte 
preparations;  
 
Cell 1 HLA type; HLA-A2; B35,55; C4,9; DR1,4; 52; DQ5 
Cell 2 HLA type; HLA-A2,3; B8,62; C7,9; DR13,17; 52; DQ2,6 
 
All six samples were positive against both cell types with RMF values for pre-
column samples ranging from 2.3 to 21.3. Following mini-column depletion all samples 
fell below our RMF cut-off of 2.3 and in the clinical setting would have been called 
crossmatch negative.  
The RMF values observed differ between the two donor cells used for FCXM, 
with values considerably higher for cell line 1. The increased sensitivity of cell type 1 is 
presumably due to the HLA type of the cell as cell 1 is homozygous for HLA-A2, 
whereas cell 2 was typed as HLA-A2,3.  
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Figure 8.5: Flow cytometry Crossmatching (FCXM) of samples treated with HLA 
columns, and reactivity and eluted antibodies. A) Relative median fluorescence 
(RMF) from pre-column, post-column, and peak elution fractions for HLA-A2 column 
cases 1-6. Positive cut-off RMF of 2.3 is indicated by the red bar. B) Flow cytometry 
dot plots showing the reduction in cell binding post-column and the restoration of anti-
donor reactivity in the antibody elution fraction. The FCXM technique in outlined in 
greater detail in section 2.6.4. 
 
 
The same donor cells were tested against the same panel of sample by CDC 
analysis. Of the six cases, cases 1 and 5, the two highest positive flow cytometry 
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In both cases the CDCXM result on the post-column sample was negative, with 
CDCXM positivity restored when testing the peak column elution sample (Figure 8.6). 
 
Figure 8.6: CDCXM data showing effect of column depletion from Case 5. Positive 
crossmatch with pre-HLA-A2 column treated sera, rendered negative by column 
absorption. CDC reactivity is then restored in the eluate. Red stained cells denote cell 
lysis and CDC positivity  
 
 
The crossmatch data clearly shows the potential of the HLA mini-column to 
reduce HLA-specific antibody to levels sufficiently low as to change the pre-transplant 
crossmatch from positive to negative. The following section shows experimental data 
from a clinical scale HLA antibody removal column. 
 
 
8.3.6 Clinical Scale HLA-Column Validation 
 
Based upon earlier column capacity analysis using the 1ml mini-columns we 
estimated that the potential binding capacity of a 50ml clinical scale column containing 
approximately 50mg of sHLA would be in the region of 12.5 to 15mg of HLA specific 
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antibody. This calculation is derived from a column capacity in the region of 250µg/ml 
as shown in figure 8.2.  
Preparations of W6/32 and the HLA-DR specific monoclonal antibody L243 
were standardised to 110mg/litre and 120mg/l respectively. Two hundred and fifty 
millilitres of W6/32 preparation was passed through the clinical scale HLA-A2 column 
at a flow rate of 50ml/min and eluted in 1 litre 100mM glycine pH11.0.  Similarly, 
250ml of L243 (120mg/l) was passed through the clinical scale HLA-DR11 column at 
50ml/min then eluted in 100mM glycine pH11.0. Column capacity was calculated by 
measuring the total protein content of the eluate from each column run (figure 8.7).  
 
Figure 8.7: Estimated column capacity using saturating concentrations of HLA-
specific monoclonal antibodies. HLA-A2 column estimated capacity 24.1mg, HLA-
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Calculation of the area under the curve provides an estimated column capacity 
for the HLA-A2 column of 24.1mg, and for HLA-DR11 of 20.7mg. These values are 
above the projected column capacities based upon 1ml column capacity. 
 
 
8.3.7 Clinical Scale HLA Column – Patient Samples. 
  
 Three patients were chosen with HLA-A2 specific reactivity and three were 
chosen with HLA-DR11 specific antibody as confirmed by luminex single antigen bead 
analysis. The plasma effluent samples were centrifuged at 4000g for 30 minutes to 
pellet any preformed cryogel and other cellular debris then diluted to a total volume of 
between 2-2.5 litres (approximately the plasma volume equivalent to a 50-60kg patient) 
using fresh frozen plasma tested negative for HLA-specific antibody (data not shown).  
Starting volumes and HLA-A2/DR11 specific MFI values are shown in Table 8.1.  
 
Table 8.1: Starting MFI levels for samples prepared for clinical scale column 
depletion.  Samples were diluted using fresh frozen donor plasma previously tested to 
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8.3.8 Clinical Scale HLA Column-Circuit Design 
 
 The clinical scale column circuit was set up as outlined in Figure 2.16. The 
circuit incorporated sampling points prior to treated sample collection so that column 
performance could be monitored at regular intervals throughout the treatment run.  
 Prior to the first patient sample run a blank column containing 50ml of unbound 
‘naked’ sepharose was set up and 2 litres of HLA antibody negative diluted FFP was 
run through the column on a continuous loop for three hours to monitor the pressure at 
each of the three pressure monitoring points built into the circuit. Figure 8.8 shows the 
pressure monitoring data over three hours. 
 
 
Figure 8.8: Clinical scale column circuit testing. Plasma was run continuously 
through the blank column for three hours. Pressure readings remained constant 
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Over the three hour period of pressure monitoring the pressure remained 
constant at each sampling point of the circuit. It was necessary to ‘prime’ the line to 
remove air that had built up in the system after around two hours of running time. The 
pressure readings were well below the estimated crush pressure of the sepharose, which 
is thought to be in the region of 100 millibars. This data enabled us to proceed to patient 
samples with confidence that the circuit would be robust enough. 
 
 
8.3.9 HLA-A2 Clinical Scale Column Depletion 
 
 Three patients were run through the HLA-A*02:01 column. The MFI values 
were measured pre-treatment, post-treatment, and at various intervals during the course 
of treatment. Eluted antibody was also purified, concentrated and assessed for correct 
specificity, soluble inhibition experiments using panels of purified soluble HLA 
proteins were used to determine epitope specific reactivity of column eluted IgG. 
Results for each of the three patients will be presented individually. 
 
Patient 1 LT66 : Column Performance 
 
 Plasma effluent from LT66 was diluted to 2 litres in HLA antibody negative 
fresh frozen plasma (FFP) and A2 reactive MFI of 5899 was measured by single antigen 
bead assay (SABA). The patient sample was connected to the column circuit as outlined 
in Figure 2.6. Following a single pass through the clinical scale column A2 reactive 
MFI had fallen to 1167, a reduction of 80.22%. Figure 8.9 shows the reactive MFI 
values measured at defined timepoints throughout the depletion cycle, samples were 
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taken every 100ml of patient plasma and selected samples were tested by microbead 
analysis. Starting values are shown at timepoint 0.   
 
Figure 8.9: Depletion of HLA-A2 specific reactivity in patient LT66. Direct 




HLA-A2 reactive MFI values are shown to gradually increase as the cycle 
progresses, presumably as the column increases in saturation and specific antibody 
binding reduces in efficiency.  
Following column depletion captured antibody was removed via alkaline elution 
using 100mM glycine pH11.0. Figure 8.10 shows the eluted MFI values at selected 
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Figure 8.10: Analysis of antibody eluted from the column following treatment of 
patient LT66. Bead reactivity of purified HLA-specific antibody at different timepoints 
in the elution cycle (left panel). Single antigen bead analysis of 100ml timepoint of 
elution cycle (right panel). 
  
 
Elution fractions of 10ml each were collected and protein content was measured 
using OD280 readings. A total of 14.4mg of HLA specific antibody was isolated from 
the clinical scale column. 
 
 
Patient 2 LT68: Column Performance 
 
 LT68 plasma effluent was diluted to 2 litres in FFP to give anti-HLA-A2 
reactivity of 6904 (table 8.1).  Patient sample was then passed through the clinical scale 
column at 40-50ml/min. Reductions in specific MFIs are shown in figure 8.11. 
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anti-B57 and anti-B58 reactivity reduced from 7805 to 1295, and 4793 to 539 
respectively. Each of these represents a percentage reduction in MFI in excess of 80% 
in a single column treatment (figure 8.11 inset). 
  
 
Figure 8.11: LT68 column depletion effectiveness.  Post-column MFI values show 
effective reduction from pre-column levels, equating to an overall reduction in excess of 
80% (inset). 
 
 The effectiveness of the column removal was monitored by measuring samples 
at specific points during the removal cycle. The levels of the relevant antibodies 
throughout the cycle are shown in figure 8.12. The clinical scale column is extremely 
efficient at removing antibody specifically with selected third party specificities (HLA-
B7,13,27,60,61,81) being left with reactivity left mainly intact.  
Figure 8.12 shows column removal for HLA-A2 shared epitope specific 
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the entire depletion cycle. This suggests that although the column removes over 80% of 
HLA specific reactivity in a single pass the column does not appear to have reached 
saturation point.  
 
 
Figure 8.12:  MFI values recorded during the antibody depletion cycle. Column 
specific and third party specificities (left panel); Column specific antibodies only (right 
panel)   
 
 
 Antibody was eluted using 1 litre of 100mM glycine pH11.0 and elution 
profiling was performed by measuring the OD280 values of protein absorbance at 20ml 
intervals. Peak elution was observed at 100ml elution buffer, with the MFI values for 
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Figure 8.13: MFI values for eluted antibodies. Peak elution fraction MFI values 
specific for HLA-A2, B57, B58 representing the 62GE epitope. 
  
  
Patient 3 LT79: Column Performance 
 
  
 LT79 plasma effluent was diluted to 2 litres in FFP to give anti-HLA-A2 
reactivity of 18151 MFI (table 8.1), therefore this patient represented a much higher 
MFI than the previous two cases. MFI values such as this are seen frequently in our 
sensitised patient cohort but are of sufficiently high level to potentially prevent the 
entrance into our HLA antibody incompatible (HLAi) transplant programme.  
Once again the sample was passed through the clinical scale column at a rate of 
40-50ml/minute. Column specific antibodies; anti-A2, A69, B57, and B58 (detailed 
epitope definition for this patient was described in section 4.3.2) showed reduction after 
one cycle of depletion as follows: anti-A2 18151>8547, anti-A69 10020>2765, anti-
B57 12201>2091, anti-B58 9940>786 MFI. Although each of these reductions were 
substantial (>50% for A2, >75% for A69, B57 and B58), there remained considerable 
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first depletion cycle were then similar to the MFI values at starting point for the 
previous two patient samples tested. Therefore, following elution of HLA specific 
antibody from the clinical scale column (details to follow) the post-column fraction was 
passed through the column for a second depletion cycle with flow rates mirroring those 
utilised for the first passage. Following the second round of depletion the specific 
reactivities were as follows: anti-A2 5141, anti-A69 1254, anti-B57 922, anti-B58 329 
MFI. Figure 8.14 details the reduction in MFI of each of these antibody specificities for 
each depletion cycle along with the calculated percentage reduction in MFI.  
 
Figure 8.14: LT79 antibody depletion. Column specific antibody (A2,A69,B57,B58) 
depleted with 2 depletion cycles. Non-column specific HLA-B7 antibody was not 




The statistics suggest that column depletion has been inferior to that observed 
















































	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  David	  Lowe	  PhD	  Thesis	  2013	  
	   233	  
compared with just over 50% in this instance. However, it must be considered that the 
antibody levels are much higher in this patient, consequently it is a very clear possibility 
that the microbead assay had exceeded the saturation point for our column specific 
antibodies, in particular antibody against HLA-A2 (see chapter 3 for more detailed 
explanation). Therefore the microbead analysis for this patient was repeated at a dilution 
factor of 1 in 10 for pre-column, post depletion cycle 1, and post-depletion cycle 2 
samples. The resulting revised figures for column depletion are shown in figure 8.15. 
 
 
Figure 8.15: Dilution analysis of patient LT79 saw greatly enhanced column 
efficiency when sample tested at 1in10 dilution. Left panel: reduction in raw MFI 
values. Right panel: percentage reduction in reactivity after each depletion cycle 
 
 
 These data clearly show that on the initial microbead analysis the assay was 
indeed saturated and that the true scale of the depletion was greater than initially 
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following a second round of depletion. After two depletion cycles almost all of the anti-
A69, B57 and B58 reactivity has been removed. 
 The analysis of column depletion through the course of the depletion cycles 
shows the high titre of the antibody leading to a plateau of antibody depletion at around 
1 litre of plasma volume passed through the column (Figure 8.16). HLA-A2 microbead 
reactivity is immediately reduced from its starting value of over 18,000MFI to around 
the 5,000 MFI level as plasma begins to flow distal to the column. MFI values then 
increase up to around 9500 whereafter the antibody level remains constant. 
The specificity of the column is again highlighted by considering the MFI values 
of the HLA-B7 microbead which remains constant, in the region of 9000-10,000MFI 




Figure 8.16: Microbead analysis of HLA specific antibody through two depletion 
cycles. High titre HLA-A2 specific antibody appears to saturate the column at around 1 
litre of plasma treated. 
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 Figure 8.16 also shows the effectiveness at removing the antibody reactive to 
epitopes shared by HLA-A69, B57, and B58. These specificities are drastically reduced 
by the first column depletion. Reactivity for these specificities is initially in the negative 
regions then begins to rise gradually through the course of the first depletion cycle. 
Although HLA-A69, B57, and B58 MFI values are low they are still competing for 
binding sites on the A2 column in very close proximity to other A2 epitope specific 
antibodies present in much higher titre. The data also suggests that a further cycle of 
depletion would be required to fully deplete HLA-A2 specific reactivity. 
 As before bound antibody was removed from the column following each 
depletion cycle using alkaline elution. Twenty millilitre fractions were taken through 
the elution cycle and each fraction was assessed for protein content using the nanodrop 
OD280 method. For each depletion cycle the elution fraction from 80-100ml contained 
the highest protein concentration. This fraction was then chosen for single antigen 
microbead analysis. The MFI values for each of the column specific eluted antibodies 
are shown in figure 8.17.   
 
  
Figure 8.17: MFI values for eluted antibodies for patient LT79. Peak elution 
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High values were recorded for all specificities of antibody eluted after depletion 
cycle 1. HLA-A2 specific reactivity measured in excess of 18,000 MFI. Similarly HLA-
A69, B57, and B58 reactivities measured 16,000,  14,000, and 10,000 respectively.  
Following a second depletion cycle once again there were significant concentrations of 
HLA specific antibody eluted from the column, in particular anti-A2 detected at 
>12,000 MFI, suggesting that once again the column had reached saturating levels. This 
is supported by the fact that an HLA-A2 MFI of 5141 was still detectable in the patient 
sample even following two rounds of column depletion. In contrast the MFI values of 
the other column specific eluted antibodies, HLA-A69, B57, and B58 were eluted in 
much lower concentration after the second depletion. This suggests that only residual 
low level reactivity remained in the patient sample, a fact borne out by the 
corresponding MFI values in the post-column patient sample (HLA-A69: 1254,  B57: 
922,  B58: 329MFI). 	  
 
 
8.3.10 HLA-DR11 Clinical Scale Column Depletion 
 
 As was performed for the HLA-A*02:01 column, three patients were run 
through the HLA-DRB1*11:01 column. The circuit design, flow rates, elution 
conditions and regeneration protocol were all performed identically to the HLA-
A*02:01 column depletion protocol. The MFI values were measured pre-treatment, 
post-treatment, and at various intervals during the course of treatment. Eluted antibody 
was also purified. As for HLA class I column depletion results for each of the three 
patients will be presented individually. 
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Patient 1 LT56: Column Performance 
 
 Plasma effluent taken from the first round of double filtration plasmapheresis 
prior to transplant for patient LT56 was diluted to a final volume of 2.2 litres using 
fresh frozen plasma. Microbead analysis of the diluted sample gave HLA-DR11 
reactive raw MFI of 4798 (Table 8.1).  The entire sample was then passed through the 
HLA-DR11 column at a steady flow rate of 40-50ml/min, with samples taken 
throughout the cycle to assess column performance. Figure 8.18 shows the depletion of 
HLA-DR11 reactivity and also the marked depletion of reactivity for a range of other 
HLA-DR specific beads. 
 
 
Figure 8.18: HLA-DR11 column depletion for patient LT56. Pre and post-column 
microbead MFI values for a range of HLA-DR specificities. 
 
 Raw MFI for HLA-DR11 was reduced from 4798 to 1762 a percentage fall of 
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effectively deplete a range of HLA-DR bead reactivities. Raw MFI values for HLA-
DR12, DR15, DR16 and DR51 were reduced by 83%, 73%, and 81% respectively. 
Specificities with markedly lower starting levels: HLA-DR1,103 and 8 were reduced by 
even larger percentages, 89%, 79%,  and 94% respectively. Indeed, of the ten bead 
specificities listed in figure 8.18 only HLA-DR4, DR13, and DR51 raw MFI values 
were less effectively depleted than the HLA-DR11 MFI.  
 The analysis of the column removal measured during the depletion cycle shows 
HLA-DR11 reactivity is reduced drastically as the first few millilitres flow through the 
column (figure 8.19). As the depletion cycle continues the DR11 bead MFI rises 
steadily as the column presumably becomes more and more saturated. 
 
 
Figure 8.19: Antibody levels monitored through the depletion cycle. HLA-DR 
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 Figure 8.19 also shows very similar removal dynamics for a range of other 
HLA-DR specificities. MFI values for the specificities listed in figure 8.19 all drop 
significantly in the early portion of the depletion cycle and follow the trend described 
for HLA-DR11 typically leading to MFI values around 50% of starting MFI when the 
final sample point at the end of the cycle is tested. The two notable exceptions to the 
trend are the MFI values corresponding to HLA-DR4 and HLA-DR13. These 
specificities appear to reduce initially then pass through in greater concentration for 
around the first 400ml, then MFI values fall again presumably as antibody is absorbed 
by the column. This continues until around 1750ml has passed through before a second 
rise in MFI to complete the depletion cycle. Possible explanations for these 
observations will be given later. 
 The column bound antibody was then eluted in the same way as before, by flow 
through of 1 litre 100mM glycine pH11 with 10ml fractions being taken throughout the 
elution cycle. Figure 8.20 shows the single antigen microbead data for all of the 
antibody specificities eluted from the column. In addition to the peak elution fraction 
(110ml as determined by OD280 protein quantification), both 40ml and 70ml elution 
fractions were also analysed by microbead testing.  
High levels of HLA-specific antibody were eluted from the HLA-DR11 column. 
At peak elution HLA-DR11 bead reactivity reached an MFI of 13459, which was 
surpassed by a DR13 peak reactivity of 16165. Interestingly, despite only a modest 
post-column reduction in MFI for HLA-DR4 reactivity (7581 down to 6049) large 
amounts of DR4 specific antibody was eluted (peak MFI: 12280). This suggests the 
presence of multiple antibodies present in the original sample, which would appear to 
be specific for a number of epitopes on the DR4 molecule. Some of these presumably 
share epitopes with the DR11 molecule but others do not- as suggested by a post-
column DR4 specific MFI of 6049 and a percentage reduction of just over 20%. 
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Figure 8.20: LT56 column specific antibody elution. A range of antibody specificities 
were eluted from the DR11 column. 
 
 
Patient 2 LT65: Column Performance 
 
 Plasma effluent from patient LT65 was diluted to 2 litres using fresh frozen 
plasma to give a HLA-DR11 reactive MFI of 2742. The sample was then passed 
through the 50mg HLA-DR11 column as before. Figure 8.21 shows the fall in DR11 
MFI post-column from 2742 down to 703 a reduction of 74.4%. A number of other 
specificities were also reduced by a similar magnitude; DR8 down by 73.8%, DR12 
down 53%, DR13 down by 65.8%, DR14 down by 67%, DR15 and 16 down by 77.9 
and 75.1% respectively. Other specificities such as DR4, DR17, and DR18 were also 
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column MFI levels for HLA-DQ7,8, and 9 were completely unaffected following 
column depletion.  
 
 
Figure 8.21: Reduction of HLA reactivity in patient LT65. Pre and post-column 
microbead MFI values for a range of HLA-DR are depleted. HLA-DQ specificities 
remain unchanged  
 
  
 The time-course analysis of bead reactivity during the depletion cycle is shown 
in figure 8.22. A number of specificities show a significant early reduction in MFI from 
starting level (Figure 8.22A) which then reach a plateau following around 500ml of 
plasma treated. It should be noted that the very early reduction in MFI is due mainly to 
the dilution effect of switching from PBS running through the column to plasma as 
indicated clearly by the initial reduction in HLA-DQ7,8,9 reactivity which rapidly 
stabilises at pre-column levels after around 200ml of treated plasma. 
 It can be seen in figure 8.21 that some specificities, for example DR11, 8, 
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mentioned earlier this is presumably due to the presence of multiple epitope specific 
antibodies, some of which are present on the DR11 protein. This appears to be a 
particularly common occurrence of antibodies directed against HLA-DR4 as this was 
also observed in patient LT56.  
 
 
Figure 8.22: HLA-DR11 column dynamics for depletion of patient LT65. A) MFI 
values of antibody specificities through the depletion cycle. B) HLA-DR11 and DR4 
bead specific MFI values  
 
 Figure 8.22B highlights the difference in MFI reduction between these two 
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reactivity. HLA-DR11 antibody was measured at a relatively low level of <3000 MFI 
prior to treatment which is then reduced to well below 1000MFI upon commencing the 
depletion cycle. Reactivity then remains at low levels throughout the entire treatment, 
remaining below 1000MFI throughout. Conversely, HLA-DR4 reactivity is initially 
reduced by around 50% following the first 400ml of plasma treatment as the HLA-DR4 
reactive component which share one or more epitopes with DR11 are absorbed by the 
column. Reactivity then increases steadily through the duration of the cycle as the 
column becomes increasingly saturated with DR11 epitope specific antibody. As before 
the bound antibody was then eluted from the column using glycine pH11.0 collected in 
10ml fractions and assessed for protein content using OD280 readout. Figure 8.23 
shows the eluted antibody profile at selected fractions using single antigen microbead 
analysis. 
Figure 8.23: HLA-specific antibodies eluted from HLA-DR11 column for patient 



















40ml" 60ml" 80ml" 110ml"
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  David	  Lowe	  PhD	  Thesis	  2013	  
	   244	  
It can be seen from figure 8.23 that large amounts of all specificities that had 
previously shown MFI reduction could be eluted from the DR11 column. With the 
slight exception of DR12 the MFI values across the whole range of HLA specificities 
detected are extremely consistent, taking the 110ml elution fraction as an example and 
omitting DR12, the lowest detected MFI is 10889MFI for DR12 rising to 14226 for 
DR17. This observation suggests that the epitope composition of the antibodies reacting 
with these beads is probably identical and that the differences in MFI observed can be 
attributed to the variation in antigen density on each of the beads.  
It is also of interest to note that DR17 gives the highest MFI reactivity upon 




Patient 3 LT45: Column Performance  
 
 As with the other patient samples plasma effluent from patient LT45 was diluted 
to a final volume of 2 litres using HLA antibody negative fresh frozen plasma (FFP) to 
give HLA-DR11 reactive MFI of 6580. Sample was run through the clinical scale 
column as before and the degree of HLA-specific antibody removal is summarised in 
figure 8.24. HLA-DR11 reactive MFI was reduced by 62%, MFI falling from 6580 to 
2524. A range of other specificities was also reduced by between 60 and 80% 
suggesting the presence of a common reactive epitope, which will be analysed in more 
detail later. 
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Figure 8.24: Patient LT45 antibody removal. HLA-DR11 reactive MFI reduced by 
62%,  a range of HLA-DP specificities reduced by between 65 and 82% 
 
 
As observed with earlier examples antibodies specific for the HLA-DQ locus 
were unaffected by column treatment. In this instance antibodies were detected against 
HLA-DQ5 and DQ6 and also the DQ alpha chain (figure 8.24).  
 Analysis of column reduction in real-time as the depletion cycle progressed 
showed that many of the specificities detected pre-column are depleted effectively only 
over the first 400ml of plasma flow (Figure 8.25 top panel). This data supports the 
finding in figure 8.24 which shows many of the specificities are only partially depleted, 
10-30% only in many cases highlighting the fact that there are many epitope specific 
antibodies present that are not expressed on the DR11 protein.  HLA-DR11 specific 
reactivity (figure 8.25 bottom panel) shows that the column was steadily saturated by 
DR11 epitope specific antibodies, with detectable anti-DR11 reactivity rising steadily 
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Figure 8.25: Antibody depletion through the column cycle for patient LT45. Many 
antibody specificities quickly reach saturation level (top panel). HLA-DR11 specific 
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 Antibodies were then eluted from the column as before and specificity and titre 
was measured by microbead assay. Figure 8.26 shows the reactivities of all the positive 
beads in the microbead assay. 
 
Figure 8.26: Specificities of LT45 patient antibodies eluted from clinical scale 
HLA-DR11 column. Samples were taken at key timepoints in the elution cycle and 
tested by microbead analysis. 
 
It was immediately apparent that a range of antibody specificities had been 
eluted from the column indicating the presence of antibodies directed against numerous 
epitopes present on the DR11 protein. The effective elution of antibody directed against 
a range of HLA-DP locus proteins indicates the presence of antibody specific for the 
70D/55D epitope. This common epitope is shared between DR11 and the HLA-DP 
specificities listed in figure 8.26. The amino acid positions of this shared epitope are 
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Figure 8.27: Ribbon diagram highlighting the position of the 70D / 57-59DEE 
epitope carried by HLA-DR11 and numerous HLA-DP specificities. Epitope 
positions on the beta chain of the class II HLA molecule are highlighted in blue. 
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8.4 DISCUSSION 
 
Sepharose columns containing immobilized HLA protein provide a highly 
effective, selective, and specific method to absorb high titres of HLA-specific antibody 
from clinical scale preparation of human blood. HLA protein mini-columns and also 
clinical, large scale columns were highly effective at removing HLA specific antibody 
in an epitope specific manner. Highly specific antibody reduction, typically 50-80%, in 
a single absorption was routinely observed. 
The use of HLA protein columns to specificially deplete HLA-specific 
antibodies may open up the possibility of transplantation to those patients with high titre 
broadly reacting antibodies. Patients who currently present with over 90% PRA are 
often unsuitable for HLA antibody incompatible transplantation. Indeed, a number of 
patients have failed to be accepted into our HLAi programme by virtue of excessive 
HLA-specific antibody titre.   
The priniciple of these columns is identical to that of the Glycosorb columns 
used to selectively deplete ABO specific antibodies from patients prior to ABO-
incompatible transplantation. As is the case with the columns used to remove ABO 
specific antibodies we aniticipate that specific HLA depletion columns will be much 
better tolerated by the patient and will not lead to a detrimental depletion of other serum 
proteins, such as clotting factors, and will also avoid issues involving hypotension 
observed with plasma exchange and DFPP[111]. In addition, the general maintenance of 
immune equilibrium so lead to a substantially reduced level of risk to the patient, 
particularly in the perioperative period. 
The column approach compares very favourably with our experience of plasma 
exchange or double filtration plasmapheresis, both of which usually lead to overall 
antibody reduction of less than 50% with each round of treatment [91, 129, 130]. 
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Antibody specificities that did not detect the epitope carried on the column protein were 
retrieved completely. Current protocols to reduce the levels of donor HLA-specific 
antibody prior to HLA incompatible transplantation have the major disadvantage of 
being non-specific, leading to a general comprising of overall humoral immunity. This 
study describes the use of soluble HLA proteins and their ability to inhibit the anti-HLA 
response  in solid phase (mini-column and clinical scale column) format. The treatment 
of sera with HLA columns was highly effective in rendering highly positive 
donor/recipient crossmatches negative (figure 8.5). The fact that a strongly positive 
crossmatch was rendered negative following just a single round of HLA column 
depletion was highly encouraging as in the clinical settings it often requires mulitple 
round of DFPP to achieve a negative crossmatch, and in many cases we proceed to 
transplantation even in the presence of a reduced titre positive crossmatch [90].  
Extensive testing has been carried out to demonstrate the structural integrity of 
the sHLA protein is maintained following multiple rounds of antibody depletion and 
column regeneration (figure 8.2) via the use of a monoclonal antibody directed against 
beta-2 microglobulin. This is important as the loss of protein from the column could be 
harmful to the patient and may have lead to increased levels of additional sensitisation. 
This study has also highlighted the potential to reuse clinical scale HLA 
columns. We were able to effectively remove HLA-specific antibody from the column 
matrix leaving the HLA-protein intact. Any potential clinical use column would be 
expensive as a result of the high cost of GMP grade protein manufacture demanded by 
regulatory bodies so the option to reuse a particular column on the same patient 
following a regeneration protocol would provide enhanced cost-effectiveness. 
The fact that patients are able react against a wide array of mismatch HLA 
epitopes does lead to difficulties when designing HLA protein columns. There are 
therefore two disctinct possiblities to be considered when attempting to design a colimn 
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for therapeutic use. In the study described here a single HLA specificity (HLA-
A*02:01) was coupled to the column matrix and patients’ were subsequently chosen on 
the basis of anti-A2 reactivity. In reality patients will have antibodies to many different 
and often multiple HLA specificities, therefore the decision must be made whether to 
produce a depletion column containing a panel of soluble HLA proteins, or to produce a 
‘bespoke’ HLA column containing only the HLA specificities which correspond to the 
patients’ HLA-specific antibody profile. In the case of a multiple antigen columbn 
careful consideration must be given to the composition of the HLA panel, with the aim 
being to optimise the number of proteins required to represent the widest array of 
potential epitopes. We have estimated that 30 separate class I antigens would be 
required to cover all of the currently identified epitopes. The obvious pitfall to this 
appraoch is that the individual proteins (and as a consequence epitopes) would be 
‘diluted’ out as lower concentration of each specificity would need to be used. It may be 
prudent to deliberately omit certain epitopes which are only present on less common 
HLA antigens as these would be less likely to give rise to antibody formation. 
The specific elution of HLA-directed antibodies from patient sera provides a 
valuable research tool. Many studies are ongoing to investigate the effects of HLA-
specific antibody binding on various cell types linked to rejection of solid organ 
transplants. Recently, our group published data that indicated that the binding of HLA-
specific antibody to cells of the human microvascular endothelium results in a 
significantly increased localised synthesis of complement component C4 [175]. This 
study, as with many other similar studies, used human serum containing donor cell 
HLA-specific antibody as the source of humoral stimulation. The common criticism of 
this approach is that it only indirectly suggests that HLA-specific antibody is the 
causative agent as there are a mulitude of other proteins that may be responsible for the 
effect observed. The use of purified HLA-specific antibody directed against donor HLA 
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will address this shortcoming and the fact that we are able to effectively quantify these 
antibodies can aid potential study design with the addition of antibody concentrations 
that reflect antibody concentration ranges seen in vivo. 
Our group have published a series of studies describing the antibody responses 
involved in HLA incompatible transplantation. A key area of research remains to 
identify why certain individuals experience rejection episodes when faced with rising 
DSA levels and others do not. The ability to select and isolate these antibodies directly 
will provide us with a valuable tool with which to study various aspects of the humoral 
response. We will be able to determine the isotype of a particular antibody specificity, 
and also gain valuable insights into potential variation in antibody affinity and 
glycosylation.  
This data provides encouraging evidence that a direct assay to identify anti-
idiotypic antibodies can be developed. Until now the direct detection of anti-idiotypic 
antibodies specific for HLA has not been possible. These antibodies may interfere with 
the currently established methods of identifying HLA specific antibody. They may also 
account, in part, for the dramatic changes in HLA antibody levels seen often during the 
course of an HLA incompatible trasnplant, for example the presence of an anti-isotypic 
antibody directed against HLA specific antibody may lead to a false low readout on the 
luminex assay. The successful isolation of a patients’ own HLA specific antibody 
population may in turn lead to successful purification of anti-HLA idiotypic antibodies 
prior to transplantation. 
This study shows that in principle it is possible to deplete the HLA-specific 
antibody pool in large volumes of human plasma. This is a promising therapeutic 
strategy which also allows the direct isolation of HLA-specific antibody for use in 
various areas of research. 
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9.1 INTRODUCTION 
 
Complement dependant cytotoxic (CDC) crossmatch was one of the tools which 
was used to define the early immunological ‘rules’ of transplantation, importantly it was 
observed that the presence of donor specific antibodies (DSA) defined by CDC were 
associated with a higher frequency of hyperacute or acute rejection [20, 25]. 
Consequently for many years the presence of a positive CDC crossmatch was 
considered to be an absolute contraindication to transplantation. CDC does have 
shortcomings: it is relatively insensitive, with flow cytometry crossmatching widely 
available as a more sensitive crossmatch technique. In addition CDC uses rabbit serum 
as a source of complement and therefore does not accurately represent the normal 
physiological condition. 
CDC was also applied to screen and identify HLA specific antibodies. More 
recently a range of solid phase assays (most notably ELISA and luminex microbead 
based assays) have been developed which use purified HLA molecules bound to the 
appropriate solid phase platform [176]. Beads are now the most commonly used and 
these assays have the additional advantages of speed (particularly in antibody 
characterisation) and also being able to resolve specificities which can be difficult using 
cell-based assays because of co-expression of HLA and linkage disequilibrium. Further 
advantages of bead assays are the adaptability to investigate further properties of HLA 
reactive antibodies- recently methods have been developed to investigate the cytotoxic 
potential of antibodies that bind C4d and C1q [121, 123, 177]. The C1qScreen assay 
(OneLambda Inc) uses a R-phycoerythrin labelled anti-human C1q antibody to detect 
complement activating anti-HLA antibodies.  
An issue with solid phase assays is that of sensitivity, with many contrasting 
opinions being expressed as to the clinical relevance of many of the additional HLA 
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reactive antibodies defined by such assays [178-181]. According to early studies the use 
of the C1qScreen assay in conjunction with standard microbead assays can identify 
clinically relevant anti-HLA antibodies and predict AMR in cardiothoracic 
transplantation [123, 177]. We have observed early rejection rates of just under 50% in 
our HLA incompatible kidney transplant cohort thus far so identification of antibody 
characteristics leading to prediction of rejection are crucial [90].  
In contrast, CDC relies upon the detection of antibodies bound to HLA 
molecules present on the surface of viable donor cells, usually lymphocytes (B and T) 
derived from peripheral blood, spleen, or lymph node. There are a wide array of cell 
surface molecules that may interfere with the CDC assay and antibody binding to any of 
these can lead to a false positive CDC result. 
A true positive CDC result however assumes that the antibody bound to the cell 
surface is HLA specific and is also one of the major complement fixing 
immunoglobulin isotypes (IgM, IgG1 and IgG3). It is the emergence of the solid phase 
assays that has lead to many studies aiming to define more closely the role of 
immunoglobulin isotype, in particular with regard to complement fixing ability, in 
successful solid organ transplantation [121, 182].   
IgM is the most effective immunoglobulin isotype for complement activation 
but is usually excluded in CDC crossmatches by using DTT such that IgG reactivity can 
be measured. This is primarily because of the high false positive rate observed due to 
the presence of non-HLA specific IgM.  Of the IgG subclasses, IgG3 has the greater 
complement fixing activity, followed by IgG1, then IgG2, with IgG4 having the least.   
As has been outlined in chapters 6 and 7, the bead assay can be further exploited 
to measure the relative levels of IgG subclasses with the aim to address the question; 
‘What determines cytotoxicity?’ The contributing factors are likely to be: 1) Quantity of 
antibody, 2) Subclass / function, 3) Epitope density / distribution on the target cell, 4) 
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Composition of antibody specificities within the serum. Or put more simply; ‘Is 
cytotoxicity a property of an antibody or the serum?’ 
 




Initially fifty one patients who received HLA antibody incompatible (HLAi) 
renal allografts between Jun 2003 and October 2008 at University Hospital Coventry 
and Warwickshire were included in the study. All recipients underwent flow cytometry 





CDC crossmatching was performed using donor peripheral blood lymphocytes 
with rabbit serum as a source of complement, and in the presence of dithriothreitol 
(DTT). Acridine orange / ethidium bromide cocktail was used for cell visualisation. 
Where anti-human globulin (AHG) augmentation was used it was done in accordance 
with manufacturers instructions. Patient cohort details are given in table 9.1. 
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Table 9.1: Patient cohort demographics. Patients were transplanted between 2003 and 
2009 at University Hospital Coventry and Warwickshire as part of the HLA antibody 





Pan-IgG donor specific (DSA) and third party (TPA) antibody levels were 
monitored daily both pre- and post-transplant on the luminex platform using the 
Labscreen Single Antigen bead assay (One Lambda, Canoga Park, CA).  
Antibody analysis was carried out in accordance with manufacturers instructions 
as previously described [91, 116], goat anti-human IgG1-4 isotype specific monoclonal 
antibodies (Southern Biotech, Birmingham, AL) were used to determine levels of IgG 
subclass reactivity. The validation process for these antibodies was outlined in chapter 
6. Positive control beads were supplied by the vendor and in all cases their MFI 
exceeded 1000 with a positive/negative control bead ration >2.0 in all cases. Antibody 
strength was taken as raw median fluorescence intensity (MFI), and for each crossmatch 
the corresponding MFI values for each donor specific antibody (DSA) were summed to 
give a total donor reactive MFI.  
2 3/51&(6%)3 3/51&(6%)Pre.transplant&crossmatch&statusCDC+ve 17/51&(33%)FC+ve 18/51&(35%)Microbead&+ve/FC.ve 16/51&(31%)
Mean&duration&treatment&for&ERF 11.5Previous&transplants1 26/51&(51%)19/51&(37%)0
Number 51Mean&Age&(years) 40.9Male/female 18/33
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Complement binding was analysed using the C1qScreen assay (OneLambda Inc) 
in accordance with manufacturers instructions and given in detail in the methods 
chapter (chapter 2, section 2.7.6). All samples were analysed using a Luminex analyser 
and a positive cut-off of 500 MFI was used.  
The distribution of these total MFI levels were compared between cytotoxic 
positive and negative cases for each IgG subclass using the Mann Whitney U-test. 
 
 
9.2.3 Antibody Fractionation 
  
 A panel of 1mg sHLA columns were used to selectively fractionate HLA 
specific antibodies from patients from the University Hospital Coventry and 
Warwickshire HLAi transplant programme (see chapter 8). Patient sera was subjected to 
successive rounds of column absorption with specific sHLA columms in order to 
achieve a mono-epitope specific population, and this is outlined in figure 9.1. Antibody 
specificity was determined by soluble inhibition analysis and luminex single antigen 
microbead testing (chapter 4). Antibody preparations were buffer exchanged and 
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Figure 9.1: Isolation of mono-specific antibody preparations. Samples from LT45 
and LT66 were re-passed through a second HLA column of selected specificity (HLA-
A24 for LT45, HLA-B57 for LT66) and a single epitope specific preparation was 





9.3.1 IgG Subclass Composition and CDC Positivity 
 
Of the 51 crossmatches 35 were CDC negative, 16 were positive.  Donor 
specific IgG was confirmed in all cases by single antigen bead assay (One Lambda Inc, 
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higher donor reactive MFI levels, with median MFI values for the positive and negative 
crossmatch cases given in table 9.2.  
 
Table 9.2: Analysis of median MFI levels in CDC crossmatch outcome. Median 
MFI values for total DSA of each IgG isotype in crossmatch positive and negative 





This data shows that the strongest association with cytotoxicity is due to the 
higher levels of IgG1, although the levels of all subclasses are raised in the CDC 
positive group (figure 9.1). However 4 of the 17 CDC positive sera lacked donor-
specific IgG3 (<5 x negative control bead) whereas all contained IgG1.  
This indicates that in these cells lymphocytotoxicity depended on the presence 
of IgG1 and that the higher levels correlate with cytotoxicity. However, figure 9.2 
shows that the two highest IgG1 levels were not cytotoxic and there is a considerable 
overlap between the levels of CDC positive and CDC negative IgG1 antibodies. This 
factor alone is not a sufficient explanation of the cytotoxic property of serum. 
IgG Subclass CDC XM +ve CDC XM -ve P
IgG1 4284 854 >0.00003
IgG2 649 80 >0.0005
IgG3 210 31 >0.003
IgG4 60 10 >0.02
Median Total DSA (MFI)
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Figure 9.2: IgG subclass specific DSA levels in CDC positive and negative 
crossmatch cases. In general CDC positivity is associated with increased levels of 
IgG1, however there are notable outliers where high level IgG1 DSA does not result in 
a CDC positive crossmatch. 
 
 
9.3.2 Correlation between the C1qScreen Assay and CDC Positivity 
 
All 51 cases were analysed for classical complement pathway activation with the 
C1qScreen assay (One Lambda). Of the 16 CDC positive cases 8 had detectable C1q 
binding donor specific antibodies (DSA) with a mean MFI of 5219 (range: 1430-
20504). In 35 CDC negative patients C1q binding antibody was negative in all but one 
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case where a C1q binding donor specific anti-DQ2 was detected at 853MFI, presumably 
below the threshold for CDC positivity (Table 9.3). 
 
 
Table 9.3: Comparison of C1qScreen positivity and CDC crossmatch result. The 
analysis shows a significant association between CDC crossmatch positivity and 
detection of complement fixing antibodies using the C1qScreen assay. Test groups were 




Two cases in particular were unusual as they had high levels of donor specific 
IgG1 given as total DSA MFI>10000 (cases 8 and 48). There were also a small number 
of cases which displayed elevated IgG3 levels but were CDC negative (cases 6 and 32). 
Those cases with high donor specific IgG1 all tested negative for C1q binding thus 
confirming the earlier negative CDC crossmatch. The samples which gave the highest 
donor specific IgG3 levels in the absence of IgG1 were all negative for C1q binding, 
again confirming the earlier CDC negative. Other examples showed C1q binding HLA 
specific antibodies that were directed against third party antigens.    
  
C1q+ C1q- P
CDC+ (n=16) 8 8
CDC- (n=35) 1 34 0.0002
DSA
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The data described here, although providing a significant correlation between 
CDC crossmatch outcome and C1qScreen positivity, does not provide a definitive 
answer to the factors defining serum cytotoxicity. There are eight CDC positive cases 
which still do not ‘fix complement’ in the C1qScreen assay. This in part shows that the 
lack of CDC positivity against donor lymphocytes in some cases can be explained by a 
lack of C1q binding. The question is why some cases of high levels of IgG1 cannot bind 
C1q. The explanation may be in the requirement of C1q to cross-link adjacent Fc 
chains, and this is explored in the next section.  
 
 
9.3.3 Effect of Epitope Distribution on CDC Positivity. 
 
  
It has been demonstrated in other antigen-antibody interactions that cytotoxic 
potential of antibody displays the hallmarks of a synergistic response, i.e the mixture of 
two or more antibodies against a target cell far exceeds the cytotoxic capacity of each 
antibody in isolation [183, 184]. Indeed, studies have shown that this synergy is greater 
when antibodies were directed against separate antigenic determinants on the same 
molecules rather than against two different determinants on the same cell [184]. With 
regards to HLA the mechanisms by which complement activation may potentially occur 
are summarised in figure 9.3. 
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Figure 9.3: Proposed mechanisms of cytotoxicity. A) Presence of a single epitope 
specific antibody at a high enough level in sera to bind C1q and initiate the classical 
complement cascade. B) Presence of two or more antibodies recognising epitopes on 
different HLA molecules on the cell surface. C) Two or more antibodies specific for 
separate epitopes on the same HLA protein. 
 
 In the models of complement activation outlined in figure 9.3 it is important to 
note that: 1) There is the same amount of antibody per specificity present in each model. 
2) Differences are in proximity of Fc chains and therefore C1q binding potential. 3) The 
prediction is that model C should show increased cytotoxicity over model B based upon 
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To investigate this, antibody eluted from patients LT45 and LT66 using the 
clinical scale HLA-A2 column were used (see chapter 8 for full details). For patient 
LT45 antibody eluted from the HLA-A2 column and which displayed reactivity specific 
for HLA-A2, 23, 24, 68 was re-fractionated using a HLA-A24 column, from which a 
preparation was obtained that contained reactivity against only the 127K epitope (HLA-
A2,23,24,68,69). In the case of patient LT66 antibody eluted from the clinical scale 
HLA-A2 column showed reactivity against HLA-A2, B57, and B58 only with soluble 
inhibition data indicating the additional presence of 43Q+ epitope which is carried on 
HLA-A2 only (see chapter 4 for full analysis). The elutions were re-fractionated using a 
HLA-B57 column which was effective in producing separate mono-specific antibody 
preparation specific for 43Q+ and 62GE (HLA-A2, B57, B58). Specificities were 
confirmed using soluble inhibition assays. This process is summarised in figure 9.1. 
Each mono-specific antibody preparation was then tested by microbead analysis 
following a serial dilution. The resulting MFI values are given in table 9.4. In addition 
the antibody preparations were shown to consist almost exclusively of IgG1 (table 9.5).  
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Table 9.4: Serial dilution of isolated HLA-specific antibody preparations. 
Microbead analysis of mono-epitope specific sample dilution. A pan-IgG specific 





Table 9.5: Subclass composition of fractionated antibody. Each antibody was tested 
with IgG subclass specific monoclonal antibody as described in chapters 6 and 7. Raw 




Next, the cytotoxic capability of each preparation individually was assessed. 
Each preparation was tested at a concentration range from neat down to 1 in 32 by CDC 
against a panel of ten lymphocytes all of which carried at least one epitope defined by 
the antibody preparations. The CDC was carried out both with and without the addition 
of AHG. The results of this analysis are summarised in table 9.6. 
  
 
A2#Bead#Mean#MFI Neat 1#in#2# 1#in#4 1#in#8 1#in#16 1#in#32
Epitope#1#(43Q+) 5750 3984 2584 2046 1180 100
Epitope#2#(62GE) 9652 7028 5293 2426 1314 402
Epitope#3#(127K) 8283 4676 2771 2205 890 416
Dilution(Factor
A2#Bead#Mean#MFI IgG1 IgG2 IgG3 IgG4
Epitope#1#(43Q+) 4544 121 8 4
Epitope#2#(62GE) 7986 88 20 2
Epitope#3#(127K) 7443 57 16 6
IgG$Subclass
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Table 9.6: Assessment of cytotoxic capability of single epitope binding. Without 
AHG augmentation the cytotoxic capacity of even high-level mono-epitope specific 
antibody is limited. Cytotoxic positive results are shaded red. Note, this data tests model 






The next stage was to test the potential synergistic effect of multiple epitope 
binding upon cytotoxic capacity. Checkerboard titrations were prepared for each pair of 
antibodies in microtitre plates. CDC crossmatching was then performed in the absence 
of AHG using 21 individual cells that were once again shown to carry various numbers 
of the epitope sites. The class I HLA type of these cells is given in table 9.7. Each cell 
was also tested against each epitope specific antibody in isolation. Cells were selected 
to represent the presence of multiple epitopes on individual molecules and also on 








43Q+ 62GE 127K 43Q+ 62GE 127K 43Q+ 62GE 127K
1 1 1 1 − − − POS0(1:1) POS0(1:1) POS0(1:1)
2 1 1 1 − − − − POS0(1:1) −
3 1 2 1 POS0(1:1) POS0(1:1) POS0(1:2) POS0(1:2) POS0(1:4) POS0(1:2)
4 1 1 1 − − − POS0(1:1) POS0(1:1) POS0(1:1)
5 1 1 1 − − − POS0(1:1) POS0(1:1) POS0(1:1)
6 1 1 1 − − − POS0(1:1) POS0(1:1) POS0(1:1)
7 0 0 1 − − − − − −
8 1 1 1 − − − − POS0(1:1) POS0(1:1)
9 1 1 1 − POS0(1:1) − POS0(1:1) POS0(1:1) POS0(1:1)
10 1 1 1 − − − POS0(1:1) POS0(1:1) POS0(1:1)
Number0of0each0epitope0present0on00cell0type Antibody0Only Antibody0+0AHG
Cell0No
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The determination of cytotoxicity was taken as the end point dilution at which 
an antibody loses its CDC reactivity when titrated into an undiluted second antibody 
specificity (figure 9.4). There are a number of approaches that could be taken to the 
determine end-point of reactivity, previous studies in other antigen-antibody interaction 
models suggesting this method was best suited to the format of the data here [185]. 
 
Cell HLA'A HLA'B HLA'C
1 2,3 7,8 7
2 1,2 8,44 5,7
3 2,74 57,72 2,7
4 2,11 44,51 2,7
5 2,25 62,65 8,9
6 1,2 7,8 7
7 1,68 8,60 7,10
8 1,2 7,8 7
9 2,3 7,45 6,7
10 2,29 27,44 1,6
11 2,3 44,51 1,5
12 2 44,51 2,7
13 1,2 7 7
14 29,68 57,60 6,10
15 2,3 27,35 2,4
16 1,2 7,8 7
17 2,68 7,57 5,7
18 2 44 5,7
19 2,3 60,62 9,10
20 11,24 57,62 6,9
21 2,24 8,57 6,7
Class+I+HLA+Type
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Figure 9.4: Example of epitope specific CDC checkerboard titration. In the example 
here the titration value of 43Q+ into 62GE would be 1 in 4. 62GE into 43Q+ is 
interpreted as 1 in 2. 
 
 
 The CDC positive threshold dilution values for each combination of epitope pair 
were recorded and mean values compared with the mean cytotoxic positive titre of each 
antibody in isolation. Figure 9.5 shows the increased cytotoxic potential of each 
combination of antibody pairs. Differences were analysed using Wilcoxon rank test and 
p values are indicated, values below 0.05 are considered statistically significant. 
 
1 1 in 2 1 in 4 1 in 8 1 in 16 1 in 32
1 Pos Pos Pos
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Figure 9.5: Increased cytotoxic capacity of HLA-specific antibodies due to synergy. 
Figure shows the mean dilution up to which CDC positivity was detected for all 21 cells 
tested. For all pairs of antibodies the cytotoxic capacity was significantly higher 
compared with cytotoxicity from each antibody tested alone. 
 
 
 The data in figure 9.5 show the collated data from a number of cell types 
therefore the CDC positivity could be due to any or all of the mechanisms highlighted 
in figure 9.2. Therefore the cells were divided into groups based upon epitope 
distribution on the cell surface in order to further explore the potential cytotoxic 
mechanism. Figure 9.6 shows the data from only those cells type were HLA-A2 
heterozygous, meaning that all relevant epitopes were present on one HLA protein per 
cell- i.e this tests model C from figure 9.3. 
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Figure 9.6: CDC synergy using HLA-A2 heterozygous target cells. Where one copy 
of each epitope is carried per molecule synergy is observed compared to single epitope 
specific antibodies in isolation. 
 
  
 The increased cytotoxic potential of antibodies working in synergy as shown in 
figure 9.6 was then applied to the cell types that were HLA-A2 homozygous. Therefore 
in this instance we would expect that there would be double the amount of available 
epitopes with which to bind and the degree of CDC reactivity would be increased. 
Therefore these cells can be used to again test model C, but presumably with greater 
epitope density. This data is shown in figure 9.7 and when compared to the dilutions at 
which cytotoxicity is lost in HLA-A2 heterozygous cells (figure 9.6), it can clearly be 
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Figure 9.7: Increased CDC reactivity using HLA-A2 homozygous target cells. CDC 
reactivity of most paired combinations of epitope specific antibodies are enhanced 
compared to binding to HLA-A2 heterozygous cells. 
 
Two cells were tested that carried the 62GE and 127K epitopes on HLA proteins 
other than HLA-A2. The class I HLA types of each of these cells were: 
 
HLA-A3, 24; B57, 63; Cw6,9 
HLA-A29, 68: B57, 60: Cw6,10 
  
 These cell types can be used to directly assess the cytotoxic capacity of model B, 
as the only epitopes represented on each cell are 62GE (by presence of HLA-B57 on 
each cell), and 127K (represented on HLA-A24, and A68 respectively). 
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The mean level of CDC reactivity of these cells is shown in figure 9.8. As would 
be expected it can clearly be seen that only those epitope combinations that do not 
include the HLA-A2 restricted 43Q+ display CDC reactivity. 
 
 
Figure 9.8: CDC reactivity against non-HLA-A2 restricted epitopes. CDC reactivity 
is demonstrated against the specific epitope combination that is shared between both 
cells. 62GE is carried by HLA-B57 in both cells and 127K is carried by HLA-A24, and 
A68 respectively.  
 
 
 In addition, a single cell used in the analysis had only 127K HLA-A68 as a 
potential epitope target. CDC reactivity was not achieved in this cell by any 
combination of antibody pairs. Again this cell represents the single epitope mechanism 
(model A) assumed to have poor cytotoxic potential. 
 This data set can be used to compare the cytotoxic potential of the  proposed 
mechanisms of CDC reactivity outlined in figure 9.3: By separately analysing groups of 
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cells chosen to be representative of each scenario we can analyse the cytotoxic potential 
of each mechanism. Table 9.8 shows the combination of antibody and cell types 
required to isolate each proposed mechanism. 
 
Table 9.8: Combinations required to analyse proposed mechanisms of CDC 
reactivity. The three mechanisms outlined in figure 9.3 can be analysed separately 





 The potency of each combination in the CDC assay is shown in figure 9.9. The 
mean titre point for each antibody combination is given for each mechanism. Figure 9.9 
clearly seems to suggest that the most potent mechanism for complement activation is 
where there are two separate epitope specific antibodies binding to their target on two 
separate molecules in close enough proximity to each other to cross-link C1q and 
initiate the classical complement pathway. However, the data set for this combination 
only equates to the mean of three cells tested as opposed to 12 cells for the multiple 
epitopes on the same molecule model. 
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Figure 9.9: Potential CDC reactivity of the different proposed mechanisms of 
action. Data suggests that the binding of multiple antibodies to different epitopes 




The data in figures 9.6 and 9.7 shows that the greatest degree of synergy occurs 
between the antibody pairs 43Q+/127K and 62GE/127K. The combination of 
43Q+/62GE shows reduced synergistic effect, particular in the analysis of HLA-A2 
homozygous cells. Figure 9.10 shows the relative positions of the epitope defining 
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distance between 43Q+ and 62GE is approximately 9 Angstroms (Å), far closer than 
that between 43Q+ and 127K and 62GE and 127K (figure 9.10). This suggests that the 






Figure 9.10: Positions of the 43Q+, 62GE, and 127K epitopes on the HLA*02:01 
molecule. The greater distance between 43Q+ and 127K and 62GE and 127K compared 
to between 43Q+ and 62GE appears to allow a greater degree of cytotoxicity. 
 
 
 By separating the data set for multiple epitopes recognised on the same molecule 
into the separate antibody pairs is possible to investigate this further. Figure 9.11 shows 
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Figure 9.11: Effect of epitope spacing on CDC reactivity. The higher degree of 
spatial separation on the HLA-A2 protein of the 43Q+ / 127K, and 62GE / 127K 
combinations leads to greater CDC reactivity. 
  
 The most potent combination of antibodies is clearly 62GE and 127K with a 
reactivity strength that matches that of the separate epitopes on distinct protein model 
data shown in figure 9.9. The observation that 43Q+ / 127K also displays enhanced 
synergy, albeit to a lesser extent, than the 43Q+ / 62GE combination also supports the 
theory that steric hindrance may be a factor in defining serum cytotoxicity. The 
microbead analysis of the single epitope specific antibody preparation gave a dose 
response curve consistent with the dilution of the antibody level (figure 9.12A). 
However, when the epitope specific pairs were titrated into each other as per the CDC 
checkerboard analysis and then tested with microbead analysis, it can clearly be seen 
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(HDHE) as outlined in detail in chapter 3 (figure 9.12B). The other antibody 
combinations do not show this effect, suggesting a degree of steric hindrance within the 
luminex assay. In addition as these samples were purified IgG preparations we can 
discount the potential role of IgM interfering with the binding within the luminex assay 
as has previously been reported [119].   
 
 
Figure 9.12: Competition for epitopes leading to the detection of the high dose 
hook effect. A) Titration of single epitope specific antibody samples shows a fall in 
MFI with increasing dilution of antibody as expected. B) Titration of epitope pairs 
reveals the presence of the high dose hook effect in the 43Q+ / 62GE combination 
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9.4 DISCUSSION 
 
9.4.1 IgG Subclass Level and Distribution 
  
 One of the major dilemmas faced by the modern tissue typing laboratory is how 
to interpret the antibody analysis data provided by the highly specific solid phase assays 
that are now commercially available. The opinion of the transplant community is split 
on how to define those antibodies that are clinically relevant [178-181, 186].  
 One area that seems to provide more clarity takes us back to the early days of 
transplantation and that is the presence of a CDC positive crossmatch and the associated 
increased risk to successful transplantation. Indeed recent reviews call for a risk 
stratification algorithm for sensitised patients that places the CDC positive specificities 
at the heart of the organ allocation process [14]. 
 But what defines a CDC positive serum? CDC positivity could be due to either 
the total amount of donor specific immunoglobulin present in a serum, the relative 
proportion of the different complement fixing isotypes (IgM, IgG1,IgG3), or a 
combination of both factors. Of the IgG subclasses, IgG3 has the greater complement 
fixing activity, followed by IgG1, then IgG2, with IgG4 having the least. 
 Of these factors this study clearly shows that the strongest association with 
serum cytotoxicity is with increased levels of circulating donor-specific IgG1 
(p>0.00003).  There is also a significant increase in the raw MFI values of donor 
specific IgG2, IgG3 and IgG4. It must be noted that the majority of raw MFI values 
obtained for IgG3 and IgG4 in particular are clustered around the region which would 
be deemed negative by the laboratory. The apparent contribution of each HLA specific 
IgG subclass to the overall measure of cytotoxicity closely follows the proportions with 
which each subclass is distributed in the general circulation (IgG1 9mg/ml, IgG2 
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3mg/ml, IgG3 1mg/ml, IgG4 0.5 mg/ml). Furthermore, the importance of IgG1 in 
defining cytotoxicity is supported by the observation that 4 of the 17 CDC positive sera 
completely lacked any donor specific IgG3 (MFI value <5x negative control bead), and 
all 16 CDC positive sera contain donor specific IgG1.  
 
9.4.2 C1qScreen Assay and CDC Crossmatch 
 
 However, this data set provided a number of outliers. For example two patients 
had donor specific IgG1 levels over 10,000MFI but were CDC crossmatch negative. In 
view of this all samples were tested with the C1qScreen assay (OneLambda Inc) which 
detects HLA specific antibody with the ability to bind C1q and therefore initiate the 
complement cascade via the classical pathway [123]. No C1q binding was observed for 
the DSA in these patients thus confirming the crossmatch results. This observation may 
suggest that IgG1 does not activate the classical complement pathway in all instances. 
Variation in Fab region binding would not appear to be the reason as specific binding 
has been observed in both the bead and flow cytometry assays, similarly antibody 
avidity effects are unlikely. This would suggest that variation in some part of the Fc 
region may account for the incomplete association between IgG1 and complement 
fixation. In addition those patients with the highest levels of IgG3 were all negative 
with the C1q assay although the highest MFI in this group was only 694. Eight of 
sixteen CDC positive samples showed no detectable C1q binding antibodies specific for 
the donor. This may suggest that the C1q assay does not represent the in vitro 
mechanism of classical pathway complement activation. Biologically, the spacing of the 
antibody-antigen complexes is crucial to effective C1q cross-linking. In the in vitro 
microbead assay the distribution of the antigen on the surface of the bead is notoriously 
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variable within bead batches. Thus a reduced surface expression of HLA antigen may 
not permit the proximity of antibody binding to be sufficient to crosslink C1q. 
 One case that was CDC negative gave an anti-HLA DQ2 C1q fixing antibody 
with an MFI of 853. The CDC result was confirmed negative in the presence of DTT. 
This patient provided a weakly positive flow cytometry crossmatch, suggesting that 
with an MFI of only 853 this level of antibody may be below the titre required for CDC 
positivity. Alternatively the level of HLA-DQ expression on donor derived B 
lymphocytes may be insufficient to enable stable crosslinking of antibody and 
subsequent complement activation. 
  
 
9.4.3 CDC Crossmatch Predicted by Epitope Distribution 
 
 The ability to isolate HLA-specific antibodies from human plasma using HLA 
protein columns provided a unique tool to explore in detail the factors which contribute 
towards CDC positivity. This has been achieved in other antigenic systems but has not, 
to our knowledge, been explored on the HLA setting. All three of the potential 
mechanisms outlined in figure 9.2 were shown to have at least some degree of CDC 
reactivity when tested using epitope specific purified antibodies. It has been clearly 
shown that when there is a single epitope specific antibody present, regardless of the 
level of that antibody it is highly unlikely that any reactivity within the CDC assay will 
be observed. The likely reason for this would be that the binding only occurs in one 
place on the HLA molecule, therefore to activate complement via the classical pathway 
the co-localisation of two or more separate HLA molecules on the cell surface would be 
required (figure 9.2A). The distribution of HLA on the cell membrane may be such that 
the antibodies would not be in close enough proximity to cross-link C1q.  
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 Where there is another epitope specific antibody in addition it is clear that the 
cytotoxic potential of a serum would be greatly enhanced. Figure 9.9 shows the binding 
of two antibodies specific for two separate HLA molecules present on the surface of the 
leads to enhanced cytotoxic potential via the mechanism suggested as model B in figure 
9.2. Similarly, the binding of two antibodies to separate epitopes on the same molecule 
leads to greatly enhanced cytotoxicity. This has been reported before in systems other 
than HLA [184], however this study has gone a stage further and demonstrates that this 
synergy can be inhibited if the epitope sites are situated in too close proximity on the 
cell surface (figure 9.11).  
In addition, the spacing of epitopes on the molecule has a significant impact 
upon the ability of antibodies to bind to HLA-coated microspheres (figure 9.12). The 
presence of multiple antibodies within a serum that are specific for epitopes found in 
close proximity on the molecule may introduce a degree of steric hindrance, which has 
been demonstrated here to result in the high dose hook effect. The consequences of this 
for patient antibody monitoring and subsequent clinical intervention are discussed in 
detail in chapter 3, but this added layer of complexity further confounds attempts to 
accurately quantify the HLA-specific antibody response using microbead assays. 
The earlier analysis of C1qScreen data in CDC positive cases showed that a 
CDC positive crossmatch could be correlated to a detectable C1q binding DSA in only 
8/16 cases. These findings could help to explain why there is not 100% concordance 
between CDC crossmatch results and the C1qScreen assay. The manufacturer’s 
recommend that single antigen HLA beads are used to detect C1q binding antibody. 
However, classical pathway complement activation requires the proximity of at least 
two antibody molecules in order to corss-link C1q. The use of the single antigen 
microbead assay immediately removes the potential to cross-link C1q by two antibodies 
recognising epitopes on different molecules as only one protein is expressed on the 
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bead. This study suggest that this mechanism is as important as antibodies binding to 
multiple epitopes on the same molecule, therefore we can speculate from this that the 
50% concordance between CDC and C1qScreen is a direct consequence of having this 
route of CDC activation omitted. Furthermore, if we consider some of the individual 
patient data provided in table 9.4, we have evidence to support this hypothesis. Cases 2 
and 33 both have detectable IgG1 and have a donor-specific C1q binding antibody of 
12,000 and 6,500 MFI respectively. In both of these cases the donor specific antibody is 
broadly defined as being directed against HLA-A2, however, as has been demonstrated 
experimentally in chapter 4 by epitope specific soluble inhibition, and in chapter 8 by 
HLA column specific elution, HLA-A2 ‘specific’ antibodies are almost always a 
compound of two or more antibodies recognising separate epitope carried by the HLA-
A2 protein. This particular combination should be detected in the C1qScreen assay as 
multiple antibodies are able to bind to each HLA-A2 molecule present. Conversely, 
patients 8 and 48 also displays high levels of donor specific IgG1. Patient 8 had a HLA-
B63 specific DSA at 15,660 MFI and for patient 048 a HLA-A3 specific DSA at 12203 
MFI. In both of these cases the antibody reactivity measured by luminex is far more 
likely to be caused by a single epitope specificity and therefore be unable to complex 
C1q within the C1qScreen assay. In both cases this was confirmed by soluble inhibition 
assays using the requisite soluble HLA specificities (figure 9.13). 
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Figure 9.13: Soluble inhibition (sInh) analysis to confirm that DSA binding is due 
to single epitope recognition. In case 8 the DSA is specific for the 65R+/66N epitope 
shared with HLA-B57 and B58. This was confirmed by sInh using soluble HLA-B63 
and B58. In case 48 the HLA-A3 DSA recognised the 144K+ epitope shared by HLA-
A1,11,24,36,80. Entire reactivity was depleted by both HLA-A3 and A36 soluble 
inhibition. For both cases selected third party antibody specificites are shown. 
  
 
From this we can conclude that the clinical utility of the C1Screen assay is 
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alternative might be to use the C1qScreen assay with phenotype beads (microbeads that 
carry intact HLA haplotype) such that all potential mechanisms of C1q binding can be 
incorporated. Although it is important to point out that cells and beads also differ 
fundamentally in that HLA present on cells has the ability to move within the cell 
membrane, whereas microbead coupled HLA is immobile. 
 In summary, the factors which determine the cytotoxicity of HLA-specific anti-
sera have been investigated and the IgG subclass composition and level are significant 
factors. It has been demonstrated that HLA-specific antibodies act in a synergistic 
manner at the cell surface, therefore the cytotoxic effects of the mixtures of antibodies 
far exceeded the additive effects of their component antibodies in isolation. Synergy 
was comparable between binding to multiple proteins and to multiple epitopes on the 
same protein, but crucially cytotoxicity was enhanced when binding to epitopes on the 
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HLA INCOMPATIBLE COMBINED LIVER-
KIDNEY TRANSPLANTATION: 




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  David	  Lowe	  PhD	  Thesis	  2013	  
	   287	  
10.1 BACKGROUND 
Preformed donor HLA-specific antibodies (DSA) present at the time of kidney 
transplantation can cause hyperacute or accelerated rejection of allografts and are 
generally accepted as contraindications to conventional transplantation.   Recent 
developments have mitigated this risk by antibody removal or inhibition using plasma 
exchange, high dose intravenous immunoglobulin, or complement inhibitors [105, 129].   
However, these techniques require preparation pre-transplantation and are therefore 
currently best suited to elective, live donor transplantation.  Unfortunately, not all 
patients have available live donors, and for highly sensitised individuals the chance of 
finding a suitably matched organ is generally low. Important clinical series from 
Olausson and colleagues report good outcomes from combined liver-kidney 
transplantation in the deceased-donor setting, the presumed mechanism of which is 
antibody absorption onto the liver which is implanted before the kidney, and is itself 
resistant to immediate antibody mediated rejection [187, 188]. Despite such reports, 
data is lacking to describe the dynamics of HLA-specific antibodies following 
transplantation, and how these correlate with outcome. Herein we describe a case where 
combined liver-kidney transplantation was performed in the presence of high level, 
cytotoxic, donor specific anti-HLA antibodies.  In particular, we describe detailed 
characterisation and post-transplant dynamics of these antibodies, specifically regarding 
epitope reactivity, which may help explain the outcomes of these potentially high-risk 
procedures. 
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10.2 DESCRIPTION OF THE CASE 
A 43-year-old lady with autosomal dominant polycystic kidney disease 
presented for combined liver and kidney transplantation. Two years prior to 
transplantation, she complained of increasing weight loss, anorexia, early satiety and 
right-sided hypochondrial discomfort.  Imaging revealed liver enlargement causing 
compression of upper abdominal viscera.  Despite conservative measures, weight loss 
continued and she was listed for liver transplantation to alleviate the mass effect of her 
native liver.  A gradual decline in renal function over time was observed, and when her 
estimated glomerular filtration rate (eGFR) fell below 25ml/min kidney transplantation 
work-up was initiated.  As part of this, antibody reactivity against multiple class I HLAs 
(negative against any class II) was identified by single antigen bead assay (LSA104, 
One Lambda Inc, Canoga Park, CA), with a calculated reaction frequency of 99%.  She 
had not received blood products or a transplant, and the assumed source of sensitisation 
was four pregnancies. 
 
10.3 TRANSPLANTATION- CLINICAL COURSE 
 
Transplantation proceeded 18 months after listing. Immunosuppression 
consisted of anti-CD25 monoclonal antibody induction, tacrolimus (0.3mg/kg/day), 
mycophenolate mofetil (2g/day) and methylprednisolone 500mg at operation followed 
by oral prednisolone 20mg enterally then tapering.  Intravenous immunoglobulin (IVIG) 
was administered (0.5g/kg/day) for the first five post operative days.  The surgical 
procedures were uneventful and immediate liver and kidney graft function established.  
By post-operative day 5, her serum creatinine had fallen to 108µmol/L. However, 
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between days seven and ten the serum creatinine rose progressively to 197µmol/L.  A 
kidney biopsy undertaken on day nine displayed acute tubular injury with vacuolation, 
diffuse C4d staining, but no inflammatory infiltrate in interstitium, large vessels, peri-
tubular capillaries or glomerulus (Figure 1b,c).  The tacrolimus level on the day of 
biopsy was 15ng/ml (high performance liquid chromatography/tandem mass 
spectrometry).  A clinical diagnosis of tacrolimus toxicity was made, and the tacrolimus 
dose reduced resulting in a tacrolimus level of 8ng/ml three days later.  Renal function 
subsequently improved (day 13 creatinine: 145µmol/L; day 16 creatinine: 120µmol/L).  
No adjunctive escalation in immunosuppression was undertaken; her subsequent clinical 
course was uneventful with stable renal function 40 months post-transplantation (serum 
creatinine:126µmol/L; eGFR:47ml/min; urine albumin:creatinine ratio:14.2mg/mmol).  
 
10.4 POST-TRANSPLANT ANTIBODY DYNAMICS 
 
The recipient and donor HLA types were A23,30; B44,53; Cw6; DR11, 15; DQ 
6,7; and A2,3; B7,60; Cw7,10; DR 8,15; DQ4,6; respectively.  The patient’s immediate 
pretransplant serum was reactive against all class I HLA mismatches except A3 giving a 
cumulative donor-specific reactivity corresponding to an MFI of 55,000 (sum of all 
DSA bead values).  Forty minutes following liver arterial anastomosis (just prior to 
kidney implantation) a further serum sample was taken followed by daily samples for 
two weeks, then at weekly intervals. Changes in MFI values for each bead carrying 
HLA corresponding to donor mismatches are shown in Figure 10.1a, and the following 
key points noted: 1] The sample taken 40 minutes following liver transplantation 
showed a dramatic reduction of all detectable HLA antibody specificities (including 
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those against non-donor antigens).  Thus all the patient’s HLA-specific antibodies were 
absorbed by HLA epitopes on the donor liver. 2] Retrospective cytotoxic crossmatches 
(complement-dependent, CDC, without AHG augmentation) showed a strong reaction 
(8 score) with the pretransplant sample, and a negative reaction with the 40 minute 
sample.  3] On day five reactivity against HLA Cw7 returned (MFI: 2,150), and the 
remaining DSAs reappeared on day six.  4] Between days nine and ten all DSAs 
appeared to return to their pretransplant levels after which all DSAs spontaneously fall, 
and all except those for Cw7 return to baseline 35 days post-transplantation. 5] Finally, 
the specificities of the pre- and post-transplant antibodies are the same and differ only 
quantitatively. 
Examination of the pre- and the peak post-transplant levels for each DSA 
(Figure 10.2a) shows that two DSAs rise above pretransplant levels (A2 and Cw7), B7 
reactivity is unchanged, while reactivity against both B60 and Cw10 is greatly reduced.  
Assuming antibody levels measured in the post-transplant samples represents the 
difference between adsorption and synthesis, this shows it took at least five days for 
antibody resynthesis to overcome adsorption onto donor tissue.  This therefore suggests 
that the relative rates of adsorption and synthesis vary for the different DSAs.  For 
example, after day five the synthesis of antibodies binding to Cw7 greatly exceeds their 
adsorption rate (rapidly rising serum level) but less so for Cw10-binding antibodies. 
Assuming there is equivalent expression of these two antigens then the difference is 
likely related to their different rates of synthesis.  However, this assumption is partially 
inaccurate because HLA specific antibodies are composed of epitope-specific 
antibodies, and such epitopes can be shared between different HLA allotypes and 
isotypes.  Thus antibody reactivity against Cw7 and Cw10 may be due to a shared 
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epitope and therefore the same antibody. Indeed this seems to be partly the case, as 
demonstrated in the following analysis: 
 
 
Figure 10.1: Changes in antibody levels and changes in histology over the early 
post-transplant period. a) Changes in donor reactive bead MFI values through the 
early pre- and post-transplant period; transplant on day 0.  b,c) Kidney graft histology at 
day 9 post transplantation. b) H&E staining showing vacuolation of occasional proximal 
tubules without cellular infiltrate; c) C4d immunohistochemistry showed diffuse linear 
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Epitope specificities of the recipient’s antibodies were determined using the 
Matchmaker programme, specifically designed for this purpose and freely available [81, 
82, 146, 189]. Epitopes are described in accordance with previously published notations 
[80, 147] and an estimate of epitope reactivity in the recipient’s sera is given in Table 
10.1a, which shows which antigens carry the respective epitopes.  Note that one epitope, 
80N (corresponding to the serological type Bw6), is present on four of the mismatched 
antigens, and epitopes 253Q and [163E+166E] are each carried by two separate 
mismatched antigens.  Conversely, HLA A2 and B60 reactivities are likely due to two 
different epitope-specific antibodies in each case, and both B7 and Cw7 reactivities are 
due to three epitope-specific antibodies.  As Cw10 reactivity seems to be due only to 
antibody specific for 80N the attenuated post-transplant response to this antigen might 
more accurately be described as an attenuated response to 80N.  As four mismatched 
antigens carry 80N it could be the greater representation of this epitope increasing the 
adsorption rate of the corresponding antibody.  To track this and the other epitope-
specific antibodies, selected specific beads from the bead assay were chosen that carry 
the minimum number of each of the epitopes shown in Table 10.1b, and we analysed 
these rather than the beads matching the donor HLA.   The selected beads and results of 
this analysis are shown in Figure 10.2b.  Four beads were selected that each carried a 
single epitope recognised by the patient’s sera, although there were no beads to resolve 
70Q from 80N, 253Q from 267Q or 142T from 253Q. 
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Table 10.1: Summary of donor specific reactivity.  Reactive epitopes are shown 
alongside the HLA mismatched donor antigen (a) and the third party antigens (b) on 
which they are expressed. *The full description of this epitope is given as 
[41A+46E+67Y/43P+46E+67Y/43P+46E+70Q]/43P+69A+70Q/43P+70Q+76E/[46E+
65Q+67Y/46E+65Q+70Q] in El-Awar et al (10); this has been abbreviated to 70Q for 
ease of use. 
 
a.  HLA mismatch                            Epitope specificity of donor reactive antibody 
 142T 253Q 80N 70Q* 267Q [163E+166E] 
A2   +  +     
A3       
B7    +   +          + 
B60    +           + 
Cw7   +  +     +  
Cw10    +    
b.  Tracker antigens       
A69  + +     
A25  +     
B47            + 
B42   + +   
B8   +    
Cw17  +     +  
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The changes in epitope-specific antibodies are expressed as percent of starting 
level to normalise the data and take account of variation in antigen density between 
beads, and pre- and peak post-transplant levels compared to show the maximal response 
of each antibody (Figure 10.2b).  The lowest response at peak was seen for antibodies 
against epitopes 253Q and 80N, at 10% and 20% of their pretransplant levels.  In 
contrast the peak level of [163E+166E] specific antibody was 440% of the pretransplant 
level.  The level of antibody against 70Q appears to be similar for pretransplant and 
peak (80%) although this is confounded by 80N.  The response against 267Q could not 
be directly assessed as the beads carrying this also carried confounding epitopes, but 
using a Cw17 bead (253Q and 267Q) bead a 180% change from pretransplant to peak 
level was observed and, as we know that the antibody against 253Q was greatly 
reduced, it is clear that the increase against this Cw17 bead is due to reactivity against 
267Q and that the change in this antibody is likely to be underestimated.  Similarly the 
response against 142T is likely to be greater than the 150% when tracked with the A29 
(142T and 253Q) response. 
When approached from the perspective of epitope-reactivity, dramatic responses 
are evident which are not apparent when looking at whole antigen-specific responses.  
The response measured against an antigen gives a net change: thus the peak level of 
antibody against HLA B7 was similar to the pretransplant level.  This is because the B7 
reactivity is due to antibodies against 70Q (little change), 80N (reduction) and 
163E+166E (increase). Indeed if the MFIs of the three epitope-specific reactions are 
summed, the result is 18,700 for the pretransplant sample and 15,100 for the peak post-
transplant sample.  A rebound to pretransplant levels suggests a null humoral response 
to the graft whereas an increase indicates an active, memory response.   
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Figure 10.2: Changed in antibody levels assessed using the bead specificities and 
refined epitope specificities. a) Overall change in donor reactivity from pre-transplant 
to post-transplant DSA peak for each donor-specific antibody.  b) Net change in donor 
reactivity from pre-transplant to post-transplant peak DSA for each epitope specific 
donor reactive antibody.  Surrogate antigens were used to analyse epitope-specific 
reactivity. 
 
Although overall the pretransplant and peak post-transplant levels were broadly 
similar, the reaction pattern of the HLA-specific antibodies changed dramatically with 
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was strongly cytotoxic (killing score 8), but at postransplant days 9 and 10 when the 
overall antibody levels had reached or exceeded the pretransplant levels, cytotoxicity 
was noticeably lower with killing scores of 2 and 4 respectively (shown in Figure 
10.1a).  At this timepoint, serological reactivity was dominated by antibodies against 
142T (A2), [163E+166E] (B7 and B60), and 267Q (Cw7) while antibodies against 80N 
fell dramatically.  Perhaps these antibodies intrinsically differ in their pathogenicity or 
perhaps certain combinations of antibodies are required for optimum cytotoxicity as 
suggested in chapter 9.  Serum creatinine did rise with the rising donor-specific 
antibodies (and, interestingly, C4d staining on biopsy) but tacrolimus levels were above 
target, and tacrolimus nephrotoxicity implicated, with an improvement in graft function 
following tacrolimus dose reduction and subsequent stability over considerable follow-
up.  High levels of early antibody resynthesis were therefore seemingly insufficient to 
cause rejection. Although it is tempting to speculate that this is a protective effect of the 
liver, this phenomenon has also been described in more conventional HLA antibody 
incompatible kidney transplantation [90]. 
The final phenomenon revealed by frequent antibody testing during the first few 
post-transplant weeks is the rapid rise followed by a seemingly spontaneous fall in 
antibody levels. No treatment such as IVIG, rituximab or bortezomib, was used to 
modulate the resynthesis of the DSA following its reappearance, yet by post-operative 
day 35 most of the antibodies had all but disappeared.  The cause of this modulation is 
unknown but again this is not unique to combined liver-kidney transplantation, having 
been described in antibody-incompatible transplantation following extracorporeal 
antibody removal [91]. 
In summary, this case confirms the utility of simultaneous liver transplantation 
in allowing successful kidney transplantation in the face of preformed, high level DSA, 
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which would normally be associated with hyperacute rejection and kidney graft failure.   
Antibody characterisation in terms of epitope specificity is more accurate and 
informative than antibodies described as “antigen-specific” and a method is suggested 
here for identifying and tracking these antibodies - i.e. follow the epitope reactions and 
not the antigen reactions.  This will give better insight into the behaviour and 
pathogenicity of HLA-specific sera.  In the case presented here this approach has 
revealed some novel features of the post transplant antibody response in a sensitised 
recipient.  These illustrate three phenomena that challenge current dogmas - an early 
resynthesis of DSA does not necessarily cause antibody-mediated rejection, high levels 
of DSA can spontaneously modulate, and measurement of antibodies in terms of solely 
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11.1 SUMMARY 
 
11.1.1 Monitoring HLA-Specific Antibodies 
  
 This thesis has highlighted some of the pitfalls involved in the use of microbead 
assays to monitor the changes in HLA-specific antibody levels. Factors to consider 
include the density of antigen bound to the bead, the composition of the antibodies 
within the sera, and also the relevant concentrations of these antibodies. The 
identification of the high dose hook effect (HDHE) as a cause of false low readings in 
the microbead assay is of importance when determining relative changes in antibody 
level through the course of a transplant. Data shown in chapter 9 demonstrated that 
steric hindrance is the likely cause of the HDHE, as antibodies competing for binding 
sites in close proximity to each other prevent successful binding. It is important to note 
that the HDHE is only one of a multitude of factors that may lead to false low readings. 
Assay interference due to IgM binding, or the presence of the prozone effect must also 
be considered when interpreting microbead data. 
 
11.1.2 Epitope Determination by Soluble Inhibition (sInh). 
 
 Defining the epitope specific nature of anti-HLA antibody binding using soluble 
inhibition provided a valuable insight into the hidden levels of complexity associated 
with the HLA-specific antibodies found in patient sera. The observation that anti-A2 
reactivity for example is often a mixture of 2,3 or 4 different antibodies, demonstrates 
that antibody formation in response to foreign HLA is a complex process, indeed there 
is a need to stop thinking of HLA mismatching in terms of a mismatched antigen but 
rather in terms of potential mismatched epitopes.  
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 The large panel of sHLA specificities available for this project allowed the 
identification of a range of HLA class I epitope specificities to be established and also 
provided the early proof of principle data to allow us to proceed with attempts to design 
a HLA-specific antibody depletion column with confidence. Indeed this increased 
understanding of the epitope specific nature of anti-HLA binding was used in the 
clinical setting to better understand the changes associated with the combined kidney-
liver transplant case study outline in chapter 11. Without the knowledge of the epitopes 
the antibody data would have been much more difficult to interpret, and we could not 
have fully understood the extraordinary dynamics of antibody absorption displayed by 
the donor liver. 
 
11.1.3 Quantification of HLA-Specific Antibodies. 
 
 There had been no previous reports of successful quantification of HLA-specific 
antibodies. Recently, there has been much attention on the use of MFI values to monitor 
changes in antibody levels but these do not give insight into the typical range of 
concentration at which these antibodies circulate. Using HLA-specific monoclonal 
antibodies which were then purified and accurately quantified, we were able to 
construct standard curves using single antigen beads and for the first time it was 
possible to estimate the typical circulating concentration ranges of these antibodies.  
 In sensitised waiting list patients circulating HLA-specific antibodies are 
typically found at concentrations of up to 50µg/ml, and at times of rapid antibody 
production, such as during an episode of acute antibody mediated rejection, can rise to 
four or five times this concentration. This range of concentration typically means that 
HLA-specific antibodies will make up less than 1% of circulating IgG. 
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 Due to the fact that HLA-specific antibodies typically share epitopes it is 
important to be able to distinguish the exact epitope specificity of an antibody before 
attempting to quantify using standard curves. Therefore the sInh process to determine 
epitope specificity went hand in hand with attempts to determine the serum 
concentration of these antibodies. Without epitope level characterisation it is impossible 
to accurately quantify these antibodies, as many MFI values would be a composite of 
more than one antibody, each one at a different concentration. 
 
11.1.4 HLA-Specific IgG Subclass Distribution and Clinical Relevance. 
 
 Chapter 6 provided the first full description of HLA-specific IgG subclasses. 
The data also correlated the subclass distribution with the likely mode of sensitisation. 
Antibodies stimulated by pregnancy and previous transplant mismatched antigen 
showed the greatest degree of class switching, with a large proportion of responses class 
switching all the way though to IgG4.  
 It was also of note that IgG4 characterised nearly all HLA DQ-specific 
antibodies stimulated by graft rejection (p=0.006). Such widely varying IgG subclass 
heterogeneity is likely to be due to underlying immunological processes dependent on 
the route of sensitisation. This diversity, which implies functional variation, may help 
explain why HLA-specific antibodies are an obstacle to transplantation in some 
circumstances but not others. The subclass association with rejection has potential as a 
biomarker for chronic rejection. 
 Therefore chapter 7 investigated the influence of IgG subclasses in HLAi 
transplantation. Recent studies which analysed the pre-transplant samples in an 
incompatible transplant cohort suggested that there is little clinical benefit to measuring 
IgG subclass levels pre-transplant [158]. However, a more detailed analysis here 
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showed that pre-transplant class II IgG4 DSA levels were associated with rejection in 
the early post-transplant period. In addition, post-transplant IgG4 levels displayed 
unique kinetics compared to the other subclasses (figure 7.4).   
 
 
11.1.5 Development of HLA Columns 
 
 Current technologies to remove antibodies prior to transplantation do not 
provide the specificity and often remove antibodies to other targets which may 
compromise patient immunity. Therefore the aim was to develop a device in the form of 
a column containing HLA antigen bound onto a substrate, through which the patient’s 
plasma will be passed and the HLA antibodies removed. 
 The soluble HLA (sHLA) proteins used had been previously tested and 
characterised and used to define epitope specificities. The ability of HLA columns to 
deplete anti-HLA reactivity exceeded initial expectations, with a 1mg HLA column able 
to deplete over 90% of specific reactivity from 5ml of patient serum or plasma (figure 
8.3).  
 The project then described pilot studies using clinical scale HLA-A2 and HLA-
DR11 column containing around 50-55mg of immobilised HLA. These columns were 
also highly effective in depleting HLA-specific reactivity, this time from sample 
volumes in excess of 2 litres in a single treatment. These proof of principle studies 
provide early promise that a fully licensed therapeutic device may in time be developed. 
There is still much to be considered, for example a single HLA specificity per column 
would be of limited clinical benefit in a patient with multiple DSA specificities. The 
strategy for such patients would have to be considered carefully;  multiple columns with 
different specificities could be used, or alternatively a single column containing a panel 
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of carefully selected HLA specificities designed to cover as many common epitopes as 
possible. 
 The other great benefit that HLA columns provided was the unique ability to 
isolate HLA-specific antibody from patient material and enrich these antibodies for use 
in further research. From clinical scale depletion and elution cycles it was possible to 
isolate up to 20mg of HLA-specific antibody. This valuable resource has many potential 
applications in both research and clinical service provision. HLA-specific antibodies, 
fractionated and carefully standardised could serve as an excellent standard reagent for 
antibody screening, identification, and crossmatch procedures.  
 An example of a research application for fractionated HLA-specific antibodies 
was described in chapter 9. The use of carefully produced antibody preparations specific 
for a single HLA epitope allowed the thorough examination of the factors which 
determine cytotoxicity. This analysis was able to identify that these antibodies act in a 
synergistic manner to more effectively cross-link C1q and bring about a cytotoxic 
reaction. It was also demonstrated that this synergy is also dependant upon the physical 
location of the epitopes on the HLA moleucle with the added layer of complexity being 
that if two epitopes are too closely situated together then cytotoxicity can be reduced 
due to a steric hindrance effect. This same situation occurred on the surface of the single 
antigen bead, thus serving to further highlight the importance of being able to 
effectively identify the epitope specific nature of HLA-specific antibody binding. The 
correct interpretation of both microbead analysis, and cellular crossmatching is reliant 
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11.2 FUTURE DIRECTIONS 
 
11.2.1 Defining HLA-Specific Antibody Affinity 
 
The work done in this thesis to characterise the antibodies that give rise to the 
complications within antibody incompatible renal transplantation will provide important 
insights into the mechanisms underpinning donor organ rejection. However, one area of 
antibody incompatible transplantation that remains under-represented is that of 
understanding the biochemical affinity of antibody-antigen interactions. As described in 
chapter 1 many recipients are able to accommodate organs in spite of their producing 
antibodies against donor antigens, whilst others suffer severe rejection episodes.  One 
hypothesis relating to this states that the production of donor specific antibodies with 
high affinity for incompatibility antigens leads to the generation of immune complexes 
of greater stability within the donor kidney.  
Surface plasmon resonance (SPR) is a powerful biophysical technique that 
facilitates the determination of biochemical kinetic parameters such as association and 
dissociation constants.  Measurements are made in real time and can be supported 
within temperature ranges between 4-40°C.  Sample quantity requirements operate very 
comfortably within the microgram range.  Broader analyses can be carried out using this 
technique including equilibrium kinetics, concentration measurements and 
thermodynamics.   
The University of Warwick has recently made significant investments in the 
field of surface plasmon resonance with the purchase of a Biorad XPR36 biosensor, 
installed at the Walsgrave Campus site of site of the Clinical Sciences Research 
Institute.  At present it is one of only two such instruments installed with a UK 
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university (the other in Oxford) and is the only one of its kind in the UK to be installed 
proximal to a major hospital and renal transplantation site.  The instrument utilises a 
removable chip system wherein selected ligands are immobilised on a nano-gold surface 
via a variety of conjugation chemistries including amine coupling, streptavidin-biotin 
and thiol coupling. The microfluidic flow-cell set-up can accommodate up to 36 
simultaneous sensorgrams involving up to 6 immobilised ligands on the chip and 6 
fluid-phase analytes in the flow scheme. The XPR36 instrument is ideally suited to the 
kinetic analysis of donor-specific antibodies, with the capacity to provide large datasets 
efficiently from modest amounts of patient plasma.   
We have begun work to characterise the binding of HLA-specific antibodies 
using sHLA coupled to the chip surface. Early validation experiments have been 
performed using HLA-specific antibodies purified from the HLA protein columns and 
human HLA-specific monoclonal antibodies kindly donated by Dr Arend Mulder at the 
University of Leiden, the Netherlands.  Figure 11.1 shows the example of a HLA-
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Figure 11.1: SPR sensorgram showing binding of fractionated HLA-specific 
antibody. The response curve in the association phase can provide an ‘on-rate’, with the 
rate of dissociation showing the ‘off-rate’ of the antibody. The chip surface can then be 
regeneration using alkaline elution. 
 
 
The binding of HLA-specific antibodies is expected to be highly complex in 
patient sera, with antibodies existing as a polyclonal mixture of antibodies albeit 
exhibiting the same binding specificity. This assumption is based upon work carried out 
by our research group on ABO antibodies, which demonstrated the complex mix of 
antibodies present within sera. With this in mind we have entered into a fruitful 
collaboration with colleagues in the Engineering Department at the University of 
Warwick, and have published work describing the modelling of SPR data to define 
ABO and HLA binding affinities [190, 191]. 
Work will continue to define the assay and a clinical study is planned to monitor 
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Lowe, D., R. Higgins, et al. (2013). "Significant IgG subclass heterogeneity in 
HLA-specific antibodies: Implications for pathogenicity, prognosis, and the 
rejection response." Hum Immunol. 
 
Abstract: IgG subclasses differ in their ability to fix complement and bind Fc receptors. 
This study describes a detailed analysis of the distribution of HLA-specific IgG 
subclasses in order to define how this varies in sensitised waiting-list patients. We 
found significant variation in the level, presence and combinations of each HLA-
specific IgG subclass between and within individuals and this is influenced by the type 
of sensitising event. Graft failure in particular provokes higher levels of IgG1 (vs 
transfusion, p=0.071 and pregnancy, p=0.042), IgG2 (vs transfusion, p=0.001 and 
pregnancy, p=0.016), and IgG4 (vs transfusion, p=0.052). Both graft failure and 
pregnancy tend to stimulate multiple IgG subclass responses against HLA, whereas 
transfusion stimulated antibodies are dominated by responses limited to IgG1 (p=0.033) 
and have a low incidence of IgG4 (p=0.046). In marked contrast, IgG4 characterised 
nearly all HLA DQ-specific antibodies stimulated by graft rejection (p=0.006). Such 
widely varying IgG subclass heterogeneity is likely to be due to underlying 
immunological processes dependent on the route of sensitisation. This diversity, which 
implies functional variation, may help explain why HLA-specific antibodies are an 
obstacle to transplantation in some circumstances but not others. The subclass 
association with rejection has potential as a biomarker for chronic rejection. 
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Higgins, R., D. Lowe, et al. (2011). "Human leukocyte antigen antibody-
incompatible renal transplantation: excellent medium-term outcomes with 
negative cytotoxic crossmatch." Transplantation 92(8): 900-906. 
 
Abstract: Human leukocyte antigen (HLA) antibody-incompatible renal transplantation 
has been increasingly performed since 2000 but with few data on the medium-term 
outcomes. METHODS: Between 2003 and 2011, 84 patients received renal transplants 
with a pretreatment donor-specific antibody (DSA) level of more than 500 in a 
microbead assay. Seventeen patients had positive complement-dependent cytotoxic 
(CDC) crossmatch (XM), 44 had negative CDC XM and positive flow cytometric XM, 
and 23 had DSA detectable by microbead only. We also reviewed 28 patients with HLA 
antibodies but no DSA at transplant. DSAs were removed with plasmapheresis 
pretransplant, and patients did not routinely receive antithymocyte globulin 
posttransplant. RESULTS: Mean follow-up posttransplantation was 39.6 (range 2-91) 
months. Patient survival after the first year was 93.8%. Death-censored graft survival at 
1, 3, and 5 years was 97.5%, 94.2%, and 80.4%, respectively, in all DSA+ve patients, 
worse at 5 years in the CDC+ve than in the CDC-ve/DSA+ve group at 45.6% and 
88.6%, respectively (P<0.03). Five-year graft survival in the DSA-ve group was 82.1%. 
Rejection occurred in 53.1% of DSA+ve patients in the first year compared with 22% in 
the DSA-ve patients (P<0.003). CONCLUSIONS: HLA antibody-incompatible renal 
transplantation had a high success rate if the CDC XM was negative. Further work is 
required to predict which CDC+ve XM grafts will be successful and to treat slowly 
progressive graft damage because of DSA in the first few years after transplantation. 
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Higgins, R., D. Lowe, et al. (2010). "Double filtration plasmapheresis in antibody-
incompatible kidney transplantation." Ther Apher Dial 14(4): 392-399. 
 
Abstract: Double filtration plasmapheresis (DFPP) was used in preference to plasma 
exchange in our program of antibody-incompatible transplantation, to treat higher 
volumes of plasma. Forty-two patients had 259 sessions of DFPP, 201 pre-transplant 
and 58 post-transplant. At the first treatment session, the mean plasma volume treated 
was 3.81 L (range 3-6 L), 55.5 mL/kg (range 36.2-83.6 mL/kg). Serum IgG fell by 
mean 59.4% (SD 10.2%), and IgM by 69.3% (SD 16.1%). Nine patients did not require 
increases in plasma volumes treated, and six did not tolerate higher plasma volumes. In 
the remaining patients, the mean maximum plasma volume treated pre-transplant was 
6.67 L (range 4-15 L), 96.1 mL/kg (range 60.2-208.9 mL/kg). The complement 
dependent cytotoxic crossmatch was positive in 14 cases pre-treatment, and remained 
positive in six (42.8%) cases. The flow cytometric crossmatch was positive in 29 cases 
pre-treatment, and in 21 (72.4%) after DFPP. Post-transplant, DFPP was ineffective at 
reducing donor specific antibody levels during periods of rapid donor specific antibody 
synthesis. Post-transplant, the one year graft survival rate was 94%, although there was 
a high rate of early rejection. In summary, DFPP enabled the treatment of plasma 
volumes that were almost double those that would have been feasible with plasma 
exchange. Despite this, most patients were transplanted with a positive crossmatch, and 
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Higgins, R., D. Lowe, et al. (2009). "Rises and falls in donor-specific and third-
party HLA antibody levels after antibody incompatible transplantation." 
Transplantation 87(6): 882-888. 
 
Abstract. After human leukocyte antigen (HLA) antibody-incompatible transplantation, 
donor specific and third party HLA antibodies may be found, and their levels fall in a 
donor-specific manner during the first month. However, these changes have not been 
previously described in detail. METHODS: Donor-specific HLA antibody (DSA) and 
third-party HLA antibody (TPA) levels were measured using the microbead method in 
44 presensitized patients who had renal transplantation. RESULTS: DSA+TPA fell in 
the first 4 days after transplantation, and greater falls in DSA indicated absorption by 
the graft. This occurred for class I (57.8% fall compared with 20.2% for TPA, 
P<0.0005), HLA DR (63.0% vs. 24.3%, P<0.0004), and for HLA DP/DQ/DRB3-4 
(34% vs. 17.5%, P=0.014). Peak DSA levels occurred at a mean of 13 days 
posttransplant, and they were higher than pretreatment in 25 (57%) patients and lower 
in 19 (43%) patients (P=ns). The risk of rejection was associated with peak DSA levels; 
15 of 25 (60%) patients with DSA at median fluorescence intensity (MFI) more than 
7000U experienced rejection, compared with 4 of 7 (57%) patients with peak DSA MFI 
2000 to 7000U, and 2 of 12 (17%) patients with peak DSA MFI less than 2000U 
(P<0.02). DSA levels subsequently fell in a donor specific manner compared to TPA. 
CONCLUSION: DSA levels may change markedly in the first month after antibody 
incompatible transplantation, and the risk of rejection was associated with higher 
pretreatment and peak levels. 
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Higgins, R., M. Hathaway, D. Lowe et al. (2007). "Blood levels of donor-specific 
human leukocyte antigen antibodies after renal transplantation: resolution of 
rejection in the presence of circulating donor-specific antibody." Transplantation 
84(7): 876-884. 
 
Abstract: Accommodation to antibody is an important mechanism in successful ABO-
incompatible transplantation, but its importance in human leukocyte antigen (HLA) 
antibody-incompatible transplantation is less clear, as sensitive techniques facilitating 
daily measurement of donor-specific HLA antibodies (DSAs) have only recently been 
developed. METHODS: We report 24 patients who had HLA antibody-incompatible 
kidney transplantation (21 living donors, 3 deceased), 21 of whom had pretransplant 
plasmapheresis. Eight had positive complement-dependent cytotoxic (CDC) crossmatch 
(XM) pretransplant plasmapheresis, nine had positive flow cytometric (FC) XM, and 
seven had DSA detectable by microbead analysis only. After transplant, DSA levels 
were monitored closely with microbead assays. RESULTS: Rejection occurred in five 
of eight (62.5%) CDC-positive cases, in three of nine (33%) FC-positive cases, and in 
two of seven (29%) of microbead-only cases at a median of 6.5 days after 
transplantation. Resolution occurred at a median of 15 days after transplantation, in 8 of 
10 cases when the microbead level of DSA had median fluorescence intensity (MFI) 
>2000 U, in 6 of 10 when the microbead MFI >4000 U. In 8 of 10 cases, the microbead 
MFI at the time of resolution was greater than at the onset. DSA did not always cause 
clinical rejection. In five cases with a posttransplant DSA peaking at MFI >2000 U on 
microbead assay, rejection did not occur. CONCLUSION: These data suggest that the 
dominant method of successful transplantation was function of the transplant in the 
presence of circulating DSA, and they also define the period during which this occurred. 
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